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ABSTRACT 
INHIBITION AND COFACTOR TARGETING OF HYPOXIA-SENSING 
PROTEINS 
 
MAY 2015 
CORNELIUS TAABAZUING, B.S., UNIVERSITY OF MASSACHUSETTS 
AMHERST Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Michael J. Knapp 
 
Hypoxia Inducible Factor (HIF) is a transcription activator considered to be the 
main regulator of O2 homeostasis in humans. The transcriptional ability of HIF is 
regulated by the Fe
2+/αKG-dependent enzyme, Factor Inhibiting HIF (FIH). FIH uses 
molecular oxygen to catalyze hydroxylation of an asparagine residue (Asn
803
) in the C-
terminal transactivation domain (CTAD) of the HIFα subunit, abrogating HIF target gene 
expression. The mechanism of FIH and other αKG-dependent oxygenases involves the 
ordered sequential binding of αKG, substrate, and O2, which becomes activated to form a 
reactive ferryl intermediate that hydroxylates the substrate. The key to understanding 
FIH’s function as an oxygen sensor, and the chemistry of the broader class of enzymes, is 
to elucidate steps coincident with O2 binding and activation. These steps are shared 
amongst this class of enzymes and are the least understood. 
 In order to understand structural factors that influence O2 binding and reactivity, 
we solved the crystal structure of FIH in the presence of NO, an O2 mimic. Our data 
suggests that the sterics of the target asparagine residue modestly influences O2 binding, 
but plays a major role in stimulating O2 reactivity by orienting bound gas productively for 
vii 
 
decarboxylation chemistry. The increased O2 reactivity in the presence of CTAD would 
ensure tight coupling of O2 binding and activation to hydroxylation. The reorientation of 
bound O2 may be the mechanism utilized by the broader class of αKG oxygenases to 
activate molecular oxygen.  
 The active site of the Fe
2+
/αKG-dependent enzymes is highly conserved. The Fe 
cofactor is typically ligated by 2 His residues and 1 carboxylate residue. A class of αKG-
dependent enzymes that catalyze halogenation chemistry ligate the Fe cofactor with only 
2 His residues, and bind a halide ion in place of the carboxylate ligand. In order to 
understand the structural factors that control the incorporation of alternative ligands such 
as halides, we mutated Asp
201 
in FIH to Glu (D201E), and Gly (D201G). The D201G 
variant activity was dependent on chloride, and the crystal structure suggested that 
chloride was bound at the active site. XAS data indicated that chloride was bound, 
implicating D201 in controlling ligand access. Other non-native ligands such as azide, 
and cyanate were able to access the active site Fe cofactor of D201G, consistent with 
relaxed ligand selectivity upon mutation of the facial triad carboxylate. The identification 
of exogenous ligands targeting the Fe cofactor raises the possibility that FIH can be 
engineered for alternative rebound chemistry. 
 Recently, there have been many reports of “gasotransmitters” such as NO and 
H2S impacting HIF controlled gene expression in cells, suggesting that the HIF 
hydroxylases are potential physiological targets. We tested the effect of H2S on the 
activity of FIH. Our data suggests that H2S binds to the Fe cofactor of FIH to inhibit 
activity. H2S was also demonstrated to reduce inactive ferric FIH back to the ferrous 
viii 
 
state, restoring activity. The dual regulation of FIH activity provides a rationale for some 
of the observed physiological responses to H2S treatment.  
 Taken together, our data suggests that the active site of FIH relies on several 
structural motifs to direct chemistry. The active site carboxylate controls the access of O2 
and other ligands to the Fe cofactor. The target asparagine residue stimulates O2 
reactivity by provided the proper steric environment to orient O2 productively for 
chemistry. However, certain ligands such as H2S are able to access the Fe cofactor to 
inhibit chemistry, implicating them in the hypoxia sensing pathway in cells.  
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CHAPTER 1 
AN OVERVIEW OF OXYGEN SENSING AND THE KEY PLAYERS 
This chapter has previously been published as: Taabazuing, C. Y.; Hangasky, J. A.; 
Knapp, M. J. Oxygen Sensing Strategies in Mammals and Bacteria. J. Inorg. Biochem. 
2014, 133, 63–72.  
1.1 Introduction 
 Oxygen is the terminal electron acceptor used during aerobic respiration, making 
it essential for the survival of nearly all organisms. During respiration, the reduction of 
O2 into H2O is coupled to the production of cellular energy in the form of ATP. Too little 
oxygen results in inefficient respiration and a switchover to anaerobic metabolism or cell 
death if the proper adaptive response is not elicited. Conversely, too much oxygen can 
lead to oxidative stress and the production of reactive oxygen species (ROS) that can 
damage the cellular machinery and cause cellular death. As a result of the necessity to 
regulate O2 availability, organisms have evolved complex and elegant systems for 
sensing and maintaining O2 homeostasis. O2 sensing pathways typically utilize 
metalloproteins to either reversibly bind O2 or to catalyze irreversible O2-dependent 
reactions, leading to transcriptional and metabolic changes in response to varied pO2.  
 The atmosphere is composed of ~ 21 % oxygen, leading to an appreciable 
concentration of dissolved O2 in water under ambient conditions (288 µM at 20 °C).
1
 
However, due to the limits of diffusion and metabolic demands, intracellular O2 levels are 
often less than 10% of this ambient value in mammalian tissues. Further deviations from 
this value are possible depending on the tissue, cell type, and developmental stage of the 
mammal.
2
 It is estimated that O2 concentrations ([O2]) are ~5% of the ambient level in 
typical adult tissue.
3
 As a result, the body relies on number of finely tuned responses to 
variations in [O2] that work over a narrow range of pO2.  
2 
 
 
In relation to biology, environments with sufficient [O2] are considered to be 
normoxic while conditions in which [O2] is deficient are considered hypoxic. Hypoxia 
has a significant effect on the pathogenesis of many human diseases, including chronic 
heart and lung disease, myocardial ischemia, pulmonary hypertension, and cancer, all of 
which are major contributors to the mortality rate worldwide.
3–7
 Therefore, a 
comprehensive understanding of O2 sensing can potentially improve therapeutics for 
treating diseases related to poor or over oxygenation.  
1.2 Acute Hypoxia Sensing by Mammalian Tissue  
 Mammals follow distinct sensing strategies for acute hypoxia (time scale of 
minutes) and chronic hypoxia (time scale of hours to days). Acute hypoxia sensing starts 
at the tissue level with specialized cells responding to changes in pO2 through the effects 
of potassium and calcium ion channels on the membrane potential of the cells.
2,8,9
 The 
two dominant physiological responses to acute hypoxia are hypoxic systemic vasodilation 
and hypoxic pulmonary vasoconstriction, which change vascular tension to modify blood 
flow. Vasodilation is a response that increases the perfusion of blood to the affected 
tissue while vasoconstriction is a regulatory mechanism that balances perfusion to 
ventilation. Although these acute responses are crucial for tissues experiencing hypoxia, 
and are thought to be mediated within the cell by ion channel signaling pathways, the 
specific molecular mechanisms linking changes in pO2 to ion channel activity are not 
well understood.   
1.2.1 Neuroepithelial Bodies (NEBs) and Type 1 Glomus Cells 
 The first step in acute hypoxia response is facilitated by specific chemosensory 
cells termed neuroepithelial bodies (NEBs), and type 1 glomus cells of the carotid body. 
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NEBs are the first responders to pO2 as they line the mucosa of mammalian airways. 
NADPH oxidase (NOX) has been experimentally demonstrated to mediate the hypoxic 
response in NEBs via ROS generation.
10
 Activation of NOX by protein kinase C (PKC) 
leads to superoxide (O2
-
) production, which may be the signal to close K
+
 channels.  
Counter intuitively, hypoxia results in increased production of O2
-
 by NOX.
11
 Whether 
the chemical signal is O2
-
 or H2O2 is ambiguous as O2
-
 can dismutate to H2O2 and direct 
addition of H2O2 boosts the whole cell K
+
 channel current in NEBs (Figure 1.1).
12
  The 
shift in membrane potential due to K
+
 channel closure causes an influx of Ca
2+
, triggering 
neurotransmitter release (serotonin and neuropeptides) from NEBs (Figure 1.2).
13
  
Although activation of NOX by PKC led to hypoxia sensitive K
+
 channel closure in the 
immortalized model NEB H146 cell line
14
 NOX inhibitors failed to fully suppress this 
response, suggesting that multiple mechanisms may be utilized by these cells to sense 
O2.
15
   
 
Figure 1.1: Proposed mechanism for ion channel O2 sensing in NEBs. NADPH oxidase 
mediates the hypoxic response in NEBs via O2
-
 or H2O2. 
  
 Type 1 glomus cells are specialized chemoreceptor cells belonging to the carotid 
body, and are similar to NEBs. In type 1 glomus cells, hypoxia results in closure of K
+
 
channels, which depolarizes the cellular membrane. The resultant membrane 
depolarization triggers an influx of Ca
2+
 and the release of neurotransmitters (dopamine) 
to the carotid-sinus nerve that relays the information to the central nervous system and 
stimulates ventilation (Figure 1.2).
9,16
 In contrast to the role NOX plays in NEBs, NOX 
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suppresses K
+
 channel closure in type 1 glomus cells,
11,17
 indicating that the mechanism 
for O2-sensing is subtly tweaked from tissue to tissue. As the same ion channel types can 
be either potentiated or inhibited depending on cell types, this would allow individual 
tissues to fine tune the hypoxic response. 
1.2.2 Smooth Muscle Cells (SMCs) 
 Smooth muscle cells (SMCs) work in concert with NEBs and type 1 glomus cells 
to facilitate tissue-specific responses to acute hypoxia. In pulmonary artery SMCs, acute 
hypoxia closes the K
+
 channels, which  leads to an increase in intracellular [Ca
2+
], 
triggering neurotransmitter release and vasoconstriction.
18
 In contrast, the hypoxic 
response in many other tissues is vasodilation due to the function of systemic SMCs. In 
systemic SMCs, hypoxia causes ATP sensitive K
+
 (KATP) channels to open and 
hyperpolarize the membrane, inhibiting Ca
2+
 influx and causing muscle cell 
relaxation.
18,19
 These findings and the observation that inhibiting oxidative 
phosphorylation drastically influences O2 sensing in NEBs and SMCs led to the model 
that the energy demands of the cell ultimately govern the response to hypoxia, however 
the scientific literature contains conflicting data regarding this model. For example, 
myocite relaxation can occur at pO2 levels that don’t compromise energy metabolism, 
suggesting that decreased energy metabolism is not a requirement for hypoxia sensing by 
ion channels.
8
 For a more in depth discussion of this evidence the reader is directed to 
more focused reviews on that subject.
2,8
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Figure 1.2: Acute hypoxia sensing in mammalian tissues. Acute hypoxia causes 
inhibition of K
+
 channels in type 1 glomus cells and NEBs. The depolarization increases 
intracellular [Ca
2+
], leading to neurotransmitter release and improved ventilation. Acute 
hypoxia causes KATP channels to open in systemic SMCs, inhibiting calcium influx and 
causing vasodilation. Inhibition of K
+ 
channels in pulmonary artery SMCs causes 
depolarization and calcium influx that results in vasoconstriction. 
 
 Adaptation to hypoxia may involve vasodilation or vasoconstriction, depending 
on the affected tissue; however, both result from changes in membrane channels that 
cause myocite contraction or relaxation. In this manner, adaptation to acute hypoxia relies 
on a carefully orchestrated response that involves neuroepithelial cells, type 1 glomus 
cells, and smooth muscle cells. The cellular machinery that play a role in the acute 
hypoxic response are just now emerging and understanding of the molecular details 
awaits further research. 
 1.2.3. Heme Oxygenase (HO) 
 The challenges with distinguishing O2-sensing processes from those that merely 
consume O2 are exemplified by heme oxygenase (HO). One isoform of HO (HO-2) has 
been proposed to sense hypoxia based on data from genetic knockouts in mice, but the 
literature is conflicting.  Heme oxygenases oxidatively cleave hemes into CO and 
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biliverdin, consuming O2 and NADPH.
20
 There are three isoforms of HO identified, of 
which the first two have been well characterized and reported to have a high affinity for 
O2 (P50(O2) values: HO-1 = 0.036 μM , HO-2 = 0.013 μM).
2,21
 HO-1 is an inducible heme 
oxygenase that is expressed in response to stresses such as hypoxia,
22
 whereas HO-2 is 
constitutively expressed and is proposed to modulate Ca
2+ 
activated K
+ 
channels in the 
membranes of glomus cells.
23
 While the extremely low P50(O2) of HO-1 and -2 indicates 
that these enzymes will be saturated with respect to [O2] over the physiological range of 
O2, and incapable of a response proportionate to changes in pO2, HO-2 has intriguing 
connections to cellular hypoxia responses.   
 HO-2 was proposed to respond to hypoxia due to the HO-2 produced CO 
increasing K
+
 channel activity.
23
  This model requires that hypoxia leads to decreased 
[CO], thereby closing the K
+
 channels and leading to Ca
2+
 influx and neurotransmitter 
release.
24
  While the very low P50(O2) value for HO-2 appears to eliminate a direct link 
between CO production and physiologically relevant changes in [O2], a number of 
observations suggest a connection between HO-2 and responses to hypoxia. At the 
organismal level, HO-2
 
deficient
 
mice were reported to be hypoxaemic (decreased pO2 in 
the blood) and exhibited signs of vasoconstriction activity.
25
 Cell-based assays showed 
that both HO-2 activity and CO could open K
+
 channels, implicating HO-2 in the O2 
sensing pathway for pulmonary artery SMCs.
25,26
  In contrast, other cell-based assays 
produced conflicting data on the role of HO-2 in glomus cells,
25,27
 which may be due to 
the use of cells from different species in these studies. These findings underscore the 
need to resolve the mechanisms linking hypoxia to ion channel function, in order to have 
a more comprehensive understanding of O2 sensing in mammalian tissue.   
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An important aspect of acute hypoxia sensing that remains elusive is a molecular 
view connecting decreased pO2 with K
+
 channel activity. The proposals described above 
are further muddied by patch-clamp experiments indicating that K
+
 ion channels may 
sense O2 directly as there is an absence of detectable modifications to the cytosolic 
environment, such as changes in pH, ATP levels or [Ca
2+
].
8
 Although NOX regulates ion 
channels,
10–12
 the specific molecular players connecting NOX to K
+
 channels remain to 
be clarified.  Whether CO, O2
-
, or the recently proposed H2S (see below), the chemistry 
underneath acute hypoxia sensing promises to be a fertile field for investigation.   
1.3 H2S as an O2 Sensor 
 A recent proposal for hypoxia sensing in higher organisms is that hydrogen 
sulfide (H2S), or some other sulfur species, is the direct sensor for acute hypoxia in many 
tissues of higher organisms.
28,29
 While controversial, there are compelling correlations 
between O2 and H2S biochemistry, suggesting a connection between these gases. H2S 
elicits responses similar to those caused by hypoxia in many tissues,
29
 and the molecular 
players are more fully identified than for the CO and O2
-
 models discussed above.  The 
key features of this hypothesis are: the O2-sensitive speciation of sulfur into reduced and 
oxidized pools to signal changes in pO2; and the transduction of this signal by an 
unknown mechanism into cellular responses to hypoxia.   
 At a very basic level, the speciation of sulfur into reduced (H2S) and oxidized 
(SOx) pools depends on the availability of O2, leading to a correlation between hypoxia 
and elevated [H2S] within cells.
30
 While a simplified view suggests that this is due to the 
balance between the cytosolic metabolism of S-containing compounds to produce H2S 
and the mitochondrial oxidation of H2S to SSO3
2-
 and SO4
2-
 (Figure 1.3), the story is 
somewhat more complex.  In particular, the distribution of various enzymes involved in 
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sulfur metabolism may be more varied than previously thought.  As oxidation to form 
SSO3
2-
 and SO4
2-
 are slowed under conditions of low pO2, the reduced sulfur pool 
increases under hypoxic conditions.  But other factors, such as H2S consumption by 
ROS
31–33
 and H2S production promoted by elevated glutathione levels,
34
 indicate that H2S 
levels do not respond solely to changes in pO2.  This interplay between various redox 
pools, pO2 and [H2S], combined with the challenges in measuring different sulfur 
species,
31,35,36
 makes it difficult to establish a clear causal link between hypoxia and 
elevated levels of reduced sulfur species. 
 A simplified view of the production of H2S centers on the transsulfuration 
pathway and on cysteine catabolism.
31,32,37,38
 In the transsulfuration pathway, H2S is 
liberated from cysteine, homocysteine, and cystathionine by the pyridoxal phosphate 
(PLP)-dependent enzymes cystathione β-synthase (CBS) and cystathione γ-lyase (CSE), 
which are typically cytosolic enzymes.
39
 However, data suggests that CBS and CSE 
translocate to mitochondria under cellular stress, which may account for cysteine 
metabolism within the mitochondria.
40,41
  H2S is also produced from Cys by the 
sequential action of the enzyme cysteine aminotransferase (CAT), which uses αKG as a 
co-substrate, and mercaptopyruvate sulfotransferase (MST); while CAT and MST are 
predominantly cytosolic, MST is also found within the mitochondrion.
42
 Whereas 
oxidation of mitochondrial H2S to SO4
2-
 leads to excretion, the fate of cytosolic H2S is 
less clear (Figure 1.3). Connections between the metabolism of glutathione (GSH), 
cysteine, and H2S (as reviewed by Gojon
31
), imply that cytosolic H2S equivalents are fed 
into the mitochondria for oxidation.  Indeed, it was recently proposed that H2S oxidation 
rather than H2S production is the crucial step in hypoxia sensing.
43
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 Mitochondrial enzymes oxidize H2S within the mitochondrial matrix, connecting 
H2S catabolism to respiration through the quinone pool in the inner membrane.
37
 The 
membrane enzyme sulfide quino-oxidoreductase (SQR) oxidizes S
2-
 to S
0
 using the 
quinone pool, transferring the S
0
 equivalent to glutathione to form a persulfide (GSSH) 
and sending electrons into the respiratory redox chain via catechols. The S
0
 equivalent is 
then oxidized to the S
4+
 oxidation state (sulfite) by the enzyme persulfide dioxygenase 
(ETHE1)
37,38,44
 with subsequent conversion either by sulfite oxidase to sulfate, or by 
rhodanese, which combines a S
0
 equivalent (RSSH) with sulfite to form thiosulfate 
(SSO3
2-
).  The non-enzymatic reduction of thiosulfate by GSH has been shown to rapidly 
produce H2S under hypoxic conditions using purified reagents or mammalian tissues, 
suggesting that this may be a reaction that will rapidly increase the H2S level under acute 
hypoxia.
34
  
 
Figure 1.3: H2S production and oxidation in the cytosol and mitochondria. Key 
compounds are cysteine (Cys), homocysteine (hCys), methionine (Met), and glutathione 
persulfide (GSSH). 
 
 Cells can both produce and consume H2S in proportion to varied pO2, with GSH, 
thiosulfate, and sulfite as key players in H2S metabolism.  Notably, the rate of H2S 
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consumption decreases when [O2] drops below ~ 20 µM in bovine tissues,
30
 suggesting 
that acute hypoxia leads to elevated H2S. Thiosulfate has been proposed to serve as a pool 
for the rapid reductive release of H2S by reducing agents such as glutathione (GSH), 
which could lead to the production of H2S under hypoxic conditions.
34
 The mitochondrial 
enzyme persulfide dioxygenase (ETHE1) catalyzes a key O2-consuming step in the 
catabolism of H2S, producing sulfite.
44
 Precisely how the concentrations of these 
molecular species vary with pO2 is crucial for the H2S-centered model for acute hypoxia 
sensing.  Intriguingly, ETHE1 is a non-heme Fe(II)-dependent oxygenase,
44
 which binds 
to the Fe(II) cofactor using a His2Asp facial triad; this is similar to the cofactor structure 
for the well-established hypoxia sensors FIH and PHD, which control the transcriptional 
activity of HIF, the hypoxia inducible factor (see below).  If H2S is a transient hypoxia 
sensor, it would be a remarkable development if yet another non-heme Fe(II) 
dioxygenase were to sense O2 in cells.  This, however, remains an open question at 
present.   
 Exogenously administered H2S (or N-acetyl cysteine) mimics the hypoxic 
response in a variety of tissues, such as vasoconstriction or vasodilation depending on the 
organism.
30
 However, the responses to elevated [H2S] and low [O2] may be 
complementary rather than identical, with much cross-talk between the two stressors.
32
 
While it has been asserted that this indicates that H2S and hypoxia are mediated by the 
same effector pathways within cells,
28
 the molecular pathways linking H2S to tissue 
responses have not yet been identified for testing.  An intriguing study from 2011 found 
that while HIF-1 was required for the transcriptional effects of chronic H2S in C. elegans, 
the identity of genes regulated by chronic H2S administration were distinct from those 
11 
 
regulated by hypoxia.
45
 It is possible that better discrimination of responses to acute 
hypoxia from those due to chronic hypoxia would help to clarify the specific effector 
pathways induced by H2S.   
 Although the proposal that H2S levels report on acute hypoxia is consistent with a 
number of correlations, the molecular basis for signal transduction is unclear.  Two key 
questions moving forward are: How is sulfur speciation transduced as a signal?  How 
does the mitochondrial sulfur pool connect with the cytosolic sulfur pool?  It has been 
suggested that post-translational protein modification via sulfhydration is the molecular 
basis for signaling increased [H2S].
46
  In sulfhydration, a protein-bound persulfide (R-
SSH) is formed by one of several possible mechanisms.
31,47
  There is an oxidant-
promoted reaction (RSH + H2S → RSSH + 2 H
+
 + 2 e-), or sulfane transfer from an 
endogenous persulfide (GSSH + RSH → GSH + RSSH).  Notably, this signaling mode 
suggests that sulfane sulfur (S
0
) may be the sulfur signaling agent rather than H2S.
47
 We 
were unable to find any tests of sulfhydration connected to hypoxia sensing at present.   
 The connections between cytosolic and mitochondrial sulfur speciation are not 
completely understood.  Under some conditions the persulfide form of the cytosolic 
enzyme MST may be imported into the mitochondria, thereby importing S
0
 equivalents in 
limited concentrations.  However, in order to excrete the sulfide formed within the 
cytosol, there must be bulk mitochondrial import, thereby leading to oxidation to sulfate.  
Despite these gaps, the proposal that H2S senses acute hypoxia is much richer in 
molecular detail than the proposals connecting K
+
 ion channels to hypoxia via CO and 
O2
-
 signaling.   
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1.4 Hypoxia Inducible Factor (HIF) and the HIF Hydroxylases (FIH and PHD) 
 The response to acute hypoxia is largely a matter of vascular tension to modify 
blood delivery to tissues, however chronic hypoxia leads to responses within cells at the 
transcriptional level. Hypoxia Inducible Factor (HIF) is the most important monitor of 
pO2 as it controls the expression of hundreds of genes over a wide range of physiological 
O2 tensions.
48
 HIF also links acute and chronic responses to hypoxia by controlling a 
number of adaptations to pO2 including erythropoiesis, angiogenesis, glucose 
metabolism, cell proliferation, and glycolysis.
3,49
  Several isoforms of HIF are known, 
with HIF-1 being the dominant player in the human hypoxia response.   
 After the discovery of HIF-1 in the nuclear extracts of hypoxic cells in 1992,
50 
it 
was soon realized that HIF-1 was a heterodimeric protein consisting of α and β 
subunits,
51 
and that HIF-1α levels and transcriptional activity increased with decreasing 
cellular O2 concentrations.
52
 Three isoforms of the HIFα transcription factor have been 
identified, HIF-1α -3α, which are evolutionarily conserved in all metazoans53 but absent 
from bacteria, yeast, and plants. While the abundance of HIF-α increase under 
hypoxia,
49,51
 HIF-1β is a constitutively expressed protein that is also known as the aryl 
hydrocarbon receptor nuclear translocator (ARNT). Although both HIF-1α and HIF-2α 
are capable of initiating transcriptional activity, HIF-1α is believed to be the key 
regulator of the hypoxic response as the other two isoforms have varied expression levels 
depending on cell types.
3
 HIF-3α, which is incapable of initiating hypoxia induced 
transcriptional activity, is not closely related to HIF-1α or HIF-2α and appears to serve no 
direct role in hypoxic sensing.
48,54
  
 The transcriptional activity of HIF-1α decreases with increasing pO2 due to the 
competition between nuclear translocation and the post-translational hydroxylation of 
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HIF-1α. HIF-1α accumulates during hypoxia, permitting it enough time to translocate 
into the nucleus.  Once there, it can dimerize with HIF-1β to bind the transcriptional co-
activator protein p300 at the promoter regions of genes that allow the cell to survive 
hypoxia. HIF-1α undergoes O2-dependent post-translational modifications that either 
marks it for proteasomal degradation or prevents its interaction with p300, halting HIF-1 
mediated gene expression (Figure 1.4). These post-translational modifications to HIF-1α 
take the form of hydroxylations to specific Pro and Asn residues, the rates of which are 
proportional to [O2].  Consequently, the transcriptional activity of HIF-1α decreases when 
the hydroxylation rate exceeds the rate of nuclear localization.   
 The regulatory enzymes that control HIF-1 activity via posttranslational 
hydroxylation of asparagine and proline residues are the proteins factor inhibiting HIF 
(FIH) and prolyl hydroxylase (PHD). Only one isoform of FIH is currently known, but 
there are 3 isoforms of PHD (PHD1-3) identified to date, of which PHD2 is recognized as 
the main regulator of HIF-1α.55  Both PHD2 (KM(O2) = 250 μM)
56
 and FIH (KM(O2) = 90 
μM)49 are O2 sensors as they have an absolute requirement for O2 in order for chemistry 
to occur, and their activity is proportional to variations in pO2 over the physiological 
range. The dual regulation of HIF-1α likely ensures strict control of the hypoxic response 
over a wide range of pO2 levels.  
 FIH and PHD2 belong to a large superfamily of non-heme Fe(II)/αKG-dependent 
oxygenases. FIH and PHD2 are proposed to follow an ordered sequential mechanism in 
which the co-substrate αKG binds first, then substrate (a domain of HIF-1α) binds 
second, followed by O2  (Scheme 1.1). Substrate binding stimulates O2 reactivity, which 
is typically attributed to the creation of an open coordination site due to aquo release. 
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Oxidative decarboxylation generates a high-valent ferryl intermediate that abstracts 
hydrogen from an un-activated carbon, followed by rebound chemistry to hydroxylate the 
substrate (Scheme 1.1). Although hydroxylation is the typical reaction for the αKG 
oxygenases, a number of different products can be found for this class of enzymes.  For 
more comprehensive reviews on the chemistry and structural conservation of αKG 
oxygenases the reader is directed to recent reviews.
57,58
  
 
Scheme 1.1: The consensus mechanism of αKG-dependent oxygenases 
 
 PHD2 and FIH hydroxylate specific residues in the O2-dependent degradation 
domain (ODD) and the C-terminal transactivation domain (CTAD) of HIF-1α 
respectively, which leads to decreased transcriptional activity for HIF.  Hydroxylation of 
either of two proline residues (Pro402, Pro564) in the ODD by PHD2 is a prerequisite of 
HIF-1α recognition by the von Hippel-Lindau protein (pVHL) (Figure 1.4),59 with 
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hydroxylation at Pro564 being ten-fold faster than at Pro402.
60–62
 pVHL is the 
recognition component of an E3 ubiquitin-protein ligase that targets HIF-1α for rapid 
proteasomal degradation after successive rounds of ubiquitinylation.
63
 Hydroxylation of 
Asn803 in the CTAD by FIH blocks p300 from binding, stopping expression of HIF-1α 
target genes (Figure 1.4).
64
 O2 mediated regulation of HIF-1α varies slightly between 
different cells, depending on the O2 requirements in specific cell types.
65
   
 
Figure 1.4: Regulation of HIF-1α by FIH and PHD2. Posttranslational regulation of HIF-
1α by FIH and PHD2 control HIF-1α transcriptional activity and stability under normoxic 
conditions. During hypoxia, HIF-1α forms a transcription complex with HIF-1β and 
p300, and initiates target gene expression. 
 
 HIF controls the expression of several genes that help mediate the adaptive 
response to fluctuating pO2, such as NOX,
66
 HO-1,
22
 GLUT-1,
7
 and PHD2
55
, placing it at 
the center of O2–sensing and homeostasis. Although the transcriptional activity of HIF is 
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linked to both acute and chronic hypoxia sensing, the true sensors are FIH and PHD2, 
which use molecular oxygen to hydroxylate HIF-1α. Interestingly, HIF controls the 
expression of PHD2, which is induced under hypoxia. As the KM(O2) for PHD2 is high in 
relation to physiological pO2 within cells,
49,56
 PHD2 has low activity during hypoxia, but 
its expression would ensure that the proper balance to HIF-1α levels are restored upon 
reoxygenation of the cell. Whilst the critical players (FIH and PHD2) in HIF mediated 
pO2 sensing have been identified, key questions that remain to be answered include: How 
is the chemistry of O2 activation stimulated by enzyme/HIF-1α binding? Are there 
physiological effectors of PHD2/FIH activity, including other gases such as H2S, CO, and 
NO? How can we selectively inhibit or increase PHD2/FIH activity?  Resolving these 
questions would facilitate therapeutic targeting of these enzymes, as well as fundamental 
insight into the chemistry of this superfamily of non-heme Fe(II) αKG-dependent 
hydroxylases.    
 O2-activation by FIH and PHD2 is significantly stimulated by substrate binding,
67
 
as seen for other αKG hydroxylases.  This is crucial to their role as O2-sensors because 
O2-activation in the absence of HIF leads to enzyme inactivation.
68
 The best supported 
model for substrate-stimulated O2-activation in these enzymes focuses on the 
coordination geometry of the Fe(II) cofactor. The Fe(II) switches from predominantly 6-
coordinate to 5-coordinate upon substrate binding due to aquo release, as shown by 
electronic spectroscopy and computational results for several enzymes from the αKG-
dependent hydroxylase family.
67,69,70
 By creating a coordination site on Fe(II), O2 binding 
is then forced to follow substrate binding. Although the chemical mechanism of O-O 
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bond cleavage is unclear, back bonding from αKG to the metal likely plays a role in 
stimulating O2 activation at Fe(II).
69,70
   
 Despite the coordination changes observed under non-turnover conditions, certain 
features of the above model need to be refined.  For example, the kinetics of ligand 
exchange from the Fe(II) cofactor is not known – unless aquo exchange from the Fe(II) is 
very slow, O2 would be able to access the metal prior to substrate binding.  Further, the 
redox potential of the Fe(II) has been proposed to shift upon substrate binding, thereby 
facilitating its reaction with O2.
71
 These two points suggest that substrate binding may, in 
fact, simply increase the equilibrium binding affinities for O2 relative to that of H2O.  
Another broader question about this model that remains under study is how substrate 
binding alters contacts within the active site to stimulate O2 activation.  Answering these 
questions will elucidate much about the specific chemistry involved in O-O cleavage as 
related to hypoxia sensing.   
 Recent work on the HIF hydroxylases has provided some insight into the 
molecular mechanism of pO2 activation by the HIF hydroxylases. The mechanical 
linkage between HIF-1α binding and O2-activation remains unclear in FIH, however this 
is central to O2 sensing. Although FIH will inactivate in vitro through an auto-oxidation 
reaction in the absence of HIF-1α,68,72 HIF-1α binding stimulates the O2 reactivity of FIH 
many-fold. MCD and CD data of FIH in solution revealed that the Fe(II) cofactor 
geometry shifts from 6-coordinate to a mixture of 5/6-coordinate upon HIF-1α binding,67 
in agreement with the X-ray crystal structure of HIF-1α bound FIH73 and suggesting that 
aquo release may limit the O2 reactivity.
74
 As the consensus mechanism for this family of 
enzymes requires that the Fe(II) be 5-coordinate prior to binding O2,
58
 the MCD data 
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showing only partial formation of the 5-coordinate Fe(II) suggests that O2 binding or 
activation may be sluggish in FIH. Further support for this notion comes from a suite of 
mechanistic data, which points to rate-limiting O2 activation for FIH under accessible 
pO2,
75
 which would lead to a direct correlation between enzyme activity and pO2. 
Notably, modeling and mutation studies demonstrate that the second coordination sphere 
residues are pivotal for directing O2 reactivity in FIH.
67,76
 The picture that emerges is one 
in which HIF-1α binding induces structural changes near the Fe(II), including aquo 
release, which stimulates O2-activation.  
 PHD2 activity also appears to be limited by the rate of O2-activation, consistent 
with its role as an O2-sensor. Pre-steady state kinetics indicated that PHD2 reacted with 
O2 very slowly when compared to other αKG oxygenases, and related freeze-quench 
experiments failed to isolate the putative ferryl intermediate,
77
 which was consistent with 
O2-activation as the rate-limiting step in PHD2. Steady-state kinetics further supports 
rate-limiting O2-activation in PHD2.
78
 In order for the HIF hydroxylases to be good O2 
sensors, O2 binding or a step subsequent to O2 binding should be rate limiting as this 
would lead to proportionate changes in activity with pO2. The KM(O2) being higher than 
the physiologically relevant pO2 is also consistent with the notion of the HIF 
hydroxylases being O2 sensors as this would allow the rate of their chemistry be 
proportionate to pO2 near physiological levels. 
 A number of endogenously produced molecules, such as NO, CO, and H2S, are 
intriguing as putative effectors of the HIF hydroxylases as they may bind in place of O2 
and are known to regulate pathways related to hypoxia responses.  Nitric oxide (NO) 
regulates vascular tone, and has been shown to inhibit PHD2
79
 and FIH,
80
 hinting that this 
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and other transient species could be physiological effectors of the HIF hydroxylases. 
Although CO binding to the HIF hydroxylases has yet to be demonstrated, endogenous 
CO has been shown to exhibit anti-apoptotic, anti-inflammatory, and protective responses 
against hyperoxia-induced lung injury.
27
  Unpublished results show that H2S inhibits FIH 
(IC50 ~ 30 µM) (Taabazuing and Knapp, unpublished) implicating H2S in the overall 
hypoxia response.   
 Methods to inhibit the HIF hydroxylases would be highly desired, as they would 
permit therapeutic targeting of the hypoxia sensing machinery. Although a number of 
synthetic compounds have been reported to inhibit these enzymes,
81–83
 challenges include 
improving both selectivity
81
 and the relatively low affinity of the inhibitors (IC50 > 1µM).  
Inhibitors for FIH and PHD2 are typically structural mimics of αKG, able to bind to the 
Fe(II) cofactor via one or two ligation points, opening up the likelihood of cross-
reactivity with other αKG oxygenases.  Inclusion of a chiral center near the Fe(II) binding 
group improved inhibitor specificity in one study,
84
 suggesting that further improvements 
in inhibitors may be eminently achievable with further synthesis and screening efforts.  
1.5 Conclusion 
 Acute and chronic changes in pO2 lead to distinct adaptive responses in mammals, 
ranging in scale from vascular changes through transcriptional changes. While several 
biochemical pathways for pO2 sensing are known with varied levels of detail, a number 
of outstanding research questions remain that focus on the chemical interactions that 
underlay sensing. Tissue level responses to changed pO2 appear to be mediated by ion-
channels, however the molecular mechanisms for transducing pO2 into ion channel 
activity remain to be defined.  Similarly, the proteins that control the transcriptional 
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activity of HIF through post-translational hydroxylation (FIH and PHD enzymes) are 
well defined, leading to questions that largely center on the chemical mechanisms of O-O 
bond cleavage and the identification of enzyme regulators/inhibitors. Emerging data 
suggests that the speciation of sulfur compounds report on hypoxia, with two large 
questions being the connections between cytosolic and mitochondrial sulfur pools, and 
the mechanisms for transducing the signal.  Continuing research in these areas holds 
promise in treatments for diseases including ischemia and cancer, where vasculature 
development and anaerobic metabolism play significant roles in cell growth.   
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CHAPTER 2 
CRYSTAL STRUCTURE OF THE HYPOXIA SENSING ENZYME FIH 
COMPLEXED TO FE, NOG, AND NO 
 
 
2.1 Introduction  
 The Fe
2+/αKG-dependent enzymes constitute the largest family of mononuclear 
non-heme oxygenases.
1
 These enzymes activate molecular oxygen (O2) and couple the 
oxidative decarboxylation of the αKG co-substrate to important biological 
transformations, such as repair of alkylated DNA and RNA, antibiotic synthesis, and 
protein modifications.
2–5
 These enzymes appear to utilize a sequential mechanism in 
which O2 is activated to form a reactive ferryl intermediate that subsequently 
hydroxylates the primary substrate. The mechanical linkage between substrate binding 
and oxidative decarboxylation reflects a combination of increased O2 affinity and 
increased reactivity of bound O2.
5–9
 However, the details of how substrate binding 
promotes O2 binding and activation, which leads to coupled hydroxylation, are not well 
understood for this class of enzymes. 
 Factor Inhibiting HIF (FIH) is an Fe
2+/αKG-dependent enzyme that regulates the 
activity of the HIF transcriptional activator, which regulates O2 homeostasis in human 
cells.
10,11
 A key feature of FIH function is that O2 activation is stimulated by the binding 
of the CTAD domain of the HIF transcription factor, which ensures that O2 activation is 
tightly coupled to CTAD hydroxylation (Scheme 2.1).
12–14
 Recently, it was shown that 
CTAD binding leads to a mixture of 6-coordinate (6C) and 5-coordinate (5C) Fe
2+
 in 
FIH/CTAD,
7
 suggesting that O2 access to a coordination site is not the principal model to 
explain the increase in O2 reactivity in FIH. Understanding the factors governing the 
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control of O2 binding and reactivity in FIH is key to understanding its function as the 
main hypoxia sensor in human cells, and will provide fundamental insight into O2 
binding and reactivity in the broader class of αKG oxygenases.  
 In order to gain insight into the structural factors that influence productive gas 
binding in the αKG oxygenases, we used NO as an O2 mimic to study the changes in the 
O2 binding site of FIH. Nitric oxide (NO) is commonly used as an O2 surrogate to learn 
about intermediates and the chemistry of non heme O2 activating enzymes as NO adopts 
a similar geometry to that of O2.
15–17
 NO is capable of reversibly binding to Fe
2+
 within 
enzyme active sites, altering the electronic properties to allow characterization by 
conventional EPR and electronic absorption spectroscopy.
18–20
 Metal-nitrosyl complexes 
are generally described as {MNO}
n
, where n represents the sum of the metal d and NO 
π* electrons; Fe2+ bound NO is {Fe-NO}7.21 
 
Scheme 2.1: Proposed mechanism for coupling in FIH 
 Although gas binding is crucial to defining the chemistry in non heme enzymes, 
little geometrical data exists. We are aware of only one structure of NO bound to an 
Fe
2+/αKG-dependent oxygenase, clavaminate synthase (CAS).17 The structure of CAS 
with NO bound revealed a pseudo octahedral metal center with NO oriented above αKG 
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in the presence of substrate.
17
 DFT calculations in a related enzyme, taurine dioxygenase 
(TauD), indicate that NO preferentially adopts two conformations, one in which the O-
atom is directed towards αKG and another pointing over the active site carboxylate 
moeity.
16
 As only the conformation in which NO is oriented above αKG is expected to be 
reactive based on the consensus mechanism, factors governing the switch in NO 
orientation may be central to coupled turnover in αKG oxygenases.  
 Here we report our use of crystallography, electronic spectroscopy, and DFT 
calculations to investigate factors that lead to productive gas binding in FIH. CTAD 
binding, specifically the target residue (Asn
803
), was tested for its role in forming the 
proper gas binding geometry which leads to substrate hydroxylation. This is particularly 
important as evidence suggests that the gas binding geometry may be the fundamental 
process controlling turnover in the αKG-dependent oxygenases.  
2.2 Materials and Methods 
2.2.1 Protein Purification 
 Unless noted otherwise, all reagents were purchased and used as received from 
commercial vendors. FIH expression and purification was carried out as previously 
described.
14,22
 Briefly, the N-terminal His6 tagged protein was purified using a Ni-NTA 
column followed by removal of the tag via thrombin digestion. Exogenous metals were 
removed with EDTA treatment. FIH was further purified using size-exclusion 
chromatography to afford the active dimer. Protein concentrations were calculated by 
absorption spectroscopy (ɛ280 = 48800 M
-1 
cm
-1
).
22
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2.2.2 CTAD Purification 
 A 39 amino acid peptide substrate corresponding to the c- terminal transactivation 
domain of HIFα788-826 (CTAD) containing a Cys800 → Ala substitution with sequence 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN (Asn
803 
in bold) was 
ordered from EZBiolabs as a desalted synthetic peptide with free N and C termini. 
Another 39 residue peptide also with a Cys
800
 → Ala point mutation containing the target 
residue Asn
803
 → Ala point mutation with sequence 
DESGLPQLTSYDAEVAAPIQGSRNLLQGEELLRALDQVN (Ala
803 
in bold) was also 
ordered from EZBiolabs as a desalted peptide with free N and C termini. The peptides 
were dissolved in 25% acetonitrile and purified by reverse-phase HPLC as previously 
reported.
14
 After two rounds of purification, the samples were >95% pure as determined 
using matrix assisted laser desorption ionization mass spectrometry (MALDI-MS). The 
concentrations were established by measuring the UV-absorption at 293 nm in 0.1 M 
NaOH (ε = 2400 M-1 cm-1).22  
2.2.3 Crystallography and Data Refinement 
 Crystals of (Fe+NOG+NO)FIH were grown anaerobically using conditions 
similar to those previously reported in the literature.
23
 Crystals were grown in an 
anaerobic glovebox by the hanging drop vapor diffusion method by mixing 3 µL of a 20 
mg/ml protein solution containing 0.55 mM FeSO4, and 2mM αKG in 50 mM Hepes pH 
7.00 with 1 µL of the reservoir buffer containing 0.1 M Hepes, 1.2 M (NH4)2SO4, and 3 
% polyethylene glycol (PEG) 400, pH 7.50. After setting up trays, the nitric oxide donor, 
Diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEANO) was 
added only to the reservoir solution to facilitate NO release into the headspace during 
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crystallization. 100 µL of a 0.35 M stock of DEANO was added to the reservoir solutions 
(total volume = 500 µL), such that 70 mM DEANO was present, and the coverslips were 
quickly resealed. Crystals were allowed to grow in the glovebox at 23°C with NO filling 
the headspace in the wells. Yellow crystals grew within 4 days (Figure 2.8), at which 
time they were harvested on the bench top within 1 minute of the coverslip being flipped 
to minimize gas diffusion and flash frozen in reservoir solution containing 24% glycerol. 
Clear, colorless crystals of (Fe+αKG)FIH were grown anaerobically in the same fashion 
without the addition of DEANO to the reservoir solution. 
 Data was collected at the Advanced Photon Source facility in Chicago at 100 K 
using radiation of λ = 0.979 Å. 150 frames were collected at a crystal to detector distance 
of 345 mm with 1.5° oscillation and 1 second exposure per image for 
(Fe+NOG+NO)FIH. For (Fe+αKG)FIH, 150 frames were captured with 2° oscillations at 
a crystal to detector distance of 380 nm and 1 second exposure per image. The data sets 
were processed using iMOSFILM.
24
 Coordinates from PDB 3D8C
23
 were employed for 
molecular replacement using Phaser
25
 and the model building and refinement done using 
COOT
26
 and Refmac5
27
 in the CCP4
28
 software package. During refinement, 5% of the 
data was withheld and used to obtain an Rfree value. Data collection and crystallographic 
analysis statistics are reported in the supplementary material (Table 2.3). 
2.2.4 Electronic Absorption Spectroscopy 
 For anaerobic experiments, stocks of FIH, αKG, NOG, and Hepes buffer were 
sealed with rubber septa and degassed by using argon gas. FeSO4 was brought into the 
glovebox as a solid and prepared using degassed H2O while DEANO stocks were 
prepared in degassed 10 mM NaOH and the concentration verified by its published 
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extinction coefficient and characteristic UV absorbance at 250 nm (ɛ250 = 6500 M
-1
cm
-
1
).
29,30
 DEANO decomposes to form 1.5 equivalents of NO with a rate constant of 3.75 x 
10
-3
 ± 8 x 10
-5
 s
-1
 under our conditions (Figure S1). Anaerobic UV-Vis samples contained 
FIH (0.25 mM), FeSO4 (0.25 mM), αKG (0.5 mM), CTAD (0.5 mM) and DEANO (0.13 – 
2 mM) in 50mM Hepes pH 7.00. Samples were incubated in the glovebox at 23°C for 20 
minutes to permit NO release and binding. The samples were capped and then UV-Vis 
absorption spectra were collected immediately after removal from the glovebox on an HP 
8453 UV-Visible spectrophotometer from 300nm to 900nm in 1 cm path length quartz 
cuvettes. Data used to construct the binding isotherm is reported in the supplementary 
material (Figure 2.9). 
2.2.5 EPR Spectroscopy  
 Anaerobic EPR samples containing FIH (0.10 mM), FeSO4, (0.10 mM), αKG 
(0.50mM), CTAD (0.50 mM), Asn
803
 → Ala peptide (0.50 mM) and DEANO (0.50 mM) 
in 50 mM Hepes pH 7.00 were prepared and aged anaerobically at 23°C for 20 minutes. 
The samples were capped then flash frozen in liquid nitrogen (LN2) immediately upon 
removal from the glovebox. X-Band EPR data was collected using a Bruker Elexsys E-
500 EPR equipped with a DM4116 cavity and a Bruker ER 4118CF-O LHe/LN2 cryostat 
at 9.624 GHz frequency, 2.0mW power, 10G modulation amplitude, 100 GHz 
modulation frequency, 163 ms time constant at 4K.  
 The EPR data was analyzed by means of the standard spin Hamiltonian (HFe = 
β.B.g.S + S.D.S) where β is the Bohr magneton, B is the applied field, g is the electron 
Zeeman term, S is the electron spin operator, and D is the zero field splitting tensor. 
Simulations of the EPR spectra were calculated using the XSophe software package 
34 
 
version 1.1.14.
31
 As the S = 3/2 {FeNO}
7 spin is in the weak field limit (D>> hν), D was 
fixed at 10 cm
-1
, corresponding to the measured and calculated values of D for {FeNO}
7 
adducts of related enzymes 4-hydroxyphenylpyruvate dioxygenase (HPPD) and 
TauD.
15,16
  
2.2.6 DFT Calculations  
 Geometry optimizations were carried out on a truncated active site starting from 
the geometry of the crystal structure of FIH (PDB IH2L).
32
 Methyl imidazoles were used 
for His
199
 and His
279
, propionic acid for Asp
201, 2 oxopropionate for αKG, and Asn803 was 
truncated and contained a methyl group from the adjacent amino acid (Figure 2.6). The 
{Fe-NO}
7
 S = 3/2 spin state was generated using the spin-coupling scheme of a high spin 
Fe
3+
 (SFe = 5/2) antiferromagnetically coupled to two electrons from the NO
- 
 π* orbitals 
(SNO = 1) as this represents the proper electronic description of ferrous NO 
complexes.
15,19
 Using the geometry optimized structures, a rigid potential energy surface 
scan (B3LYP/6-311+g(2d,p)) was performed to investigate the energy barrier for rotating 
the bent NO ligand in the axial coordination position of FIH. The DFT calculations were 
completed with and without the target Asn
803
 residue in order to study the influence of 
the target residue on NO rotational barriers.  
2.3 Results 
2.3.1 Crystal Structure of FIH in Complex with Fe and NO 
 To gain insight into the changes in active site geometry upon O2 binding, we 
solved the crystal structures of (Fe+αKG)FIH and (Fe+NOG+NO)FIH. The structure of 
(Fe+αKG)FIH was refined to 2.4 Å with Rfactor = 20.0% and Rfree = 24.8% while the 
structure of the (Fe+NOG+NO)FIH complex was refined to 2.1 Å resolution (Rfactor = 
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19.0% and Rfree = 23.9%). The backbones were nearly identical when residues 9-349 
were aligned using PyMol (rmsd = 0.153 Å) (Figure 2.10). For both (Fe+αKG)FIH and 
(Fe+NOG+NO)FIH, the active site metal retained pseudo octahedral geometry and Fe
2+
 
was coordinated by His
199
, His
279
, Asp
201
 and αKG/NOG with the C1 carboxylate of 
αKG/NOG bound trans to His199 as previously reported for structures of (Fe+αKG)FIH33 
and (Fe+NOG)FIH.
32
  
 For (Fe+αKG)FIH, the 2Fo – Fc map displayed electron density at the 
coordination position trans to His
279
, indicating that the active site Fe of FIH was 6-
coordinate as previously suggested by spectroscopic studies on FIH
7
 and other Fe
2+/αKG 
oxygenases.
9,34
 The density was too small to accommodate a diatomic molecule such as 
O2 or two aquo ligands and refined best with one water molecule in this position (Figure 
2.1A). Previously reported structures of (Fe+αKG)FIH at resolutions of 2.84 Å and 2.4 Å 
contained unresolved density above the metal centers thought to be water molecules.
32,33
 
Although the resolution of our structure was also modest (2.4 Å), the aquo ligand was 
reasonably well ordered with a refined B-factor of 48.09 Å
2 
and a reasonable Fe-H2O 
bond length (2.0 Å). For comparison, the B-factors for the other atoms bonded to Fe 
were, 39.8 Å
2
, 39.8 Å
2
,
 
40 Å
2
,
 
34.2 Å
2
,
 
and 25.5 Å
2 
for His
279
, His
199
, O(C1αKG), O(C2αKG) 
and Asp
201
 respectively. 
 For (Fe+NOG+NO)FIH, the 2Fo – Fc map displayed electron density at the 
diffusible ligand site above the metal center which was approximately twice the density 
observed in the (Fe+αKG)FIH structure. This density was consistent with the presence of 
a diatomic molecule as a single water molecule did not adequately refine into the density. 
Additionally, the Fo(Fe+NOG+NO)FIH – Fo(Fe+αKG)FIH difference Fourier map also displayed 
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corresponding electron density at nearly the same site, the size and shape of which was 
consistent with a diatomic molecule (Figure 2.1C). We refined this as NO due to the size 
of the electron density, the spectroscopic data indicative of {FeNO}
7 
adduct formation, 
and the yellow crystals that formed.  
 
Figure 2.1: Structure of (Fe+αKG)FIH and (Fe+NOG+NO)FIH. Iron is shown in 
magenta, water in red. (A) View of the (Fe+αKG)FIH active site with the 2Fo – Fc map 
contoured to 1σ. (B) (Fe+NOG+NO)FIH active site and the 2Fo – Fc map contoured to 
1σ. (C) (Fe+NOG+NO)FIH active site with the Fo(Fe+NOG+NO)FIH – Fo(Fe+αKG)FIH map 
contoured to 1σ. (D) (Fe+NOG+NO)FIH active site measurements. PEG is colored 
yellow. 
  
 The active site metal was pseudo octahedral with NO bound at the axial ligand 
site trans to His
279
, displacing water (Figure 2.1B). The O-atom of NO pointed away 
from the distal O-atom of Asp
201
 and formed van der Waals interactions with a PEG 
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molecule at the active site (Figure 2.1D). This PEG molecule was present at nearly the 
same position in the (Fe+αKG)FIH structure. Although it cannot be interpreted from the 
density that NO ligated with the nitrogen atom, chemically, this is observed in model 
complexes and calculations.
15,16,35
 The Fe-N bond length (1.83 Å) and the Fe-N-O angle 
(132°) (Table 2.2), were within range of calculations and experimental data on Fe-N bond 
lengths (~1.70 Å – 1.88 Å) and Fe-N-O angles (~ 120° - 169°) of related enzymes and 
model complexes.
15–17,35–37
 The short Fe-NO bond length is attributed to a highly 
covalent Fe
3+
-NO
-
 bond resulting from strong orbital overlap due to charge donation from 
an NO
 σ* orbital to Fe3+.19 The B-factors for NO were 50.4 Å2 for the N atom and 67.1 Å2 
for the O atom, indicating that the N atom was reasonably well ordered while the O atom 
has some degree of mobility. The N atom of NO possessed a similar B-factor to that of 
the well-ordered N atoms on His
199
 (38.4 Å
2
)
 
and His
279
 (37.3 Å
2
) in the 
(Fe+NOG+NO)FIH structure, further supporting its location.  
2.3.2 Electronic Absorption Spectroscopy 
 As the crystallography offered direct evidence of NO binding to Fe
2+
 in FIH, we 
sought to investigate the effect of NO binding on the electronic environment. The 
interaction of NO with Fe
2+
 at the active site of non-heme enzymes is known to cause 
fairly weak (ɛ < 1000 M-1 cm-1) absorption bands near 440 nm and broad transitions 
between 500 – 700 nm, arising from limited NO π* donor interaction into the Fe t2g 
orbtals.
19,20,38
  
 Addition of DEANO to (Fe+αKG)FIH led to a bright yellow solution with the 
expected electronic absorption bands (Figure 2.2) for {FeNO}
7
 non-heme iron 
centers.
15,18,20,38,39
 Upon addition of CTAD, the spectra increased in intensity, suggesting 
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either tighter gas binding as proposed by the consensus mechanism or a geometric change 
resulting in stronger orbital overlap. Recent computational work indicates that these 
transitions are formally spin-forbidden
15
 leading to the relatively small extinction 
coefficients. 
 
Figure 2.2: Electronic absorption spectra of FIH. FIH (250 µM), FeSO4 (250 µM), αKG 
(500 µM), DEANO (2 mM) and CTAD or CTADN803A (500 µM) at 23°C in anaerobic 
Hepes (50 mM pH 7.00). 
 
 To test the effect of CTAD binding on the NO affinity of FIH, a binding isotherm 
was measured upon individual addition of aged [DEANO] to premixed samples (Figure 
2.9).  The dissociation constant (KD) for NO was obtained by fitting ΔA440 vs. [NO] to a 
saturation curve (equation 1) similar to previously reported for related extradiol 
dioxygenases
39
 and phenylalanine hydroxylase
20
 in which Amax represents the A440 at 
saturation. 
        𝛥𝐴 =
𝐴𝑚𝑎𝑥∗[𝑁𝑂]
𝐾𝐷+[𝑁𝑂]
    (1) 
 The samples were aged for 20 minutes (~7 half-lives) to allow NO release and 
binding, by which point the absorbance had ceased increasing. The NO affinity of 
(Fe+αKG)FIH (KD(NO) = 331 ± 24 μM) was moderate, and increased slightly for 
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(Fe+αKG)FIH/CTAD (KD(NO) = 203 ± 13 μM) (Table 2.1), suggesting that the gas 
binding pocket is only modestly influenced by CTAD such that substrate binding does 
not significantly promote gas binding. This is consistent with observations of a mixture of 
5/6 C Fe in the presence of CTAD.
7
 In other αKG dependent enzymes, a much more 
noteworthy increase in NO affinity ranging from 5 fold to 2 orders of magnitude was 
observed in the presence of substrate.
20,39
 
 
Figure 2.3: Binding isotherm of (Fe+NO+αKG)FIH, (Fe+NO+αKG)FIH/N803A and 
(Fe+NO+αKG)FIH/CTAD. FIH (0.25 mM), FeSO4 (0.24 mM), αKG (0.5 mM), CTAD 
(0.5 mM), N803A (0.5 mM) and DEANO (.013 - 2 mM). 
 
 To test if the steric and polar contacts created by CTAD binding promote gas 
binding, we measured the KD(NO) using a mutant substrate containing an Asn
803Ala 
point mutation (N803A). For the (Fe+αKG+NO)FIH/N803A complex, the KD(NO) = 300 
± 28 μM (Table 2.1), similar to the affinity for NO in the absence of CTAD (Figure 2.3). 
FIH has comparable affinities for CTAD (KD = 80 µM) and N803A (KD = 180 µM),
8
 and 
using the method of Ramirez et al.,
40
 we calculated that FIH was ~84% bound with 
CTAD and ~70% bound with the N803A substrate, signifying a modest contribution 
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from the substrate affinities on the gas binding affinity. This suggests that the steric 
environment produced by the Asn
803
 target residue modestly influences gas binding. A 
computational study on FIH suggested that the sterics of Asn
803 
help stimulate aquo 
release from the diffusible ligand site.
7
 
2.3.3 Electron Paramagnetic Resonance Spectroscopy 
 To gain further insight into the geometry and electronic environment of the metal 
center, electron paramagnetic resonance (EPR) spectroscopy measurements were made 
after the addition of NO to samples of FIH. The electronic fine structure of {Fe-NO}
7
 is a 
sensitive reporter of minor geometric changes in the {Fe-NO}
7
 moeity.
15,19,39,41–43
 For an 
axial spin system (E/D ~ 0), the S =3/2 Ms = ± 3/2 and ±1/2 Kramers doublets are split by 
2D; however, due to the large zero field splitting, the EPR signal arises solely from the 
lower Ms = ±1/2 doublet with a positive D.
19
 As such, the effective g values are observed 
at gx ≈ gy ≈ 4 and gz = 2.
19,39
 In light of the modest increase in NO affinity in the presence 
of CTAD, we tested the impact of CTAD binding on the geometry of the {Fe-NO}
7
 
moiety in FIH. Addition of NO to (Fe)FIH produced a yellow color and complex EPR 
line-shape near g = 4 (Figure 4), and an S = 5/2 line-shape arising from oxidation of Fe
2+
 
to Fe
3+
 as seen for related S = 3/2 {Fe-NO}
7
 sites.
15,19,20,38,39
  
 The EPR spectra of the (Fe+NO)FIH and (Fe+αKG+NO)FIH complex were 
nearly identical, implying that the geometry about the {Fe-NO}
7
 moiety was similar 
(Figure 2.4A). The spectra of (Fe+NO)FIH displayed an axial S = 3/2 line-shape with geff  
= 4.10, 3.93 (E/D = 0.014)  (Figure 4). The holo FIH spectrum for the (Fe+αKG+NO)FIH 
sample also displayed a similar line-shape for the S = 3/2 species with geff = 4.11, 3.92 
(E/D = 0.016) (Figure 2.4A). Notably, addition of CTAD containing the Asn
803
 target 
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residue led to the appearance of a new axial line-shape with geff = 4.06, 4.00 (E/D = 
0.005) (Figure 2.4A), along with the species observed in the CTAD free complex. The 
change in line-shape is indicative of a change in gas binding geometry, likely due to a 
rotational change as Solomon et al showed experimentally and computationally that the 
Fe-N-O bond length and angle do not change to any appreciable degree in the presence of 
substrate for related enzyme HPPD.
15
 This new axial line-shape corresponds to the active 
enzyme complex as CTAD containing the proper target residue was bound. With the 
addition of N803A substrate, there was no change in the gas binding environment from 
that of holo FIH as the sample (E/D = 0.014, geff = 4.10, 3.93) displayed no perturbation 
in the electronic fine structure (Figure 2.4A). 
 
Figure 2.4: Experimental and simulated X-Band EPR spectra of {FeNO}
7
 FIH 
complexes: (A) (Fe+αKG+NO)FIH/CTAD (B) (Fe+αKG+NO)FIH/N803A (C) 
(Fe+αKG+NO)FIH (D) (Fe+NO)FIH. FIH (0.10mM) , FeSO4 (0.10mM), αKG 
(0.50mM),  CTAD (0.50mM), N803A (0.50mM), DEANO (0.50 mM), 9.624 GHz 
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frequency, 2.0mW power, 10G modulation amplitude, 100 GHz modulation frequency, 
163 ms time constant, 4K. (*) = Fe
3+
 with geff  = 4.30, 4.25, present for all spectra 
 
 We simulated the three different species present in the spectra of the 
(Fe+NO+αKG)FIH/CTAD complex (Figure 2.4B) using XSophe.31 A summary of the 
simulation parameters and experimental geff values is shown in Table 1. The sum of the 
simulations overlaid well with the experimental spectra (Figure 4A), and showed that the 
spectra of Fe+αKG+NO)FIH/CTAD consisted of two S = 3/2 species and one S = 5/2 
species (Figure 2.4B). By comparing the experimental and simulated spectra, we 
observed that the more axial S =3/2 signal with E/D = 0.005 is unique to CTAD bound 
FIH in which the proper target residue is present as the N803A substrate did not exhibit 
this line-shape.  
Table 2.1: Summary of EPR Data and NO Dissociation Constants 
                                           experimental                      simulation parameters 
sample KD(NO) (µM) geff (gx, gy)   g tensors (gx,y, gz)    E/D 
(Fe+NO+αKG)FIH/CTAD 203 ± 13 4.06, 4.00 
4.13, 3.91 
2.015, 2.00 
2.015, 2.00 
0.005 
0.017 
(Fe+NO+αKG)FIH/N803A 300 ± 28 4.10, 3.93 2.010, 2.00 0.014 
(Fe+NO+αKG)FIH 331 ± 24 4.11, 3.92 2.010, 2.00 0.016 
(Fe+NO) FIH ND 4.10, 3.93 2.010, 2.00 0.014 
 
2.3.4 DFT Calculations of FIH-{Fe-NO}
7
 
 CTAD binding led to a new EPR line-shape which suggested that the geometry of 
the {Fe-NO}
7
 moiety changed. As O2 would have to be oriented over the C2 keto group 
to facilitate oxidative decarboxylation, we reasoned that CTAD binding, specifically 
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Asn
803
, imposed steric constraints that changed the Fe-NO geometry to support oxidative 
decarboxylation. To gain further insight into the geometry of the {Fe-NO}
7 
moiety, we 
used DFT calculations to test the effect of CTAD-Asn
803
 sidechain on the Fe-NO 
geometry.  
 Coordinates for the 2-His 1-Carboxylate active site containing Fe
2+, αKG, and 
Asn
803
 were generated from the crystal structure of CTAD bound FIH (PDB IH2L).
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Calculations employed a formal high spin Fe
3+
 (S = 5/2) antiferromagnetically coupled to 
NO
- 
  (S = 1).
15,16,19
 Following geometry optimization, a reference position defined by the 
Fe-N-O-C2(αKG) vector was chosen with the Fe-N bond defining the z-axis, and NO was 
rotated around the equatorial plane along the Fe-N bond.  
 Two well-defined minima were found for (Fe+αKG+NO)FIH that were nearly 
isoenergetic but differed in the orientation of NO with respect to αKG (Figure 2.5). In 
orientation A, NO was positioned near the C1 carboxylate group of αKG. Orientation B, 
which was ~ 4.5 kJ/mol more stable, depicted NO pointing away from the distal O atom 
of Asp
201 between the π-acceptor groups of His199 and the C2 keto of αKG, as expected 
for {Fe-NO}
7 
complexes (Figure 2.6).
16
 This further supported the crystallographic 
refinement as the orientation in which NO faced away from the distal O atom of Asp
201
 
(orientation B), represented the global minimum and was the same orientation seen in the 
(Fe+NOG+NO)FIH crystal structure. The calculated Fe-N bond length was 2.29 Å and 
the Fe-N-O angle was 146° (Table 2.2). These results were in agreement with 
calculations of TauD-{Fe-NO}
7
.
16
 Two well-defined minima were also observed in the 
TauD-{Fe-NO}
7 
complex with one orientation of NO positioned above the protein 
carboxylate ligand and another orientation that was ~5.4 kJ/mol more stable showing NO 
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oriented above αKG.16 Electron spin echo envelope modulation experiments (ESEEM) 
were integrated with crystallographic studies to model NO in TauD, corroborating the 
orientation of NO above αKG near the C1 π-acceptor group with an estimated Fe-N bond 
of 1.98 Å and an Fe-NO angle of 122°.
44,45
  
 
Figure 2.5: Rigid scanned potential energy surface for rotation about the Fe-NO axis in 
the FIH-{FeNO}
7 
complex (inside) schematic diagram showing the relative orientations 
of NO with respect to the C2 carbon of αKG. Minima are denoted with letters. 
 
 In the presence of Asn
803
, a single energy minimum was found (orientation C) 
(Figure 2.5), representing a conformation in which NO was oriented towards the C1 
carboxylate of αKG (Figure 2.6), in agreement with the crystal structure of NO bound to 
CAS. The dihedral angle in orientation C (55°) was nearly the same as that of orientation 
A (56°). Although the Fe-N-O angle in the presence of Asn
803
 (143°), was nearly 
identical to that found in the absence of Asn
803
 (146°), there was a large energetic barrier 
to rotation imposed by Asn
803
. The presence of Asn
803
 led to a 4 fold higher energetic 
barrier than that of the facial triad aspartic acid (Figure 2.5).  
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Figure 2.6: Optimized geometries of A, B, and C used in DFT calculations as models for 
FIH-{Fe-NO}
7
 
 
 The geometry changed from pseudo octahedral (Fe+αKG+NO)FIH to distorted 
octahedral for (Fe+αKG+NO)FIH/Asn803. The Fe-N bond length shortened from 2.29 Å 
in the absence of Asn
803
 to 1.85 Å in the presence of Asn
803
. In addition, the Fe-His
279
, 
Fe-His
199
, and Fe-O(C2αKG) bonds lengthened from 2.08 Å, 2.12 Å, and 2.17 Å to 2.24 Å, 
2.23 Å, and 2.35 Å respectively (Table 2). As a result of Asn
803
 being positioned above 
Asp
201
 and His
199
, bound NO was pushed away from Asn
803
 and the N(NO) – Fe – N(His199) 
and N(NO) – Fe – O(Asp201) angles increased from 93 and 87 to 102 and 100 respectively, 
placing the uncoordinated O atom of NO 0.5 Å closer to the equatorial ligands (Table 
2.2). The presence of Asn
803 
caused NO to be pushed towards the equatorial ligand 
without altering the Fe-N-O angle when compared to the position in the absence of 
Asn
803
. This suggests that the steric environment created by the target residue plays a 
significant role in directing O2 for nucleophilic attack on the keto position by placing 
bound gas closer to the equatorial ligands.   
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Table 2.2: Comparison of Calculated and Experimental Geometric Parameters for FIH-{Fe-
NO}
7 
and related enzymes 
 FIH
a
 B
b
 C
c
 CAS
d
 HPPD
e
 TauD
f
 
ΔE(rotation) (kJ/mol)  34 147   9.4
 f
 
Fe – N (Å) 1.83 2.29 1.85 1.79 1.76 1.88f (1.98) g 
N – O (Å) 1.20 1.43 1.17 1.16 1.17 1.17f (1.19)g 
Fe – N – O (deg) 133 146 143 146 149 144f (122)g 
│Fe – N – O – C2(αKG) (deg)│ 34.4 74 55 6.4   
Fe – O(C1-O αKG) (Å) 2.02 2.13 2.01 2.01  2.06
f
 
Fe – O(C2=O αKG) (Å) 2.15 2.17 2.35 2.27  2.37
f
 
Fe – N(His199) (Å) 2.03 2.12 2.23 2.10   
Fe – N(His279) (Å) 2.00 2.08 2.24 2.23   
Fe – O(Asp201) (Å) 2.04 2.05 1.98 2.06   
O(NO) – C2(αKG) (Å) 3.88 4.16 3.50 2.85   
N(NO) – Fe – N(His199) (deg) 91 93 102 93   
N(NO) – Fe – O(Asp201) (deg) 75 87 100 99   
a 
Measured from the Fe+NOG+NO)FIH structure. 
b 
FIH-{FeNO}
7
 orientation B 
c 
FIH-
{FeNO}
7
 orientation C. 
d 
Measured from PDB: 1GVG (reference 17). Values given 
correspond to residues in the same position as those for FIH. 
e
Taken from reference 15. 
f 
Taken from reference 16. 
g 
Taken from reference 45 based on ESEEM data. 
 
2.4 Discussion 
 A number of mechanistic and spectroscopic studies have been undertaken to study 
coupling in αKG-dependent enzymes,12,16,46–52 as uncoupled chemistry typically leads to 
loss of function.
47,53
 Understanding factors governing O2 binding and reactivity are key to 
understanding the function of the Fe
2+/αKG-dependent oxygenases as these factors 
ensure that ferryl formation leads to substrate hydroxylation. A comprehension of factors 
governing O2 reactivity may also provide novel targeting strategies for the αKG 
oxygenases. In light of the fact that primary substrate does not ligate directly to Fe
2+
,
 
and 
the observation that the second coordination sphere residues greatly influence 
reactivity,
14,54
 it suggests that changes in steric and non-covalent interactions formed as a 
result of substrate binding stimulate O2 binding and reactivity. The present study 
integrated spectroscopic, computational, and crystallographic analysis to test the effect of 
the target residue of FIH on gas binding geometry. Our structure of (Fe+NOG+NO)FIH 
47 
 
offers the first direct insight into the O2 binding geometry in the hypoxia sensing enzyme 
FIH. Our data suggests that Asn
803
 plays a pivotal role in directing O2 reactivity by 
providing steric constraints which orients O2 productively for oxidative decarboxylation, 
resulting in coupled turnover. 
2.4.1 CTAD Binding has a Modest Effect on Gas Affinity 
 Spectroscopic studies on non-heme iron enzymes have revealed that the Fe
2+
 
center typically converts from a 6C geometry to a 5C geometry upon substrate 
binding,
34,55
 implying that access to a coordination site stimulates O2 reactivity. For FIH, 
a mixture of 5C and 6C geometries were observed,
7
 indicating that other structural factors 
may engender reactivity. In related enzymes, the coordinative switch leads to a large 
increase in NO binding affinity. For example, phenylalanine hydroxylase exhibits nearly 
a 5 fold increase in gas binding affinity (KD(NO) = 31 µM) while protocatechuate 4,5-
dioxygenase has a 2 orders of magnitude increase in NO affinity upon substrate binding 
(KD(NO) = 3 μM).
20,39
 Compared to related enzymes, FIH has a weak gas binding affinity 
as the affinity for NO increased only ~ 1.5 fold upon CTAD binding (KD(NO) = 203 µM), 
indicating that CTAD binding modestly induces gas binding. Mutation of Asn
803
 → Ala 
had minimal effect on gas binding (KD(NO) = 300 μM) and the NO affinity was similar to 
that of CTAD free FIH (KD(NO) = 331 μM), suggesting that the local environment was not 
responsive to the shortened target residue.   
 The weak binding of NO to FIH is congruent with the reported KM(O2) being on 
the higher end of bioavailable O2 (KM(O2)  = 90-150 µM).
56
 Along with earlier 
spectroscopic and mechanistic studies,
7,12
 our observations are consistent with the 
catalytic cycle of FIH being in accord with the proposed consensus mechanism for non-
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heme O2 activating enzymes, however the coordinative switch is not the dominant model 
to explain the increased O2 reactivity in FIH as O2 binding is not gated by CTAD binding.  
2.4.2 CTAD Binding Introduces Steric Barriers that Reorient Gas for Productive 
Reaction 
 The rhombicity for (Fe+αKG+NO)FIH decreases from E/D = 0.016 to E/D = 
0.005 upon binding CTAD. As the E/D ratio reflects the difference in π-symmetry 
interactions between the Fe dxy and dyz orbitals and the π-acceptor orbitals on the His
199
 
and αKG ligands, we attribute the decreased rhombicity to a stronger π-symmetry overlap 
with the αKG ligand due to rotation about the Fe-N-O-keto dihedral angle. As O2 attacks 
the keto position during turnover, such a geometric change would facilitate O2 activation 
by lining up the gas with the keto position. Calculations in TauD demonstrated that NO 
orients towards the π-acceptor (C=O) groups of the equatorial ligands,16 and calculations 
on FIH suggest that CTAD binding enhances H-bond contacts to αKG that lower the 
carbonyl LUMO, activating it for nucleophilic attack.
7
  This suggests that productive gas 
binding in FIH, and other αKG oxygenases is favored when primary substrate is bound.  
 We propose that the more rhombic S=3/2 species (E/D = 0.016) represents a 6C 
Fe
2+
 center in which NO is bound in a less reactive orientation. The change to a more 
axial (activated) electronic fine structure is likely due to rotation about the Fe-NO bond 
axis as a result of CTAD binding. DFT calculations suggest that NO adopts at least 2 
conformations in αKG oxygenases,16 and the “activated” conformer gives rise to the more 
axial (E/D = 0.005) S = 3/2 line-shape.  A similar interpretation was applied to 
Protocatechuate 4,5-dioxygenase and catechol 2,3-dioxygenase where protein 
conformational changes as a result of pH variations resulted in multiple S = 3/2 species.
39
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 As the EPR line-shape is unchanged with addition of the Asn
803
 → Ala substrate, 
it suggests that the geometry at the active site is unperturbed and gas binding is 
unproductive without Asn
803
 providing the proper steric constraints. The CTAD bound 
form of the enzyme is the active enzyme complex, implying that the new axial electronic 
line-shape produced by CTAD binding represents an active site environment “activated” 
for chemistry to occur. Notably, FIH fails to hydroxylate the CTAD-Asn
803
 → Ala 
substrate, but hydroxylates CTAD containing the proper target residue (Asn
803
) with kcat 
= 31 min
-1
 and KM(CTAD) = 77 μM.
8,14
 Hence, the gas binding site is not created by CTAD 
binding, but it is influenced by it such that the presence of Asn
803 
directs O2 activation, 
leading to coupled turnover. Such a mechanism provides rationale for the ordering of the 
reaction in FIH suggested by steady state kinetics.
12
 
 We note the presence of an S = 5/2 electronic fine structure in the EPR spectra 
with geff = 4.30, 4.25, which arises from formation of an S = 5/2 Fe
3+
 species. In the 
absence of NO, (Fe+αKG)FIH generates an S = 5/2 EPR spectra with geff = 4.30, 4.25, 
suggesting that the S = 5/2 signal is due to a protein centered oxidation. The sum of the 
simulated EPR spectra was comprised of 10% S = 5/2 (E/D = 0.32), 75% S = 3/2 (E/D = 
0.005) and 15% S = 3/2 (E/D = 0.017). Similarly, it was found that the S = 5/2 species in 
protocatechuate 4,5-dioxygenase accounted for 3% – 25% of the total Fe content in the 
{FeNO}
7
 adduct.
41
  
 Further support for a reorientation of NO upon CTAD binding comes from our 
observation of increased intensity in the UV-Vis spectra for CTAD bound FIH. The 
charge transfer intensity is dependent on the ligand-metal overlap.
19
 For a linear binding 
mode, the charge transfer transitions are predicted to be nearly degenerate, but for a bent 
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binding mode, the charger transfer intensities are ordered as follows: NO
-
 in-plane 2π* → 
Fe
 
dx
2
 – y
2 
< NO
-
 in-plane 2π* → Fe dxz < NO
-
 out-of-plane π* → Fe dyz.
19
 The weak 
transitions are within reason based on electronic structure calculations of {FeNO}
7
 
adducts (ɛ < 1000 M-1 cm-1), and suggest a limited π donor interaction into the Fe d 
orbitals.
19
 We propose that NO primarily interacts with the Fe dxy orbitals in the absence 
of CTAD,
19,20
 but in the presence of CTAD containing Asn
803
, bound NO rotates to 
produce new ligand-metal overlap with the Fe dyz orbital, giving rise to a more intense 
charge transfer. If O2 were bound, stronger orbital overlap would result in a stronger Fe-
O2 bond, polarizing the bound O2 and giving the distal O-atom more nucleophilic 
character. Our calculations suggest that CTAD binding strengthens the Fe-N bond as the 
bond length shortened in the presence of Asn
803
. 
 Our calculations lend further credence to the bond axis rotation model as NO 
adopts a more stable orientation in the presence of CTAD that is different than the most 
stable orientation in the absence of CTAD. The Fe-N-O angle (~144°) in the presence or 
absence of CTAD remained relatively unchanged and are comparable to previous 
calculations of TauD and HPPD,
15,16
 indicating that the multiple EPR line-shapes 
observed are not due to changes in the Fe-N-O bond angle, but rather a change in NO 
orientation.  
 Combined with the EPR data which shows a unique electronic environment 
forming when the proper steric constraints are present, and the crystallographic data 
which depicts the NO orientation in the absence of CTAD, the calculations support a 
model in which productive gas binding is stimulated by substrate binding. When CTAD 
containing Asn
803
 binds, the expected changes in the gas geometry would be (i) bound 
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gas bends closer to the equatorial ligands (αKG) (ii) the gas rotates over αKG, and (iii) 
the gas bond becomes polarized such that the uncoordinated O atom gains more 
nucleophilic character, enhancing reactivity.  
2.4.3 The Gas Binding Pocket of FIH 
 The active site of FIH was conserved between the (Fe+αKG)FIH and 
(Fe+NOG+NO)FIH structures. There was a PEG molecule above the NO ligand that 
interacted with NO via van der Waals interactions. As the active site of FIH is solvent 
exposed, the presence of PEG, an artifact from the crystallization buffer, suggests that 
FIH prefers to have peptide like constructs bound above the metal center. There was also 
a water molecule above NO that likely plays a stabilizing role and “locks” bound gas in 
this orientation. The energetic penalty to reorientation is approximately equal to the bond 
dissociation energy to break H-bonds, which is 23 kJ/mol per H-bond.
57
 The structure of 
FIH/CTAD shows that the target asparagine residue occupies nearly the same space 
occupied by PEG and the water molecule,
32
 suggesting that CTAD removes stabilizing 
contacts to the bound ligand. These alterations likely trigger a rotation to a productive 
conformation for nucleophilic attack on the keto position of αKG. Similarly, slight shifts 
in nearby residues accommodated substrate and NO binding in the oxygen binding cavity 
in the extradiol dioxygenase BphC.
36
  
 Two well defined energy minima that differed in energy by ~ 4.5 kJ/mol were 
observed in the absence of Asn
803
. Despite the small difference in energy only the most 
stable conformer (orientation B) was observed in the crystal structure of 
(Fe+NOG+NO)FIH. It’s possible that the difference in energy stabilizes B enough such 
that it is the only conformation observed crystallographically. In the proposed consensus 
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mechanism, nucleophilic attack on the C2 keto group of αKG initiates decarboxylation, 
leading to formation of the ferryl oxidant.
2
 In order for nucleophilic attack to commence, 
O2 has to be in close proximity to the C2 keto position. The distance from the O atom of 
NO to the C2 of NOG was ~ 3.6 Å. We interpret this orientation of NO to represent 
unproductive gas binding as the substrate is not present, and NO is not ideally positioned 
for oxidative decarboxylation. Support for this orientation being unproductive comes 
from observations that uncoupled chemistry in the absence of prime substrate occurs at a 
slow rate.
58
 Uncoupled chemistry has been reported to be a slow process in TauD as 
well.
53
  
 As the most accessible site in the gas binding pocket rests directly over αKG and 
the gas binding affinity was modestly influenced by CTAD binding, it suggests that steric 
occlusion of NO due to the presence of Asn
803
 plays a more dominant role in directing O2 
reactivity than increased gas binding affinity. The EPR line-shape for the Asn
803 → 
Ala 
point mutation implied a malformed gas binding pocket owing to improper steric 
constraints, indicating that Asn
803
 is the major factor influencing gas orientation. FIH 
hydroxylates CTAD-Asn
803
 with kcat = 31 min
-1 
but fails to hydroxylate the CTAD-
N803A substrate,
8,14
 implying that reorientation to the proper geometry greatly stimulates 
O2 reactivity.   
 Interestingly, the calculated orientation in the presence of Asn
803
 appeared to be 
non-optimal for nucleophilic attack as it was 3.5 Å from the C2 keto group of αKG and 
the dihedral angle to the C2 carbon was 55°. However, the barrier to rotation over the C2 
carbon of αKG was minimal, ~ 10 kJ/mol. In the structure of CAS with NO bound, NO 
was poised over αKG and was in a fairly optimal geometry for nucleophilic attack as the 
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NO to C2 carbon of αKG was 2.85 Å and the dihedral angle to the C2 carbon was 6.4°, 
suggesting productive gas binding in the presence of substrate.
17
 The moderately high B-
factor (~60 Å
2
) for the distal O atom of NO in FIH suggests that it has some degree of 
mobility.  
 Our calculations showed that in the presence of Asn
803
, NO adopted a 
conformation in which it was positioned near the C1 π-acceptor group of αKG, consistent 
with the observed orientation of NO in substrate bound CAS,
17
 suggesting that this 
orientation may depict the lowest energy state in the αKG-dependent oxygenases upon 
substrate binding. Paradoxically, NO binding to Fe
2+
 in CAS displaced the bound aquo 
ligand concomitant with rearrangement of the C1 carboxylate of αKG to the position 
previously occupied by water, suggesting that ferryl formation would be incorrectly 
positioned for substrate oxidation.
17
 Despite this implication, NO was oriented towards 
αKG as if poised to initiate nucleophilic attack, supporting the notion that altered local 
contacts which result from substrate binding help direct productive gas binding. It is 
possible that the ferryl may rearrange in CAS but at present there is no evidence to 
support this. In contrast to CAS, NO binding in FIH displaced water at the diffusible 
ligand site, leading to a geometry in which ferryl formation would be positioned 
appropriately for coupled substrate oxidation. Unfortunately, we were unable to obtain a 
crystal of NO bound in the presence of CTAD that diffracted well, therefore it is unclear 
if such a rearrangement also occurs in FIH, but our DFT calculations and those of related 
enzymes suggests that a rearrangement is unlikely.
16
      
 In the case of FIH, CTAD binding imposes steric constraints on NO which would 
be minimized by NO rotating away from His
199
 towards the most stable orientation 
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observed in our calculations. This path poses the least barrier to rotation, but importantly, 
CTAD binding causes stronger orbital overlap, making the distal O-atom of NO more 
nucleophilic and the carbonyl carbon of αKG more electrophilic.7,19 NO, which is angled 
closer to the equatorial plane, encounters the C2 keto π acceptor group during rotation 
before any other π acceptor groups.  
 Taken together, the crystal structure of the CAS-{Fe-NO}
7 
complex and 
calculations of the TauD-{Fe-NO}
7 
complex suggest that gas reorientation may be a 
general mechanistic strategy employed by the αKG-dependent oxygenases whereby 
substrate binding stimulates O2 reactivity thereby ensuring tight coupling to substrate 
oxidation. Although speculative, if we consider the ratio (~ 6) of the mole fraction of the 
unproductive to productive orientations based on their relative energies, multiplied by the 
~ 2 fold increase in gas binding affinity, CTAD binding could account for approximately 
a 12 fold increase in O2 reactivity. 
2.5 Conclusion  
 In summation, we have provided evidence that suggests the coordinative switch 
model is not the dominant model to explain increased O2 reactivity in FIH.  NO is able to 
access the active site of FIH, however, the orientation, which is stabilized by a network of 
H-bonds, is non-optimal for decarboxylation. Based on our data, we propose that CTAD 
binding stimulates O2 reactivity via rotation about the Fe-O2 bond axis, thereby 
positioning “activated” O2 over the keto position of αKG for oxidative decarboxylation. 
The sterics of the target residue and changes in local contacts are important for forming 
the proper gas binding pocket which leads to coupled turnover. Substrate induced rotation 
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about the Fe-O2 moiety may be a strategy utilized by the broader class of αKG 
oxygenases to facilitate O2 reactivity. 
2.6 Appendix 
 
2.6.1 Supplemental 
2.6.2 DEANO Decomposition in 50 mM Hepes pH 7.00 
 The rate of DEANO decomposition to form NO in 50 mM Hepes pH 7.00 was 
determined in accordance with a previously described method.
59
  Hepes was degasses by 
bubbling argon gas through the solution before use in the glovebox. DEANO was 
prepared in 10 mM NaOH and 2.6 µL of a 15.4 mM stock was added to 197.4 µL of 50 
mM Hepes pH 7.00. The cuvette was capped and the disappearance at 250 nm was 
monitored at 23°C on an HP 845x UV-Visible spectrophotometer for 20 minutes. Under 
our conditions, the rate of NO release followed first order exponential decay kinetics with 
time (Figure S1). The rate constant (k = 3.75 x 10
-3 
± 8.46 x 10
-5
 s
-1
) was determined from 
the average of 5 runs. The half-life (3 mins) was calculated using the relationship: t1/2 = 
0.693(1/k) as previously described.
30
  
 
Figure 2.7: Example of the first order decay plot used to calculate the rate of DEANO 
decomposition in 50 mM Hepes pH 7.00 at 23°C. 
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Figure 2.8: Crystal of (Fe+NOG+NO)FIH grown in the presence of DEANO used for 
data collection 
 
Table 2.3: Data collection and refinement statistics. Values in parentheses represent the 
highest resolution shell 
Data set (Fe
2++αKG)FIH (Fe2++NOG+NO)FIH 
λ (Å) 0.979 0.979 
Space group P41212 P41212 
Unit cell (Å) a = b = 86.6, c = 147.2 
α = β = γ = 90° 
a = b = 86.6, c = 147.7 
α = β = γ = 90° 
Resolution (Å) 74 – 2.42 (2.51 – 2.42) 61 – 2.1 (2.17 – 2.1) 
Rmerge (%) 13.9 (121) 9.7 (109) 
Rpim (%) 3 (29) 2.5 (36.9) 
Mean I/σ (I) 18.2 (2.9) 16 (1.9) 
Completeness 100 (100) 99.6 (96.8) 
Multiplicity 22 (18.6) 15.9 (13.6) 
Refinement   
Resolution range (Å) 74 – 2.42 61 – 2.1 
Number of Reflections 22043 33489 
Average B factor (Å
2
) 55 54.05 
Rwork/Rfree  (%) 20.0/24.8 19.0/23.9 
R.m.s deviations   
Bond lengths (Å) 0.015 0.020 
Bond angles (Å) 1.73 1.91 
Ramachandran plot, 
residues in (%) 
  
Preferred region 94.40 94.4 
Allowed region 5.60 5.60 
Disallowed region 0 0 
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Figure 2.9: UV-Vis data used to construct binding isotherm (top left) 
(Fe+NO+αKG)FIH/CTAD (top right) (Fe+NO+αKG)FIH (bottom left) 
(Fe+αKG+NO)FIH/N803A: FIH (0.25 mM), αKG (0.50 mM), FeSO4 (0.25 mM), CTAD 
(0.50 mM), N803A (0.50 mM), DEANO (0.015 – 2 mM),) in 50 mM Hepes pH 7.00 at 
23°C 
 
 
Figure 2.10: Structure of (Fe+αKG)FIH and (Fe+NOG+NO)FIH. Overlay of 
(Fe+αKG)FIH (green) and (Fe+NOG+NO)FIH (cyan) showing the conserved β-strand 
jelly roll core.  
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CHAPTER 3 
CONTRIBUTIONS OF THE FACIAL TRIAD CARBOXYLATE TO LIGAND 
ACCESS IN FACTOR INHIBITING HIF (FIH) 
3.1 Introduction 
The Fe
2+/αKG-dependent oxygenases are a functionally diverse family of 
enzymes that catalyze a wide array of chemical transformations, including epoxidation, 
chlorination, desaturation, and most commonly, hydroxylation.
1–3
 These enzymes 
typically functionalize unactivated aliphatic carbons, a major hurdle in synthetic 
chemistry that still remains elusive to chemists. It has been shown that the chlorinating 
enzyme, SyrB2, can also catalyze bromination,
4
 hydroxylation,
5
 and more recently 
azidation and nitration chemistry,
6
 suggesting that these enzymes can be engineered to 
catalyze alternative reactions.  
Factor inhibiting HIF (FIH), is an O2 sensing Fe
2+/αKG-dependent enzyme that, 
under normoxic conditions, catalyzes the hydroxylation of an asparagine residue (N803) 
in the Hypoxia Inducible Factor (HIF) transcription activator, thereby repressing HIF 
gene expression. Installing functional groups on specific aliphatic carbons, especially 
during late stages of a synthetic sequence, is a challenging task. As the natural substrate 
for FIH is a peptide, FIH is an attractive target for redesigning alternative chemistry. 
Elucidating factors that control ligand access to the Fe cofactor is the first step in 
understanding how to engender FIH with alternative chemistry such as azidation, which 
could open novel avenues for “biorthogonal” conjugation chemistry.  
 The active site of the Fe
2+/αKG-dependent enzymes is comprised of a highly 
conserved motif known as the 2-His-1-carboxylate facial triad motif.
7–9
 The facial triad 
provides three protein derived ligands for iron binding while the other coordination sites 
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are occupied by αKG in a bidentate fashion, and a water molecule at the diffusible ligand 
site (Figure 3.1).
10–13
 A subset of the Fe
2+/αKG-dependent enzymes that catalyze 
halogenation chemistry have evolved to bind the Fe cofactor with only two protein 
derived His residues, and a halide ion in place of the carboxylate ligand.
14,15
 FIH affords 
a unique opportunity to understand how the protein active site differentiates between 
halides and other ligands as it was recently demonstrated to be active with a mutated 
facial triad carboxylate.
16
 
The consensus mechanism for Fe
2+/αKG-dependent oxygenases involves the 
sequential binding of αKG, prime substrate, then O2.
2
 A combination of crystallography 
and VTVH MCD and CD spectroscopy have shown that substrate binding leads to 
release of the aquo ligand in the axial coordination site, permitting O2 binding.
10,11,17–19
 
Oxidative decarboxylation of αKG to succinate releases CO2 and generates a reactive 
ferryl intermediate, which has been observed in the halogenases CytC3
20
 and SyrB2,
21
 
and the hydroxylases prolyl hydroxylase 4 (PH4)
22
 and taurine dioxygenase (TauD),
22,23
 
and identified as the species responsible for hydrogen atom transfer (HAT). Following 
HAT, radical rebound chemistry leads to the desired chemical product. For halogenases, 
halogen rebound chemistry ensues while hydroxide rebound occurs in the hydroxylases 
such as FIH.  
A key feature of the consensus mechanism is that substrate binding stimulates O2 
binding and reactivity, ensuring formation of the reactive ferryl intermediate is tightly 
coupled to substrate modification. The crystal structures of (Fe+αKG)FIH reveal that the 
active site is solvent exposed (Figure 3.1), and when primary substrate (CTAD) binds, 
there is a channel that opens up at the diffusible ligand site.
11
 As the active site is solvent 
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exposed, the Fe cofactor would be susceptible to binding by endogenously produced 
molecules that are similar to O2, such as NO, and CO, suggesting that mechanisms may 
exist to differentiate between different ligands.  In the structures where the aquo ligand is 
resolved, the uncoordinated O-atom hydrogen bonds (H-bonds) to the coordinated water, 
and forms new H-bond contacts to the backbone amide of CTAD upon substrate binding 
(Figure 3.1).
11,13
 Recent studies have suggested that the facial triad carboxylate plays a 
role in stabilizing the axial aquo ligand at the diffusible ligand site, implicating this 
residue in controlling ligand access.
19
  
 
 
Figure 3.1: Surface representation of FIH in the absence of substrate showing the 
solvent exposed active site. PDB IDs: 1H2N
11
, 3P3P
13
, 1H2L
11
. 
 
We reasoned that the facial triad carboxylate regulates the access of exogenous 
ligands, and disruption of the H-bond to the axial aquo ligand would facilitate exogenous 
ligand access to the Fe cofactor. In the present work, the facial triad carboxylate of FIH 
(Asp
201
) was mutated to Glu (D201E) and Gly (D201G) in order to study the effect of the 
facial triad carboxylate in ligand access. Our data indicates that exogenous ligands are 
able to access the active site of FIH in the D201E and D201G variants, but not WT-FIH. 
This data implicates the facial triad carboxylate in controlling ligand access, and suggests 
that FIH can be engineered for alternate rebound chemistry.  
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3.2 Materials and Methods 
3.2.1 Protein Mutagenesis and Purification 
Site-direct mutagenesis was carried out to insert point mutations in the pET28a-
FIH construct. The following primers were used to construct the desired mutations: 
Asp
201Gly forward, 5’-GTGACACCTGCTCACTATGGCGAGCAGCAGAAC-3’; 
reverse, 5’-GTTCTGCTGCTCGCCATAGTGAGCAGGTGTCAC-3’; Asp201Glu 
forward, 5’-GACACCTGCTCACTATGAGGAGCAGCAGAACTTTTTT-3’; reverse, 
5’-AAAAAAGTTCTGCTGCTCCTCATAGTGAGCAGGTGTC-3’.  The final 
constructs were sequenced by Genewiz to confirm that only the desired mutations were 
present before transforming into BL21(DE3) cells.  WT-FIH and the variants were 
expressed and purified according to a previously described protocol.
24
 The N-terminal 
His6 tagged WT-FIH and variants were purified using a Ni-NTA column. The His6 tag 
was removed by thrombin digestion and the eluents were treated with EDTA to remove 
exogenous metals, then further purified using size-exclusion chromatography to yield the 
active dimer ˃95% pure as assessed by SDS-PAGE. The cleaved protein contained 3 
extra residues (GSH) at the N-terminus. Protein concentrations were determined by 
absorption spectroscopy (ɛ280 = 48800 M
-1 
cm
-1
).
24,25
 
3.2.2 CTAD Purification 
A 19 residue amino acid peptide substrate corresponding to the C- terminal 
transactivation domain (CTAD19mer) of HIFα
788-807
 containing a Cys
800
 → Ala mutation 
with sequence DESGLPQLTSYDAEVNAPI (N803 bolded) was ordered from EZBiolabs 
as a desalted synthetic peptide with free N and C-termini and used as received without 
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further purification for co-crystallization studies. For steady state kinetics, a 39 amino 
acid peptide of HIFα788-826 also containing a Cys800 → Ala mutation with sequence 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN (N803 bolded) was 
ordered from EZBiolabs as a desalted synthetic peptide with free N and C-termini. The 
39-residue peptide was dissolved in 25% acetonitrile and purified to >95% purity by 
reverse-phase HPLC as previously described
24,25
 The concentration was established by 
measuring the UV-absorption at 293 nm in 0.1 M NaOH (ε = 2400 M-1 cm-1).24 
3.2.3 Crystallography   
Crystallization of (Fe+NOG+Cl
-
)D201G/CTAD19mer was carried out as previously 
described in the literature with slight modifications.
16
 Crystals were grown aerobically by 
the hanging drop vapor diffusion method by mixing 2 µL of a 20 mg/ml protein solution 
containing 0.55 mM FeSO4, 2mM NOG, and 2 mM CTAD19mer in 50 mM Hepes pH 7.00 
(100 mM NaCl) with 1 µL of the reservoir buffer containing 0.1 M Hepes, 1.2 M 
(NH4)2SO4, and 3 % polyethylene glycol (PEG) 400, pH 7.50. The crystals were grown at 
20°C and were harvested after 9 days and flash frozen in a cryoprotectant comprised of 
the reservoir solution containing 24% glycerol.  
The data was collected at the Brookhaven National Synchrotron Radiation facility 
in New York using radiation of  λ = 1.08 Å. 120 frames were collected at a crystal to 
detector distance of 300 mm with 1° oscillation and 3 second exposure per image. The 
data set was processed using HKL2000.
26
 Coordinates from PDB 3D8C
16
 were used for 
molecular replacement and the refinement completed using COOT
27
 and Refmac5
28
 in 
the CCP4
29
 software package. 5% of the data was withheld during refinement and used to 
obtain an Rfree value.  
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3.2.4 UV-Vis Spectroscopy 
All reagents were degassed using argon gas and brought into an anaerobic 
glovebox except for FeSO4 and DEANO which were brought in as solids and dissolved in 
degassed water and 10 mM NaOH respectively. The ligands were also brought in as 
solids and dissolved in buffer. Samples contained FIH (400 µM) or the variants D201E 
(400 µM) and D201G (400 µM), αKG (400 µM), FeSO4 (375 µM), and 2 mM of each 
respective ligand (NO, NaCN, NaN3
-
, NaCO3, NaOCN
-
, NaSCN, NaC2H3O2) in 50 mM 
Hepes pH 7.00 containing 100 mM NaCl. Each ligand was added to an individual sample 
of (Fe+αKG)Protein and the spectra were collected from 300 – 900 nm on an Avantes 
AvaSpec-2084 Fiber Optic Spectrometer set up in a glovebox. Difference spectra were 
generated from subtracting the respective (Fe)Protein only spectrum from each respective 
(Fe+αKG)Protein and (Fe+αKG+Ligand)Protein spectrum.  
3.2.5 Initial Screen and Dose Response Assays 
All reactions were performed under ambient O2 (~220 μM) conditions.
30 For 
initial screens, reactions containing ascorbate (2 mM), FeSO4 (25 µM), αKG (100 µM), 
and CTAD (100 µM), were pre-incubated for 1 minute with each ligand, which were 
present at 2 mM concentrations except for CO (750 µM) in 50 mM Hepes (100 mM 
NaCl) pH 7.00 at 37°C. Reactions were initiated by adding either FIH (0.5 µM), D201G 
(2.2 µM), or D201E (5 µM). 5 μL aliquots of the reaction were quenched after 2 minutes 
in 20μL of 75% acetonitrile with 0.2% trifluoroacetic acid saturated with the matrix, 3,5 
Dimethoxy-4-hydroxycinnamic acid. Hydroxylation was monitored by determining the 
mole fraction of peptide converted to product based on measuring the ratio of the un-
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hydroxylated peptide (M+H)+, m/z = 4255) and hydroxylated peptide (m/z = 4271) using 
MALDI-MS as previously described.24,31 
Dose response assays were carried out in a similar manner according to previous 
reports from the literature.31  Assays were carried out in 50 mM Hepes containing NaCl 
(100 mM), ascorbate (2 mM), FeSO4 (25 µM), αKG (100 µM), CTAD (100 µM), and 
NaN3
- (0 – 5 mM). The NO donor DEANO was prepared anaerobically in 10 mM NaOH 
and the extinction coefficient verified by its characteristic UV absorption at 250 nm (ɛ250 
= 6500 M-1cm-1).32 Individual aliquots of DEANO were opened right before addition to 
the reaction mixtures. DEANO releases 1.5 moles of NO per mole of DEANO with a rate 
constant of k = 9.77 x 10-3 s-1 37°C (t1/2 = 1.2 minutes) at 37°C pH 7.00, such that our 
concentration of NO ranged from 0 – 0.8 mM. Aliquots (5 μL) of the reaction were 
quenched in 20μL of 75% acetonitrile with 0.2% trifluoroacetic acid at designated time 
points. Initial rates were determined by calculating the χ(CTAD
OH
) = {I(CTAD
OH
) / (I(CTAD
OH
) + 
I(CTAD))} * [CTAD].
31
 
3.2.6 X-ray absorption spectroscopy sample preparation 
The XAS sample was prepared anaerobically in a glovebox by mixing 4 mM 
D201G with 6 mM FeSO4 in 50 mM Hepes pH 7.00 containing 100 mM NaCl. The 
sample was concentrated using a 30 kDa molecular weight cutoff filter to remove 
unbound metal. The concentration was verified and NOG was added such that the final 
concentrations were 4.3 mM D201G, 5 mM NOG, 100 mM NaCl, in 50 mM Hepes pH 
7.00. The sample was immediately flash frozen in liquid N2 upon removal from the 
glovebox and stored at -80°C until analysis. ICP measurements were made on the protein 
sample and showed that the concentration of Fe was 1.5 mM. 
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3.2.7 X-ray absorption spectroscopy data collection and analysis 
Iron K-edge data were collected at Stanford Synchrotron Radiation Lightsource 
(SSRL) beamline 7-3 with ring conditions of 3 GeV and 495 – 500 mA.  Dedicated 
beamline optics for 7-3 was used, including a Si (220) double crystal monochromator 
with a rhodium-coated mirror upstream for focusing and harmonic rejection.  The sample 
was cooled to ~10K during data collection with a liquid helium cryostat (Oxford 
Instruments).  X-ray fluorescence was collected with a 30-element germanium detector 
(Canberra) and scattering was minimized with a 3mm Mn filter and Sӧller slits placed in-
between the sample chamber and the detector.  An X-ray transmission spectrum of a 
reference Fe foil was collected concurrently with fluorescence data and used for 
calibrating the K-edge energy of each spectrum.   
X-ray absorption near edge structure (XANES) was analyzed by EXAFS123.
33
 as 
previously described.
34
  A cubic function was used to fit the baseline at the pre-edge 
region and the rising edge was fitted using a 75% Gaussian and 25% Lorenzian function.  
A Gaussian function was used to fit the transitions occurring below the edge (pre-edge), 
where the area of the Gussians were taken to be peak areas.  The position of the K-edge 
energy (E0) of the spectra is deduced from the first derivative of the XAS spectra. 
Data processing and background subtraction was performed using ATHENA
35
 
software using IFEFFIT.
36
  Bad detector channels were removed from each scan, and the 
K-edge energy was calibrated to the first inflection point of Fe reference foil (7112.5 eV).   
Background removal and normalization was performed using the Autobk algorithm
35
 
with E0 set to 7125 eV and Rbkg set to 1.0 with a k-weight of 3.  A linear pre-edge range 
of -150 to -30 eV and a quadratic polynomial post-edge of 150 to 900 eV relative to E0 
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was used with the edge jump normalized to 1.  Data extraction was performed using a 
spline k range of 2 to 14 Å
-1
. 
EXAFS fitting was performed using ARTEMIS
35
 software using the IFEFFIT 
engine.
36,33
  First shell scattering paths were generated for reff of Fe-N at 2.0 Å, Fe-S at 
2.2 Å, and Fe-Cl at 2.3 Å using FEFF6.  Multiple-scattering paths for Fe-imidazoles were 
generated using metal-histidine coordinates from a high resolution protein crystal 
structure (PDB ID 1Q5Y)
37
 using FEFF6.  Multiple-scattering paths for Fe-NOG were 
generated from metal-NOG coordinates from the protein crystal structure (PDB ID 
4V2W)
38
 using FEFF6.  The k
3
-weighted r-space data over a k-range of 2 – 14 Å-1 was 
fitted.  The amplitude reduction factor, S0
2
 was set to 0.9 and the E0 was allow to vary for 
each model.  For each single scattering path or set of multiple scattering paths that 
describe a ligand (imidazole or NOG), the distance between Fe and the scattering atom 
and the σ2 was allowed to vary. 
Goodness of fit was compared between different models by minimizing three 
parameters: χ2 (Equation 1), reduced χ2, and R factor (Equation 2). 
𝜒2 =  
𝑁𝑖𝑑𝑝
𝑁ɛ2
 ∑ {(𝑅𝑒(𝑓𝑖))
2}𝑁𝑖=1   (1) 
 
𝑅 =  
∑ {(𝑅𝑒(𝑓𝑖))
2+(lm(𝑓𝑖))
2}𝑁𝑖=1
∑ {(𝑅𝑒(𝜒𝑑𝑎𝑡𝑎𝑖))
2+(lm(𝜒𝑑𝑎𝑡𝑎𝑖))
2}𝑁𝑖=1
   (2) 
 
Where Nidp is the number of independent points; Nϵ
2
 is the number of uncertainties to 
minimize; Re(fi) is the real part of the EXAFS fitting function; Im(fi) is the imaginary 
part of the EXAFS fitting function. Reduced χ2 = χ2/(Nind Nvarys) (where Nvarys = the 
number of refining parameters) and represents the degrees of freedom in the fit.  
Increasing the number of adjustable parameters in the fit are expected to improve R, but 
reduced χ2 will go through a minimum with the increase indicating the model is 
73 
 
overfitting the data.  The best fit models were deduced by minimizing both R and reduced 
χ2 and deviation of σ2 values from typical values. 
3.3 Results 
The D201E and D201G variants of FIH were purified for steady state kinetic 
assays aimed at testing the role of the facial triad carboxylate in ligand access. A previous 
study demonstrated that the D201G had wild type like activity while the D201A and 
D201E variants exhibited significant uncoupling.
16
 The crystal structure of 
(Zn+αKG)D201G/CTAD revealed that in the absence of the coordinated carboxylate 
ligand, a water molecule was bound in the equatorial plane at the site normally ligated by 
D201.
16
 A carbonate ion was bound in a bidentate fashion near this position in the 
structure of (Fe+αKG)D201A structure,16 suggesting that D201 may regulate exogenous 
ligand binding to the Fe cofactor. We previously found that chloride was necessary for 
hydroxylation chemistry in D201G (Hangasky unpublished results), implying that 
chloride and other exogenous ligands may interact with the Fe cofactor in D201G.  
3.3.1 Initial Screen and Dose Response Assays 
To test the role of D201 in facilitating exogenous ligand access, we performed an 
initial activity screen in the presence of 2 mM exogenous ligands under ambient [O2] 
(~217 µM) and saturating concentrations of FeSO4 (25 µM), αKG (500 µM), ascorbate (2 
mM) and chloride (100 mM) in 50 mM Hepes pH 7.00. In contrast to WT-FIH which was 
only inhibited by NO, D201G and D201E were both inhibited by NO and azide (N3
-
) 
(Figure 3.2). NO is commonly used as an O2 mimic and is known to bind to non heme O2 
activating Fe
2+/αKG-dependent enzymes.39–42 N3
- 
has also been demonstrated to bind to 
the non heme Fe center of the chlorinating enzyme SyrB2.
6
 Although cyanide (CN
-
) 
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seemed to be a modest inhibitor in the initial screen, changes in the UV absorption 
spectrum after incubating (Fe+αKG)FIH with CN- led to the conclusion that ferricyanide 
formation caused metal sequestration, inhibiting activity. Interestingly, cyanate (OCN
-
) 
was an activator of D201G activity, suggesting that it interacted with the Fe cofactor and 
served as a counter ion in the same capacity as the missing carboxylate ligand.  
 
 
Figure 3.2: Initial inhibitor screen for FIH (top left) and the facial triad D201E (top right) 
and D201G (bottom) variants. Assays were performed in 50 mM Hepes pH 7.00 
containing 100 mM NaCl at 37°C; FIH (0.5 µM), D201G (2.2 µM), D201E (5 µM), αKG 
(500 μM), FeSO4 (25 μM), CTAD (100 μM), ascorbate (2 mM).  All inhibitors were 2 
mM except for CO which was 750 µM. 
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As the screen identified NO and N3
-
 as ligands that significantly inhibited WT-
FIH and the D201 variants, a full dose response curve was measured in order to 
determine the IC50 for both NO and N3
-
. Inhibition by NO was greatest for D201E (IC50 = 
4 µM), followed by D201G (IC50 = 22 µM) and then WT (IC50 = 65 µM) (Table 3.1), 
suggesting that disruption of the stabilizing metal-aquo H-bond relaxed ligand selectivity. 
NO has previously been demonstrated to inhibit the other hypoxia sensing enzyme prolyl 
hydroxylase domain 2 (PHD2) with IC50 = 10 µM.
43
 NO has also been shown to inhibit 
FIH activity in cells.
44
 N3
-
 significantly inhibited D201G activity (IC50 = 130 µM) 
compared to WT, and moderately inhibited D201E activity (IC50 = 280 µM) compared to 
WT (Figure 3.3 and Table 3.1).  
 
 
Figure 3.3: Dose response assays varying NO (left) and N3
-
 (right) for FIH and the 
D201E and D201G variants. Assays were performed in 50 mM Hepes pH 7.00 containing 
100 mM NaCl at 37°C; FIH (0.5 µM), D201G (2.2 µM), D201E (5 µM), αKG (500 μM), 
FeSO4 (25 μM), CTAD (100 μM), ascorbate (2 mM), NO (0 – 0.8 mM), and N3
-
 (0 – 5 
mM). 
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3.3.2 UV-Vis Absorption Spectroscopy 
To test for binding of exogenous ligands to the Fe cofactor, UV-Vis absorption 
spectra were measured in the presence of 2 mM concentrations of the ligands (NO, OCN
-
, 
and N3
-
) identified from the kinetic assays that affected FIH activity. Both the robustness 
and versatility of using spectral features to assess ligand binding has been well 
established.
6,45,46
 Bidentate chelation of αKG in the αKG-dependent enzymes leads to a 
metal to ligand charge transfer (MLCT) typically centered around 500 nm, attributed to 
transitions from the Fe t2g(π) → αKG π* orbitals.
40,46
 (Fe+αKG)FIH exhibited the 
characteristic MLCT for αKG-dependent oxygenases previously observed in FIH47 
centered at 500 nm (Figure 4.4D), indicative of αKG binding to Fe2+ at the active site. 
(Fe+αKG)D201E exhibited the same MLCT as WT-FIH centered at 500 nm (Figure 
4.4C), but (Fe+αKG)D201G exhibited a blue shifted MLCT centered at 485 nm (Figure 
4.4B), suggesting stabilization of the Fe t2g orbitals. The extinction coefficient (~ 200 M
-
1
cm
-1
)  of the MLCT for WT-FIH and the variants were similar to a previous report for 
(Fe+αKG)FIH (~ 240 M-1cm-1)47 and (Fe+αKG)TauD (~ 250 M-1cm-1).48  
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Figure 3.4: Anaerobic UV-Vis spectra showing the MLCT for WT-FIH and the D201 
variants in 50 mM Hepes pH 7.00 (100 mM NaCl). (A) WT-FIH, D20E, and D201G 
treated with NO. (B)  D201G treated with N3
-
 and OCN
-
. (C) D201E treated with N3
-
. (D) 
WT-FIH treated with N3
-
 and OCN
-
. FIH (400 µM), D201E (400 µM), D201G (400 µM), 
FeSO4 (375 µM), αKG (400 µM), NO (2 mM), OCN- ( 2mM), N3
-
 (2mM). 
 
Binding of NO to Fe
2+
 in non heme enzymes typically leads to an intense 
transition around 440 nm and a broad transition from 550 – 700 nm.39,40,49 The transitions 
are ligand to metal charge transfers (LMCT) arising from electronic transitions between 
the NO π* and Fe t2g orbitals.
41
 The spectrum of (Fe+αKG+NO)FIH exhibited a well-
defined peak at 450 nm and a broad transition from 550 – 700 nm as seen for related 
enzymes (Figure 4.4A).
39,40
 (Fe+αKG+NO)D201E also had a strong transition centered at 
450 nm and a broad transition from 550 – 700 nm while (Fe+αKG+NO)D201G displayed 
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a strong transition centered at 435 nm and a broad transition from 550 – 700 nm, 
indicative of NO binding to Fe
2+ 
in FIH and the variants. The intensity of the transition 
near 440 nm followed the same trend as the inhibition observed for NO, D201E > D201G 
> WT-FIH.  
Binding of N3
-
 to (Fe+αKG)D201G and (Fe+αKG)D201E resulted in a 15 nm 
(λmax = 500 nm) and 10 nm (λmax = 500 nm) red shift respectively (Table 3.1), consistent 
with observations of a red shift for N3
-
 and OCN
-
 binding to Fe
2+
 in (Fe+αKG)SyrB2.6 
Similarly, binding of OCN
-
 to (Fe+αKG)D201G (λmax = 500 nm) also led to a 15 nm red 
shift. The red shifts in the MLCT transitions can be attributed to destabilization of the Fe 
t2g orbitals or stabilization of the ligand π* orbitals upon binding. We did not observe any 
spectral perturbations in WT-FIH in the presence of N3
-
 or OCN
-
, consistent with the 
kinetic data which suggested N3
-
 and OCN
-
 are unable to bind the Fe cofactor to inhibit 
activity.  
 
Table 3.1: Summary of IC50 and electronic absorption spectroscopy data 
IC50 (µM)  MLCT and LMCT λ (nm) 
WT D201G D201E Ligand WT D201G D201E 
- - - αKG 500 485 500 
65 ± 11 22 ± 2.0 4.0 ± 0.4 NO 450, 550-700 430, 550-700 450, 550-700 
> 2 mM 130 ± 15 280 ± 20 N3
-
 500 500 510 
- - - OCN
-
 500 500 - 
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3.3.3 Crystal Structure of (Fe+NOG+Cl)D201G 
To gain insight into the metal geometry and examine the mode of interaction with 
the metal environment, crystallographic analysis was performed. Attempts were made to 
crystallize D201G in the presence of N3
-
, OCN
-
, and Cl
-
 but unfortunately we were 
unable to get well diffracting crystals of D201G in the presence of OCN
-
 and N3
-
. 
Crystals were grown by the hanging drop vapor diffusion method in the presence of Fe
2+
, 
N-oxalylglycine (NOG), 100 mM NaCl, and a 19 residue CTAD peptide corresponding 
to HIFα788-807, similar to previously described.11,16 NOG is a substrate analogue for αKG 
that binds in the same manner but inhibits chemistry,
11
 hence, it was used to avoid 
aberrant decarboxylation, which occurs ~ 6 fold faster in D201G compared to WT,
16
 
yielding succinate and CO2.  
The structure of (Zn+αKG)D201G/CTAD was previously reported,16 and revealed 
that the Zn center was 5 coordinate with a  water molecule bound trans to the keto group 
of αKG at the carboxylate binding site (Figure 3.6A). Overall, our structure of 
(Fe+NOG)D201G/CTAD was very similar to the structure of (Zn+αKG)D201G/CTAD 
with a rmsd = 0.184 Å when the backbones (residues 9 – 349 ) were aligned using 
PyMoL, however, significant difference were observed at the active site. The structure of 
(Fe+NOG)D201G/CTAD had unresolved density above the metal center and in the 
equatorial plane. The density was first modeled with two water molecules which resulted 
in significant positive density remaining post refinement, suggesting that water was not 
the correct model. We then tried one chloride at the carboxylate binding site and one 
water in the axial coordination position, as observed for the active site of SyrB2.
15
 The 
refinement indicated that chloride was an appropriate ligand but the axial site was still not 
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consistent with water as there was significant positive density observed. Next, chloride 
was placed in the axial position and water in the equatorial position. The refinement 
indicated that the model was consistent with chloride at the diffusible ligand site but 
water was insufficient to account for the electron density at the carboxylate binding site.  
 
Figure 3.5: Crystal structure of (Fe+NOG+Cl)D201G. (A) The active site 2Fo – Fc map 
contoured to 1σ. (B) Active site of D201G showing the metal chloride bond lengths. (C) 
The 2Fo – Fc map contoured to 1σ showing the second coordination sphere residues that 
help position the target residue. (D) D201G active site second coordination sphere 
distances to N803 
 
In the structure of (Fe+αKG)D201A, there was similar density above the metal 
center that was modelled with carbonate, assumed to result from oxidative 
decarboxylation during crystallization as D201A consumes αKG ~ 10 fold faster than 
WT-FIH.
16
 Although we did not anticipate carbonate formation due to the use of NOG, 
we modeled the density with carbonate and observed that it refined well, but carbonate 
was bound asymmetrically in a bidentate fashion with unrealistic metal-ligand bond 
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lengths. The bond length was 1.80 Å for the O-atom near the axial position and 2.01 Å 
for the O-atom near the equatorial site, which does not compare well to the 2.4 Å (axial) 
and 2.6 Å (equatorial) Fe – O bond lengths for the carbonate ligand in the structure of 
D201A.
16
  
The density refined best with two chlorides (Figure 3.5A), one at the carboxylate 
binding site as seen in SyrB2
15
 with a Fe – Cl bond length of 2.2 Å and another in the 
axial coordination position with a Fe – Cl bond length of 2.5 Å (Figure 3.5B). The Fe – 
Cl bond length of 2.2 Å agrees well with the average Fe – Cl bond (2.2 Å – 2.3  Å) 
observed for 6-cordinate Fe
2+
 model complexes.
50
 The Fe – Cl bond length of 2.5 Å is 
slightly longer than the average Fe – Cl bond in model complexes but was similar to the 
Fe – Cl bond (2.5 Å) in SyrB 2 (Figure 3.6D).15,50 An overlay of (Fe+αKG+Cl)SyrB2 and 
(Fe+NOG+Cl)D201G/CTAD showed that the equatorial chloride ligands were in nearly 
the same position (Figure 3.6E). In SyrB2, there was a water molecule above the 
coordinated chloride which was within H-bonding distance to the coordinated axial aquo 
ligand (Figure 3.6D). This water molecule likely helps stabilize bound water in a similar 
fashion to the uncoordinated O-atom of the carboxylate residue in FIH and related 
enzymes. The axially ligated chloride in our structure was close to the position of the 
uncoordinated water molecule in SyrB2 (Figure 3.6E). Similarly, the structure of 
(Zn+αKG)D201G/CTAD overlaid well with the structure of SyrB2 (Figure 3.6F) and 
showed that the equatorial aquo ligand in (Zn+αKG)D201G/CTAD was bound close to 
the Cl binding site in SyrB2 (Figure 3.6F). It appears that loss of the facial triad 
carboxylate opens a coordination site for other ligands to bind in the equatorial plane. 
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Figure 3.6: Structure of (Fe+NOG+Cl)D201G (green), (Zn+αKG)D201G (cyan), and 
(Fe+αKG+Cl)SyrB2 (white). (A) (Zn+αKG)D201G active site distances. (B) Comparison 
of (Zn+αKG)D201G (cyan) and (Fe+NOG+Cl)D201G (green). (C) Alternate view of 
(Zn+αKG)D201G (cyan) and (Fe+NOG+Cl)D201G (green) overlaid. (D) 
(Fe+αKG+Cl)SyrB2 active site distances. (E) Overlay of (Fe+αKG+Cl)SyrB2 (white) 
and (Fe+NOG+Cl)D201G (green). The Fe and Cl
-
 for SyrB2 are colored grey and green 
respectively and the Fe and Cl
-
 for D201G are colored magenta and yellow respectively. 
Waters are colored red (F) Overlay of (Fe+αKG+Cl)SyrB2 (white) and (Zn+αKG)D201G 
(cyan). The Fe and Cl
-
 for SyrB2 are colored grey and green respectively and the Zn for 
D201G is colored light grey. Waters are colored red and the ones derived from SyrB2 are 
labelled. 
 
A major difference that existed between the structure of (Zn+αKG)D201G/CTAD 
and our structure of (Fe+NOG+Cl)D201G/CTAD was the position of the target residue 
(N803) and residues that help position the target residue (Q239 and R238) for chemistry 
(Figure 3.6B). 
51,52
 Q239 formed a salt bridge with the target residue and R238 was H-
bonded to the sidechain O-atom of N803 in the structure of (Zn+αKG)D201G/CTAD, as 
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seen for WT-FIH (Figure 3.6A).
16,53
 In the structure of (Fe+αKG+Cl)D201G, the target 
residue was shifted towards αKG, causing N803 to be out of optimal H-bonding distance 
with Q239 and R238 (Figure 3.5D). R238 and Q239 were best refined when split 
between two conformations, consistent with greater mobility as a result of the target 
residue being shifted (Figure 3.5C). With respect to the position of N803 in the 
(Zn+αKG)D201G/CTAD structure, the Cα, Cβ, Cγ, and amine nitrogen were shifted 
towards NOG by 1.0 Å, 1.5 Å, 2.2 Å and 3.0 Å respectively in the 
(Fe+NOG+Cl)D201G/CTAD structure, suggesting that chloride may play a role in 
positioning N803 for hydroxide rebound chemistry (Figure 3.6B).  
When overlaid, the positions of the Cl
-
 in the Fe-D201G structure and H2O in the 
Zn-D201G structure were ~ 4 Å from the Cα of G201, similar to the distance of the Cl
-
 
ion in SyrB2 to the Cβ methyl group of A118 (~ 4 Å) (Figure 3.6C and D). Thus, it 
appears that in the absence of the carboxylate ligand, the active site of FIH provides 
enough room for exogenous ligands such as Cl
-
 to bind. All other Fe – ligand bonds 
lengths were typical of Fe
2+/αKG dependent enzymes and were all within 0.1 Å of each 
other for corresponding ligands in the (Fe+αKG+Cl)SyrB2, (Fe+NOG+Cl)D201G and 
(Zn+αKG)D201G structures.  
3.3.4 X-Ray absorption spectroscopy (XAS) 
 To further characterize the metal geometry, Fe K-edge XAS measurements were 
performed on a sample of (Fe+NOG+Cl)D201G in 50 mM Hepes pH 7.00 (100 mM 
NaCl). Analysis of the XANES pre-edge features provides information on the geometry 
and coordination number of metal complexes. Although the transition is spin forbidden, 
Fe
2+
 has vacancies in the 3d manifold, resulting in 1s → 3d electronic transitions that 
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give rise to the pre-edge features, which are sensitive to the geometric structure of the Fe 
center. The peak area of the pre-edge provides a measure of centrosymmetricity. Larger 
peak areas are associated with noncentrosymmetric geometries such as square pyramidal 
or distorted octahedral and small peak areas are observed for a centrosymmetric geometry 
such as octahedral.
54–56
  
The XANES spectrum (Figure 3.7) exhibited an observable 1s → 3d pre-edge 
peak at ~ 7113 eV. The peak areas for octahedral geometries range from (3 – 7) x 10-2 
eV.
57
 The peak area (0.12(4) eV) for (Fe+NOG+Cl)D201G was fairly large in 
comparison to the expected area for octahedral geometry, consistent with a 
noncentrosymmetric environment. This peak area was similar to the peak area (0.12(9) 
eV) of a square pyramidal ferrous model complex comprised of 4 N ligands and 1 Cl 
ligand.
55
 The large peak area can also be an indication of a 6 coordinate geometry that 
deviates from ideal octahedral geometry.
55
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Figure 3.7: Fe K-edge XANES spectrum of (Fe+NOG+Cl)D201G in 50mM Hepes pH 
7.00. 
The EXAFS region provides information on the coordination number (± 20%), 
ligand identities (Z ± 1), as well as the ligand distance from the metal center. The best 
EXAFS fit (Table 3.2 and Figure 3.8) obtained consisted of three N/O donor ligands, one 
of which was an imidazole, one chloride, and one NOG fit as a unit to represent bidentate 
coordination through the O-atoms. The EXAFS analysis suggested a distorted octahedral 
geometry, which is consistent with the XANES analysis and the crystallographic data. 
The three N/O donor bond lengths were 2.11(1) Å and the Cl
-
 bond length was 2.51(3) Å, 
in agreement with the long Fe-Cl bond (2.5 Å) found in the crystal structure. NOG was 
modelled as a bidentate ligand and the Fe-O bond lengths were 1.89(1) Å and 1.99(1) Å, 
which deviate from the Fe-O bond lengths found for αKG (2.03 Å and 2.24 Å) 
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coordinated to Fe in PHD2,
58
 and the Fe-O bonds for NOG (2.06 Å and 2.24 Å) in our 
crystal structure of Fe-D201G. The Fe-Cl bond was also longer than observed for Fe-Cl 
bonds in model complexes (~2.3 Å),
50
 but the three N/O bond lengths were in agreement 
with typical bond lengths of N/O donors of αKG dependent enzymes.  
The EXAFS region was difficult to fit owing to the heterogeneity in the sample. 
Previous XANES analysis on PHD2 revealed that there was a mix of 5/6 coordinate Fe.
58
 
Our best EXAFS fits indicated a distorted octahedral geometry, in agreement with the 
large pre-edge peak in the XANES spectrum and a noncentrosymmetric geometry. The 
best fits are the ones that yield lower R-factor and reduced χ2 values. Several fits were 
tried and based on R-factor and reduced χ2, the overall best fit suggested a model 
consisting of 3 N/O donors, 1.75 Cl, and NOG (Table 3.4 and Figure 3.9). This would 
result in a 7 coordinate Fe center which is unlikely, but suggests there is significant 
disorder at the metal center, and a second chloride may be near the Fe site. As all the best 
fits obtained involved chloride in the model (summarized in Table 3.5), it strongly 
suggests that chloride was bound to the Fe cofactor.  
Table 3.2: EXAFS Analysis of (Fe+NOG+Cl)D201G 
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 Reduced χ2 
3N/O 2.11(1) 1(1) 
0(1) 0.0900 1976.10 126.35 
(1 Imidazole)     
1Cl 2.51(3) 7(3) 
1NOG-O1 1.89(1) 
0(1) 
1NOG-O2 1.99(1) 
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Figure 3.8: EXAFS analysis of (Fe+NOG+Cl)D201G in 50mM Hepes pH 7.00. Fourier 
transform (FT) XAS data with data in black and fit in red (see fit details in Table 3.2). 
Inset: Unfiltered k
3
-weighted EXAFS spectra for the fit (red) and data (black).  Fits were 
performed in r-space (Δk=2 – 14Å-1; Δk=1 – 4.0Å) as described in materials and 
methods. 
 
3.4 Discussion 
The 2-His 1-carboxylate facial triad is a defining structural motif in the 
Fe
2+/αKG-dependent enzymes. The αKG-dependent halogenases coordinate Fe with only 
two protein derived His residues, and bind a chloride ligand in place of the facial triad 
carboxylate,
14,15
 suggesting that loss of the facial triad carboxylate permits binding of 
exogenous ligands to the Fe cofactor. In the consensus mechanism of αKG-dependent 
halogenases, ferryl formation leads to chloride rebound as opposed to hydroxide rebound, 
but the latter can occur as well. The partition between chloride rebound and hydroxide 
rebound is mainly dictated by substrate positioning, with substrates buried deeper in the 
active site favoring chlorination while more shallow substrates favor hydroxylation in 
SyrB2.
5,59
 This suggests that with the proper coordination environment and substrate 
positioning, alternative rebound can be directed.  
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To gain insight into structural factors that influence ligand access, the facial triad 
carboxylate D201E and D201G constructs were expressed, purified, and studied using 
kinetics, spectroscopy and crystallography. Chloride was required for D201G activity but 
not for WT-FIH or D201E (Hangasky unpublished), suggesting that Cl
-
 binds to the Fe 
cofactor in D201G to rescue activity. However, the change in the αKG-dependent MLCT 
in the presence of Cl
-
 was within the noise of our instrument and could not be measured 
accurately. Hence structural studies were undertaken to investigate the presence of 
chloride on the metal environment.  
While the D201E mutation is conservative, the D201G mutation creates an active 
site pocket that structurally mimics that of the αKG-dependent halogenases. In D201E, 
the longer sidechain may impose steric constraints that occlude water from the axial 
coordination site, resulting in a 5 coordinate geometry that reacts with oxygen and other 
ligands more readily than WT-FIH. The facial triad carboxylate has been implicated in 
being an H-bond partner for the axial water ligand and without the carboxylate, a 
weakened metal aquo bond results.
19
 With loss of the carboxylate ligand in the D201G 
variant, a 5-coordinate geometry would be favored, allowing O2 and other ligands access 
to the Fe cofactor. This line of reasoning is supported by the observation that D201E, 
D201G, and D201A catalyze oxidative decarboxylation (~ 5 – 10 fold) significantly 
faster than WT FIH.
16
 Although they were able to catalyze oxidative decarboxylation, 
significant uncoupling was observed, suggesting that substrate positioning was not 
optimal for coupled rebound chemistry.   
Our initial screen identified NO as an inhibitor of WT-FIH, D201E, and D201G, 
N3
-
 as an inhibitor of D201E and D201G, and OCN
-
 as an activator of D201G. The dose 
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response assays revealed that NO inhibited D201E (IC50 = 4 µM) the most, followed by 
D201G (IC50 = 22 µM) and then WT (IC50 = 65 µM). This data suggested that mutation 
of the facial triad carboxylate allowed exogenous ligands better access to the active site 
of FIH, an expected outcome if the Fe centers in D201G and D201E favored a 5 
coordinate state. Recently, NO was demonstrated to inhibit the HIF hydroxylase PHD2 
by binding to the active site metal.
43
 NO was also recently demonstrated to inhibit FIH 
activity in cells via an unknown mechanism.
44
 As binding of NO resulted in electronic 
absorption transitions typical of NO binding to Fe
2+
 in non heme enzymes,
39–41
 we 
interpreted this to mean that NO bound to the Fe cofactor to inhibit chemistry.   
Interestingly, the intensity of the peak at 440 nm due to NO binding was 
positively correlated to the degree of inhibition and followed the same trend, D201E > 
D201G > WT-FIH, consistent with better access to the active site in the D201E and 
D201G variants compared to WT-FIH. As the intensity depends on the amount of ligand 
character in the overlapping orbitals,
41
 it suggests that removal of the native carboxylate 
residue facilitates formation of stronger bonds with exogenous ligands. With the longer 
sidechain in D201E, the steric constraints may dictate the Fe ligand interaction, resulting 
in increased orbital overlap that gives rise to stronger Fe-ligand bonds compared to WT-
FIH. The lack of steric constraints in D201G would provide greater degrees of freedom 
for Fe-ligand interactions, which could result in the ligand adopting the most favorable 
conformation to enhance bonding interactions compared to WT. 
N3
- 
inhibited D201G the most, and then D201E, but failed to inhibit WT. The 
larger size of N3
- 
compared to NO probably contributed to this preference. The more open 
active site of D201G confers less steric barriers while D201E, even with a vacant 
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coordination site, would be expected to impose more steric barriers to ligand binding due 
to the longer sidechain. The electronic absorption spectra were consistent with N3
-
 
binding to D201E, and both N3
-
 and OCN
-
 binding to D201G. In SyrB2, N3
-
 and OCN
-
 
binding caused red shifts in the MLCT centered at ~ 500 nm to 545 and 540 
respectively.
6
 The binding affinity for azide (KD = 120 µM) in SyrB2
6
 is comparable to 
the IC50 of inhibition in D201G and D201E. OCN
-
 enhanced D201G activity ~ 3 fold, 
and the MLCT shifted from 485 nm to 500 nm, as seen for WT FIH. This suggests a 
chemical rescue and that the active site environment of D201G with OCN
-
 is similar to 
WT with OCN
-
 replacing the carboxylate ligand in D201G. We attribute the red shift to 
stabilization of the Fe t2g orbitals, likely a result of greater π symmetry overlap due to 
OCN
-
 binding in the equatorial position trans to the αKG keto group. Partial chemical 
rescue was previously observed for the D101A variant in TauD as 100 mM formate 
resulted in a ~4 fold increase in activity.
48
  
The role of the active site carboxylate has previously been defined as an H-bond 
acceptor for the bound aquo ligand based on DFT and VTVH MCD and CD experiments 
on the chlorinating enzyme CytC3 and the hydroxylase TauD.
19
 Due to the anionic nature 
of the carboxylate, the O-H bond of bound H2O becomes polarized, leading to a shorter 
Fe-O bond as more OH character is gained.
19
 The subsequent rearrangement of the 
carboxylate ligand to form new H-bond contacts with CTAD upon substrate binding 
weakens the Fe-H2O bond,
11
 stimulating aquo release and allowing O2 binding, as 
suggested by computations and spectroscopy on FIH.
52
  
In both the  CytC3 and TauD, the MCD and CD data revealed that the active site 
Fe was comprised of a distorted octahedral geometry, consistent with a weakly bound 
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H2O ligand, and switched to a mixture of 6/5-coordinate Fe
2+
 upon substrate binding with 
αKG coordinated in a bidentate fashion throughout.19 Our XAS analysis and 
crystallography are consistent with a distorted octahedral site for D201G, which 
structurally resembles CytC3 at the active site. The XANES region analysis suggested a 
mixture of 5/6 coordinate Fe centers, consistent with the existence of 2 distinct ferrous 
species seen in the MCD features of CytC3 and TauD.
19
 The EXAFS analysis best fit 
involved the coordination of Fe by 3 N/O donors, one of which was an imidazole, 1 Cl
-
, 
and NOG. The active site of (Zn+αKG)D201G/CTAD was reported to be 5-coordinate 
with the Fe coordinating ligands being 2 His residues, αKG in a bidentate fashion, and 
one H2O molecule. In our structure of (Fe+NOG+Cl
-
)D201G, the active site is similar, 
but instead of an aquo ligand, there were two Cl
-
 ligands bound to the Fe center. Perhaps 
the use of the native metal provides the proper electronic environment for Cl
-
 binding, or 
it’s a result of the crystallization conditions.  
 Although carbonate was a good fit during refinement, we excluded carbonate 
binding based on the fact that (i) the presence of 2 mM carbonate in our steady state 
assays did not inhibit D201G activity, (ii) the refinement of carbonate leads to 
asymmetric binding with unusual Fe-O bond lengths, (iii) the use of NOG prevents 
oxidative decarboxylation, limiting CO3 formation, and (vi) the EXAFS analysis was 
consistent with the presence of chloride in the Fe coordination sphere. Hence, we 
assigned the unresolved density tentatively to two chlorides as the refinement suggested 
this was the best model. We cannot rule out the possibility that some other unknown 
ligand generated during crystallization was bound. The discrepancy in the structure and 
EXAS analysis is attributed to more heterogeneity in the XAS sample compared to the 
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well-ordered crystal used for crystallography. In solution, a mix of different states (5/6-
coordinate geometries) are averaged in the XAS analysis, resulting in the data fitting best 
with a single Cl
-
 model. The heterogeneity also contributes to the different bond lengths 
observed crystallographically and by XAS.  Interestingly, the r-factor and reduced χ2 
were lowered when the model was expanded to included ~ 1 extra Cl
-
, however this 
would yield a 7-coordinate geometry which is unlikely.  
 According to the consensus mechanism, an open coordination site must exist for 
O2 binding in order for oxidative decarboxylation to occur.
2
 Hence, one Cl
-
 ligand is 
expected to dislodge and open a coordination site for O2. The long Fe-Cl bond found in 
the axial position, suggests that this Cl
-
 ligand is loosely associated with Fe and can be 
displaced by O2. The net result would be a 6C geometry in which O2 is bound in the 
expected position for ferryl formation to lead to hydroxylation. It is also possible that the 
Cl
-
 bound trans to the keto group of NOG vacates to yield an O2 binding site, however, 
this would lead to O2 being incorrectly positioned for decarboxylation chemistry and 
ferryl formation would occur at a position cis to the relative position of the target residue. 
In clavaminate synthase, the O2 mimic NO was bound to a site cis to the diffusible ligand 
site,
60
 and it cannot be ruled out as a possibility in D201G.  
 It appears that Cl
-
 binding leads to changes in the positioning of the target residue, 
hinting at a more dominant role in sterics as opposed to tuning the electronic environment 
of the Fe cofactor, consistent with the lack of observable spectral changes in the presence 
of chloride. The position of N803 is shifted towards αKG when compared to the position 
in WT-FIH,
11
 and to the position in the (Zn+αKG)D201G structure.16 The B-factor for 
N803 was high (~ 100 Å
2
) compared to the average B-factor (~ 67 Å
2
), consistent with 
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increased mobility of N803. We also observed alternate conformations for the substrate 
stabilizing residues, suggesting increased flexibility in the N803 positioning. We propose 
that Cl
-
 rescues activity by shifting the target residue to an optimal position for hydroxide 
rebound chemistry. Rescue of D201G activity was not observed in the presence of NaF or 
NaBr (Hangasky unpublished), suggesting F- and Br- fail to provide the same steric 
environment as Cl
-. It’s been suggested that substrate positioning is the dominant model 
to explain the preference for OH
-
 and Cl
-
 rebound.
5,59
 Thus, rebound chemistry in FIH 
may be tunable with the proper geometry and active site environment. Unfortunately, we 
did not detect the transfer of Cl
-
, N3
-
, or any other non-native ligand. In SyrB2, nitration 
chemistry was enhanced ~ 2.5 fold and azidation was enhanced ~ 13 fold in the A118G 
variant in the absence of Cl
-
,
6
 implying that alternative rebound chemistry can be 
achieved and improved.   
3.5 Conclusion 
Taken together with previous studies on TauD and CytC3, which lack a 
carboxylate ligand that coordinates to the axial H2O molecule, our data implicates the 
facial triad carboxylate in controlling ligand access to the Fe cofactor in the Fe
2+/αKG 
dependent oxygenases. In order for halogenation chemistry to occur, the active site must 
incorporate a halide ion to the Fe cofactor, generate the ferryl intermediate, perform HAT 
on the substrate, and transfer the bound halide to the substrate radical. Our kinetic, 
spectroscopic and crystallographic data are consistent with the binding of a halide (Cl) 
and other non-native ligands to the Fe cofactor in D201G. D201G also satisfies the 
prerequisite for ferryl formation, and HAT, but halide transfer is impeded. The lack of 
alternative rebound observed in D201G suggests that substrate positioning is not 
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optimized for alternative rebound, which perhaps may be achieved with further 
mutagenesis of the substrate binding residues (Q239 and R238). FIH provides an ideal 
model system for “biorthogonal” conjugation chemistry as it has been shown to 
hydroxylate other residues in non-native substrates, including His, Asp, Ile, Leu, and 
Ser.
13,61,62
 
3.6 Appendix 
3.6.1 Supplemental 
Table 3.3: Data collection and refinement statistics for D201G. Values in parentheses 
represent the highest resolution shell 
Data set (Fe
2+
+NOG+Cl)D201G 
λ (Å) 1.08 
Space group P41212 
Unit cell (Å, °) a = b =  86.42, c = 148.06 
α = β = γ = 90 
Resolution (Å) 74 – 2.6 (2.64 – 2.6) 
Rmerge (%) 7.7 
Mean I/σ (I) 28.3 (2.4) 
Completeness 
Multiplicity 
99.27 (99.92) 
Refinement  
Resolution range (Å) 74 – 2.6 
Number of Reflections 15948 
Average B factor (Å
2
) 66.5 
Rwork/Rfree  (%) 19.04/25.22 
R.m.s deviations  
Bond lengths (Å) 0.014 
Bond angles (Å) 1.565 
Ramachandran plot, residues in (%)  
Preferred region 93.02 
Allowed region 6.69 
Disallowed region 0.29 
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Table 3.4: EXAFS Analysis of (Fe+NOG+Cl)D201G with 1.75 Cl 
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 Reduced χ2 
3N/O 2.11(1) 1(1) 
0(1) 0.0840 1786.23 114.21 
(1Imidazole)     
1.75Cl 2.53(3) 13(4) 
1NOG-O1 1.89(1) 
0(1) 
1NOG-O2 1.99(1) 
 
 
Figure 3.9: EXAFS analysis of (Fe+NOG+Cl)D201G for 1 and 1.75 Cl in 50mM Hepes 
pH 7.00. Fourier transform (FT) window of 2 – 14 Å-1 with data in black and fits 
in red (1Cl) and blue (1.75 Cl).  Fit details for 1 Cl are in Table 3.2 and details for 
1.75 Cl are in Table 3.4). Inset: Unfiltered k
3
-weighted EXAFS spectra for the fits 
and data.  Fits were performed in r-space (Δk=2 – 14Å-1; Δk=1 – 4.0Å) as 
described in materials and methods. 
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Table 3.5: Table of EXAFS fits (continued onto next few pages) 
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 2.11(3) 1(2) 2(4) 0.2717 3413.21 416.09 3 
3N/O 2.10(3) 4(2) 1(2) 0.1744 3089.66 376.64 3 
4N/O 2.09(2) 7(2) 0(2) 0.1333 2159.28 263.23 3 
5N/O 2.08(3) 11(2) -1(2) 0.1237 1960.34 238.98 3 
6N/O 2.08(3) 14(3) -2(2) 0.1321 2145.33 261.53 3 
7N/O 2.07(4) 18(3) -2(2) 0.1494 2506.26 305.53 3 
        Fe-S(2.2) 
       
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2S 2.20(4) 6(3) -15(6) 0.3543 7216.30 879.70 3 
3S 2.21(4) 10(3) -15(5) 0.2736 5347.59 651.90 3 
4S 2.21(4) 13(3) -15(4) 0.2262 4260.11 519.33 3 
5S 2.22(4) 16(3) -15(4) 0.1980 3611.67 440.28 3 
6S 2.22(4) 19(3) -15(4) 0.1816 3231.16 393.89 3 
7S 2.23(4) 21(3) -15(3) 0.1730 3021.43 368.33 3 
        Fe-Cl(2.3) 
       
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2Cl 2.18(4) 7(3) -14(6) 0.3312 6666.47 812.68 3 
3Cl 2.18(4) 12(3) -15(5) 0.2498 4812.27 586.64 3 
4Cl 2.19(4) 14(3) -15(4) 0.2050 3800.75 463.33 3 
5Cl 2.19(4) 17(3) -15(4) 0.1808 3247.88 395.93 3 
6Cl 2.20(4) 20(3) -15(3) 0.1687 2960.08 360.85 3 
7Cl 2.20(4) 23(3) -15(3) 0.1639 2831.02 345.11 3 
        
        Fe-N(2.0) Fe-N(2.2) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 2.01(3) 1(3) 
-2(2) 0.1013 1980.93 319.34 5 1N/O 2.13(2) -4(2) 
                
2N/O 2.11(2) -1(1) 
-3(2) 0.0649 1227.08 197.82 5 2N/O 1.97(2) 2(2) 
                
3N/O 2.01(2) 5(3) 
-3(2) 0.0692 1302.00 209.89 5 1N/O 2.13(2) -3(1) 
                
4N/O 2.01(3) 10(3) 
-3(2) 0.0709 1326.12 213.78 5 1N/O 2.12(2) -2(2) 
                
3N/O 1.98(3) 6(3) 
-4(2) 0.0764 1448.24 233.47 5 2N/O 2.12(2) 0(2) 
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5N/O 2.10(2) 10(2) 
1(2) 0.0991 1690.20 272.50 5 1N/O 2.38(3) -1(3) 
                
4N/O 2.09(3) 8(4) 
1(4) 0.1237 1957.01 315.49 5 2N/O 2.32(22) 37(75) 
                
3N/O 2.27(32) 42(67) 
1(6) 0.1302 2090.02 336.93 5 3N/O 2.09(3) 6(3) 
                
6N/O 2.09(3) 13(3) 
0(2) 0.1031 1831.88 295.32 5 1N/O 2.38(3) -1(3) 
                
5N/O 2.09(3) 10(3) 
1(3) 0.1226 1952.41 314.75 5 2N/O 2.42(12) 26(39) 
                
4N/O 2.09(3) 8(3) 
2(4) 0.1240 1975.94 318.54 5 3N/O 2.36(17) 46(69) 
        Fe-S(2.2) Fe-S(2.3) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2S 2.22(4) 4(3) 
-10(5) 0.2493 4980.06 802.83 5 1S 2.40(7) 3(6) 
                
2S 2.20(4) 5(3) 
-10(4) 0.2006 3804.79 613.37 5 2S 2.38(6) 9(7) 
                
3S NO FIT   
        5 1S     
                
4S NO FIT   
        5 1S     
                
3S 2.21(3) 7(2) 
-10(3) 0.1581 2902.37 467.89 5 2S 2.41(5) 7(5) 
                
5S NO FIT   
        5 1S     
                
4S 2.23(3) 10(2) 
-11(3) 0.1339 2378.41 383.42 5 2S 2.44(4) 7(4) 
                
3S 2.20(3) 8(3) 
-10(3) 0.1435 2515.15 405.47 5 3S 2.41(5) 12(6) 
                
6S NO FIT   
        5 1S     
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5S 2.23(3) 12(2) 
-11(3) 0.1224 2119.77 341.73 5 2S 2.45(4) 7(4) 
                
4S 2.21(3) 10(2) 
-11(3) 0.1298 2209.60 356.22 5 3S 2.43(5) 12(5) 
        
        Fe-N(2.0) Fe-S(2.2) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 1.95(6) 4(5) 
-11(5) 0.2237 4514.23 727.73 5 1S 2.23(4) 2(3) 
                
1N/O 1.89(4) 0(4) 
-14(4) 0.2065 4238.71 683.32 5 2S 2.22(4) 6(3) 
                
2N/O 1.95(7) 6(6) 
-11(5) 0.2001 3670.53 591.72 5 2S 2.25(5) 8(4) 
                
3N/O 2.09(3) 4(2) 
1(3) 0.1547 2605.88 420.09 5 1S 2.60(23) 26(39) 
                
1N/O NO FIT   
        5 3S     
                
1N/O NO FIT   
        5 4S     
                
4N/O 2.09(3) 7(2) 
1(2) 0.1222 1915.89 308.86 5 1S 2.69(16) 23(31) 
                
2N/O 1.98(8) 8(7) 
-9(5) 0.1838 3164.87 510.21 5 3S 2.29(6) 15(7) 
                
3N/O 2.09(3) 4(2) 
1(3) 0.1451 2383.32 384.21 5 2S 2.61(18) 35(31) 
                
5N/O 2.08(5) 17(10) 
1(3) 1(3) 1730.69 279.00 5 1S 1.82(6) 17(12) 
                
1N/O NO FIT   
          5S     
                
4N/O 2.09(3) 7(2) 
1(2) 0.1190 1851.80 298.53 5 2S 2.70(14) 34(29) 
                
2N/O NO FIT   
        5 4S     
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3N/O 2.09(3) 5(2) 
1(3) 0.1392 2253.89 363.35 5 3S 2.62(17) 43(28) 
                
6N/O 2.06(2) 2(1) 
-3(1) 0.0630 1220.85 196.81 5 1S 2.02(2) 0(1) 
                
1N/O NO FIT   
        5 6S     
                
5N/O 2.09(3) 11(3) 
0(2) 0.1175 1851.59 298.49 5 2S 2.75(12) 31(27) 
                
2N/O 2.00(7) 8(9) 
-9(5) 0.1639 2728.01 439.78 5 5S 2.30(8) 25(8) 
                
4N/O 2.09(3) 7(3) 
1(2) 0.1179 1832.09 295.35 5 3S 2.71(14) 43(31) 
                
3N/O NO FIT   
        5 4S     
        Fe-N(2.0) Fe-Cl(2.3) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 1.94(5) 4(4) 
-11(5) 0.1964 3999.91 644.82 5 1Cl 2.21(3) 2(2) 
                
1N/O 1.89(4) 0(3) 
-14(4) 0.1770 3640.83 586.94 5 2Cl 2.19(3) 6)2) 
                
2N/O 1.92(6) 6(5) 
-12(4) 0.1769 3313.50 534.17 5 2Cl 2.22(4) 8(3) 
                
3N/O 2.09(3) 4(3) 
1(3) 0.1557 2625.13 423.19 5 1Cl 2.57(22) 28(39) 
                
1N/O 1.88(4) 1(3) 
-14(3) 0.1555 3018.69 486.64 5 3Cl 2.20(3) 10(3) 
                
1N/O 1.88(5) 2(4) 
-14(3) 0.1551 2862.09 461.40 5 4Cl 2.21(4) 15(3) 
                
4N/O 2.09(3) 7(2) 
1(2) 0.1220 1908.59 307.68 5 1Cl 2.66(17) 25(33) 
                
2N/O 1.95(9) 8(8) 
-10(5) 0.1740 3029.63 488.40 5 3Cl 2.25(6) 15(6) 
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3N/O 2.09(3) 5(3) 
1(3) 0.1466 2411.81 388.81 5 2Cl 2.58(18) 38(31) 
                
5N/O 2.09(3) 11(3) 
0(2) 0.1162 1815.24 292.63 5 1Cl 2.71(12) 20(23) 
                
1N/O 1.90(8) 5(8) 
-13(4) 0.1639 2866.47 462.10 5 5Cl 2.23(5) 19(4) 
                
4N/O 2.09(3) 7(2) 
1(2) 0.1186 1839.57 296.56 5 2Cl 2.66(14) 37(30) 
                
2N/O 1.98(9) 9(10) 
-10(5) 0.1677 2844.58 458.57 5 4Cl 2.26(7) 21(8) 
                
3N/O 2.09(3) 5(3) 
1(3) 0.1411 2282.61 367.98 5 3Cl 2.58(18) 45(29) 
                
6N/O 2.06(5) 20(11) 
0(3) 0.1176 1807.51 291.39 5 1Cl 1.79(7) 15(9) 
                
1N/O 1.68(26) 28(82) 
-17(6) 0.1621 2818.61 454.39 5 6Cl 2.18(5) 19(4) 
                
5N/O 2.09(3) 11(3) 
0(2) 0.1170 1837.87 296.28 5 2Cl 2.72(13) 34(29) 
                
2N/O 2.0097) 9(10) 
-9(5) 0.1633 2732.65 440.53 5 5Cl 2.27(8) 26(9) 
                
4N/O 2.09(3) 7(3) 
1(2) 0.1172 1813.00 292.27 5 3Cl 2.67(14) 45(31) 
                
3N/O 2.09(3) 5(3) 
1(3) 0.1371 2196.50 354.10 5 4Cl 2.59(18) 51(27) 
 
       
 
       Best 1st shell (R @ 1 - 4.0) 
     
        Fe-N(2.0) 
       
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 2.11(2) 1(2) 3(3) 0.3336 7481.57 380.94 3 
3N/O 2.10(2) 4(2) 1(2) 0.2434 5122.66 260.83 3 
4N/O 2.09(2) 7(2) 0(2) 0.2075 4191.65 213.43 3 
5N/O 2.08(2) 11(2) -1(2) 0.2011 4030.41 205.22 3 
6N/O 2.08(3) 14(3) -1(2) 0.2109 4268.92 217.36 3 
7N/O 2.08(3) 18(3) -2(2) 0.2285 4688.34 238.72 3 
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        Fe-S(2.2) 
       
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2S 2.21(3) 6(2) -14(5) 0.4230 9714.92 494.66 3 
3S 2.21(3) 10(2) -15(4) 0.3491 7787.69 396.53 3 
4S 2.22(3) 13(2) -15(3) 0.3055 6658.88 339.05 3 
5S 2.22(3) 16(2) -14(3) 0.2794 5980.22 304.50 3 
6S 2.23(3) 19(2) -14(3) 0.2640 5578.25 284.03 3 
7S 2.23(3) 21(3) -14(3) 0.2556 5354.10 272.62 3 
        Fe-Cl(2.3) 
       
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2Cl 2.18(3) 7(2) -14(4) 0.4029 9172.66 467.05 3 
3Cl 2.19(30 11(2) -15(4) 0.3282 7250.07 369.15 3 
4Cl 2.19(3) 14(2) -15(3) 0.2867 6189.14 315.13 3 
5Cl 2.19(3) 17(2) -15(3) 0.2637 5598.90 285.08 3 
6Cl 2.20(3) 20(2) -15(3) 0.2517 5282.66 268.98 3 
7Cl 2.20(3) 23(3) -15(3) 0.2464 5132.10 261.31 3 
        
        Fe-N(2.0) Fe-N(2.2) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 2.01(2) 1(3) 
-1(2) 0.1923 4193.62 237.74 5 1N/O 2.13(2) -4(1) 
                
2N/O 1.97(2) 2(2) 
-2(1) 0.1619 3471.66 196.81 5 2N/O 2.12(2) -1(1) 
                
3N/O 2.02(2) 6(3) 
-2(2) 0.1629 3481.66 197.38 5 1N/O 2.13(2) -3(1) 
                
4N/O 2.02(3) 10(3) 
-3(2) 0.1648 3519.50 199.52 5 1N/O 2.12(2) -2(2) 
                
3N/O 1.98(3) 7(3) 
-3(2) 0.1735 3721.70 210.99 5 2N/O 2.12(2) 0(2) 
                
5N/O 2.10(2) 1092) 
2(1) 0.1750 3637.89 206.23 5 1N/O 2.38(2) -1(2) 
                
4N/O 2.09(2) 7(3) 
2(2) 0.1996 4000.42 226.79 5 2N/O 2.35(11) 28(36) 
                
3N/O 2.09(2) 5(2) 
2(4) 0.2027 4081.25 231.37 5 3N/O 2.27(21) 40(37) 
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6N/O 2.09(2) 13(2) 
1(1) 0.1827 3863.80 219.04 5 1N/O 2.38(2) -1(2) 
                
5N/O 2.10(3) 10(3) 
2(2) 0.2010 4044.92 229.31 5 2N/O 2.43(9) 22(25) 
                
4N/O 2.10(3) 8(3) 
2(3) 0.2015 4058.62 230.09 5 3N/O 2.38(11) 41(42) 
        Fe-S(2.2) Fe-S(2.3) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2S 2.22(3) 4(2) 
-10(3) 0.3216 7273.49 412.34 5 1S 2.40(4) 3(4) 
                
2S 2.21(2) 4(2) 
-10(3) 0.2748 6024.33 341.52 5 2S 2.39(4) 8(5) 
                
3S NO FIT   
        5 1S     
                
4S NO FIT   
        5 1S     
                
3S 2.22(2) 7(2) 
-10(2) 0.2353 5056.08 286.63 5 2S 2.42(3) 7(3) 
                
5S NO FIT   
        5 1S     
                
4S 2.23(2) 9(2) 
-10(2) 0.2133 4508.13 255.57 5 2S 2.44(3) 7(3) 
                
3S 2.41(4) 11(4) 
-10(2) 0.2291 4826.72 273.63 5 3S 2.21(2) 7(2) 
                
6S NO FIT   
        5 1S     
                
5S NO FIT   
        5 2S     
                
4S 2.22(2) 10(2) 
-10(2) 0.2087 4323.29 245.09 5 3S 2.44(4) 11(4) 
        
        Fe-N(2.0) Fe-S(2.2) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
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2N/O 1.95(4) 5(4) 
-10(4) 0.3079 6946.53 393.80 5 1S 2.24(3) 2(2) 
                
1N/O 1.89(3) 1(3) 
-14(30 0.2949 6706.86 380.21 5 2S 2.22(3) 6(2) 
                
2N/O 1.98(6) 7(5) 
-9(4) 0.2853 6026.54 341.65 5 2S 2.28(4) 10(4) 
                
3N/O 2.10(2) 4(2) 
2(2) 0.2201 4515.90 256.01 5 1S 2.66(13) 23(25) 
                
1N/O NO FIT   
        5 3S     
                
1N/O NO FIT   
        5 4S     
                
4N/O 2.10(2) 7(2) 
2(1) 0.1897 3779.28 214.25 5 1S 2.75(6) 12(10) 
                
2N/O 1.99(5) 7(5) 
-8(3) 0.2625 5421.11 307.33 5 3S 2.30(5) 17(6) 
                
3N/O 2.10(2) 4(2) 
2(2) 0.2089 4230.68 239.84 5 2S 2.66(10) 31(19) 
                
5N/O 2.08(4) 18(9) 
2(2) 0.1896 3732.57 211.60 5 1S 1.81(5) 15(8) 
                
1N/O NO FIT   
          5S     
                
4N/O 2.10(2) 7(2) 
2(2) 0.1871 3698.66 209.68 5 2S 2.72(8) 27(16) 
                
2N/O 2.61(3) 1(3) 
-17(3) 0.2390 5196.69 294.60 5 4S 2.19(3) 13(2) 
                
3N/O 2.10(2) 4(2) 
2(2) 0.2031 4082.57 231.44 5 3S 2.66(10) 38(18) 
                
6N/O 2.17(3) 1395) 
2(2) 0.1956 4008.08 227.22 5 1S 2.22(3) 4(3) 
                
1N/O NO FIT   
        5 6S     
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5N/O 2.10(2) 11(2) 
1(2) 0.1901 3787.62 214.72 5 2S 2.74(7) 24(14) 
                
2N/O 2.01(5) 8(6) 
-8(3) 0.2413 4907.27 278.20 5 5S 2.32(6) 26(7) 
                
4N/O 2.09(2) 7(2) 
1(2) 0.1873 3703.65 209.96 5 3S 2.71(9) 36(17) 
                
3N/O NO FIT   
        5 4S     
        Fe-N(2.0) Fe-Cl(2.3) 
      
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
2N/O 1.94(4) 4(3) 
-11(3) 0.2857 6457.88 366.10 5 1Cl 2.22(2) 2(2) 
                
1N/O 1.89(3) 0(2) 
-14(3) 0.2694 6109.05 346.32 5 2Cl 2.20(2) 6(2) 
                
2N/O 1.93(5) 6(4) 
-11(3) 0.2654 5719.62 324.25 5 2Cl 2.23(3) 8(3) 
                
3N/O 2.10(2) 4(2) 
2(2) 0.2208 4528.37 256.72 5 1Cl 2.62(14) 25(26) 
                
1N/O 1.88(3) 0(3) 
-14(3) 0.2471 5430.00 307.83 5 3Cl 2.21(3) 10(2) 
                
1N/O 1.88(4) 2(3) 
-13(3) 0.2437 5222.85 296.09 5 4Cl 2.22(3) 15(3) 
                
4N/O 2.10(2) 7(2) 
1(2) 0.1912 3787.75 214.73 5 1Cl 2.68(10) 20(19) 
                
2N/O 1.97(6) 8(6) 
-9(4) 0.2565 5326.20 301.94 5 3Cl 2.26(5) 16(5) 
                
3N/O 2.10(2) 4(2) 
2(2) 0.2106 4262.60 241.65 5 2Cl 2.62(11) 34(21) 
                
5N/O 2.10(2) 11(2) 
1(1) 0.1887 3742.77 212.18 5 1Cl 2.73(7) 14(12) 
                
1N/O 1.92(8) 6(8) 
-12(3) 0.2480 5168.47 293.00 5 5Cl 2.23(4) 2(4) 
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4N/O 2.09(2) 7(2) 
1(2) 0.1874 3695.66 209.51 5 2Cl 2.67(9) 31(18) 
                
2N/O 1.99(6) 8(7) 
-9(4) 0.2473 5075.15 287.71 5 4Cl 2.28(6) 22(6) 
                
3N/O 2.09(2) 4(2) 
1(2) 0.2053 4119.70 233.55 5 3Cl 2.62(11) 42(19) 
                
6N/O 2.06(4) 22(10) 
0(2) 0.1961 3878.72 219.89 5 1Cl 1.79(5) 14(6) 
                
1N/O 1.68(24) 31(80) 
-16(5) 0.2463 5150.91 292.01 5 6Cl 2.19(4) 19(3) 
                
5N/O 2.09(2) 11(2) 
1(2) 0.1906 3793.99 215.08 5 2Cl 2.71(8) 28(16) 
                
2N/O 2.01(5) 8(7) 
-8(3) 0.2415 4919.72 278.90 5 5Cl 2.29(6) 28(7) 
                
4N/O 2.09(2) 7(2) 
1(2) 0.1873 3691.53 209.27 5 3Cl 2.67(10) 41(19) 
                
3N/O 2.09(2) 5(2) 
1(2) 0.2022 4034.03 228.69 5 4Cl 2.61(11) 49(19) 
 
       
 
       Best 1st shell + imid (R @ 1 - 4.0) 
     
        Fe-Im(1Q5Y) - NOG(4V2W) - 4 
     
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
4N/O 2.10(2) 6(2) 
4(2) 0.2437 5167.57 263.12 3 (1Im0)     
                
3N/O 2.04(2) 6(3) 
-1(1) 0.1332 2828.56 160.35 5 1Im0 2.12(2) -1(1) 
                
4N/O 2.08(2) 6(2) 
2(2) 0.2771 6000.68 305.54 3 (2Im0)     
                
2N/O 2.00(3) 4(3) 
-1(1) 0.1744 3817.51 216.42 5 2Im0 2.11(2) 1(1) 
                
3N/O 2.00(2) 4(2) 
-1(2) 0.1758 3929.48 222.76 5 
(1Im0)     
1Im0 2.12(1) -2(1) 
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2N/O 2.03(3) 5(5) 
-2(1) 0.1375 3008.11 192.34 7 
1Im0 2.11(2) -2(1) 
1Im0 1.98(5) 3(5) 
                
3N/O 2.00(2) 4(2) 
-1(2) 0.1707 3762.48 213.30 5 
(1Im0)     
1Im7 2.12(1) -3(1) 
                
2N/O 2.01(3) 5(4) 
-2(1) 0.1400 3022.98 193.29 7 
1Im0 2.01(5) 3(7) 
1Im7 2.12(2) -3(1) 
                
4N/O 2.07(2) 6(2) 
0(2) 0.2755 5873.01 299.04 3 (2Im7)     
                
2N/O 1.99(2) 3(3) 
-1(1) 0.1762 3822.12 216.68 5 2Im7 2.11(2) 0(1) 
                
3N/O 2.00(2) 4(2) 
-1(2) 0.1740 3854.21 218.50 5 
(1Im7)     
1Im7 2.11(1) -3(1) 
                
2N/O 2.04(4) 6(6) 
-2(1) 0.1382 2991.25 191.26 7 
1Im7 2.11(2) -3(1) 
1Im7 1.97(5) 1(4) 
                
2N/O 2.12(2) 0(2) 
-1(2) 0.2085 4728.08 268.04 5 
1NOG-O1 1.92(3) 
2(3) 1NOG-O2 2.01(3) 
                
2N/O 2.11(2) 0(1) 
0(2) 0.1928 4516.26 256.03 5 
(1Im0)     
1NOG-O1 1.92(2) 
2(3) 1NOG-O2 2.02(2) 
                
1N/O 1.90(2) -2(1) 
-4(2) 0.1422 3258.72 208.36 7 
1Im0 2.07(2) 0(2) 
1NOG-O1 1.98(2) 
0(2) 1NOG-O2 2.08(2) 
                
2N/O 2.11(2) 0(1) 
0(2) 0.2010 4660.57 264.21 5 
(1Im7)     
1NOG-O1 1.92(2) 
1(2) 1NOG-O2 2.02(2) 
                
1N/O 2.14(3) -2(2) 
-1(2) 0.1702 3904.46 249.65 7 
1NOG-O1 1.91(3) 
1(5) 1NOG-O2 2.01(3) 
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1Im7     
                
3N/O 1.96(4) 7(3) 
-8(3) 0.2708 5895.08 334.19 5 
(1Im0)     
1Cl 2.23(3) 3(2) 
                
2N/O 2.00(2) 3(2) 
-3(2) 0.1480 3148.39 201.31 7 
1Cl 2.38(6) 13(8) 
1Im0 2.10(2) -2(1) 
                
3N/O 1.96(4) 7(3) 
-8(3) 0.2715 5957.39 337.73 5 
(1Im7)     
1Cl 2.23(3) 3(2) 
                
2N/O 1.99(2) 2(2) 
-3(2) 0.1487 3155.21 201.74 7 
1Cl 2.37(5) 11(7) 
1Im7 2.10(2) -3(1) 
                
3N/O 1.98(4) 8(3) 
-7(3) 0.2651 5686.02 322.34 5 
(2Im0)     
1Cl 2.24(3) 4(2) 
                
1N/O 1.93(2) -1(2) 
-4(2) 0.1911 4158.21 265.88 7 
1Cl 2.32(5) 11(7) 
2Im0 2.07(2) 0(1) 
                
2N/O 1.95(2) 1(2) 
-4(2) 0.1577 3450.59 220.63 7 
(1Im0)     
1Im0 2.09(2) -3(1) 
1Cl 2.31(4) 9(5) 
                
1N/O 1.98(5) 3(6) 
-4(2) 0.1388 3007.96 220.53 9 
1Cl 2.32(4) 10(6) 
1Im0 1.95(4) 0(4) 
1Im0 2.09(2) -3(1) 
                
3N/O 1.98(4) 7(4) 
-7(3) 0.2620 5607.41 317.89 5 
(2Im7)     
1Cl 2.24(3) 4(3) 
                
1N/O 1.92(2) -2(1) 
-4(1) 0.1689 3682.88 235.48 7 
1Cl 2.33(5) 10(6) 
2Im7 2.06(2) 0(1) 
                
2N/O NO FIT   
          
(1Im7)     
1Im7     
1Cl     
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1N/O 1.97(5) 2(7) 
-4(2) 0.1323 2861.62 209.80 9 
1Cl 2.33(1) 35(43) 
1Im7 1.96(2) -4(1) 
1Im7 2.09(4) -1(4) 
                
2N/O 1.96(2) 1(2) 
-4(2) 0.1531 3296.78 210.80 7 
(1Im0)     
1Im7 2.09(2) -4(1) 
1Cl 2.33(4) 8(5) 
                
1N/O 2.02(4) 0(5) 
-4(2) 0.1412 3079.45 225.77 9 
1Cl 2.32(5) 10(7) 
1Im0 2.09(1) -2(1) 
1Im7 1.92(3) -1(2) 
                
1Cl 2.19(3) 2(2) 
-15(3) 0.2230 5066.99 323.99 7 
1Im0 1.71(9) 10(12) 
1NOG-O1 1.85(4) 
1(2) 1NOG-O2 1.95(4) 
                
1Cl 2.22(3) 4(3) 
-10(4) 0.2376 5280.73 337.65 7 
1NOG-O1 1.92(6) 
3(4) 1NOG-O2 2.02(6) 
1Im7 1.86(6) 3(5) 
                
        Fe-Im(1Q5Y) - NOG(4V2W) - 5 
     
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
5N/O 2.09(2) 8(2) 
3(2) 0.2158 4416.64 224.88 3 (1Im0)     
                
4N/O 2.04(2) 10(2) 
-1(1) 0.1112 2313.84 131.17 5 1Im0 2.11(1) -1(1) 
                
5N/O 2.08(2) 8(2) 
1(2) 0.2314 4822.40 245.54 3 (2Im0)     
                
3N/O 2.01(2) 8(3) 
-2(1) 0.1325 2806.18 159.08 5 2Im0 2.11(2) 2(1) 
                
4N/O 2.01(2) 7(2) 
-1(1) 0.1318 2862.90 162.30 5 
(1Im0)     
1Im0 2.12(1) -2(1) 
                
3N/O 2.03(3) 9(4) 
-2(1) 0.1049 2232.75 142.76 7 1Im0 1.98(5) 5(6) 
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1Im0 2.11(2) -1(1) 
                
4N/O 2.01(2) 7(2) 
-1(1) 0.1342 2873.71 162.91 5 
(1Im0)     
1Im7 2.12(1) -2(1) 
                
3N/O 2.05(3) 9(4) 
-2(1) 0.1069 2290.43 146.45 7 
1Im0 2.11(2) -1(1) 
1Im7 1.95(5) 3(4) 
                
3N/O 2.09(3) 5(3) 
1(3) 0.2185 4468.49 253.32 5 
1NOG-O1 2.09(18) 
27(24) 1NOG-O2 2.18(18) 
                
3N/O 2.12(2) 2(1) 
0(2) 0.1718 3923.04 222.40 5 
(1Im0)     
1NOG-O1 1.91(2) 
2(2) 1NOG-O2 2.00(2) 
                
3N/O     
          
(2Im0)     
1NOG-O1   
  1NOG-O2   
                
2N/O 1.98(5) 4(3) 
-2(2) 0.1252 2675.61 171.08 7 
1Im0 2.10(2) -2(1) 
1NOG-O1 2.03(5) 
9(10) 1NOG-O2 2.12(5) 
                
1N/O 1.89(2) -2(1) 
-3(1) 0.1121 2540.80 162.46 7 
2Im0 2.07(2) 3(2) 
1NOG-O1 1.98(2) 
1(2) 1NOG-O2 2.07(2) 
                
2N/O 1.95(4) 4(3) 
-3(2) 0.1304 2911.34 186.15 7 
(1Im0)     
1Im0 2.10(2) -2(1) 
1NOG-O1 1.98(4) 
6(6) 1NOG-O2 2.07(4) 
                
1N/O 1.89(3) 0(3) 
-4(1) 0.1036 2343.33 171.80 9 
1Im0 1.98(6) 3(9) 
1Im0 2.10(2) -1(3) 
1NOG-O1 1.98(2) 
2(3) 1NOG-O2 2.09(2) 
                
2N/O 1.97(4) 4(4) 
-3(2). 0.1371 3020.27 193.12 7 (1Im0)     
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1Im7 2.10(2) -3(1) 
1NOG-O1 1.97(4) 
9(8) 1NOG-O2 2.06(4) 
                
1N/O 1.90(3) -1(2) 
-4(2) 0.1112 2517.42 184.57 9 
1Im0 2.09(4) 0(3) 
1Im7 2.00(12) 6(19) 
1NOG-O1 1.99(2) 
1(3) 1NOG-O2 2.08(2) 
                
3N/O 2.11(2) 2(1) 
0(2) 0.1801 4060.93 230.21 5 
(2Im7)     
1NOG-O1 1.91(2) 
2(3) 1NOG-O2 2.00(2) 
                
1N/O 2.12(2) -2(1) 
-2(2) 0.1496 3339.41 213.52 7 
2Im7 2.05(6) 8(6) 
1NOG-O1 1.91(3) 
5(4) 1NOG-O2 2.01(3) 
                
4N/O 2.11(2) 5(2) 
5(2) 0.2150 4530.30 256.82 5 
(1Im0)     
1Cl 2.79(6) 10(9) 
                
4N/O     
          
(2Im0)     
1Cl     
                
3N/O 2.01(2) 6(2) 
-2(1) 0.1073 2210.68 141.35 7 
1Cl 2.43(7) 18(10) 
1Im0 2.11(1) -1(1) 
                
4N/O 2.05(3) 7(2) 
0(3) 0.2509 5149.33 291.92 5 
(1Im7)     
1Cl 2.39(11) 18(16) 
                
2N/O 1.97(2) 3(2) 
-3(1) 0.1340 2828.19 180.83 7 
1Cl 2.38(6) 15(9) 
2Im0 2.10(2) 1(1) 
                
3N/O 1.97(2) 4(2) 
-3(1) 0.1176 2508.19 160.37 7 
(1Im0)     
1Im0 2.10(1) -2(1) 
1Cl 2.34(5) 11(6) 
                
2N/O 2.00(3) 6(5) 
-4(1) 0.0975 2056.04 150.74 9 
1Cl 2.36(5) 13(7) 
1Im0 1.97(5) 3(5) 
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1Im0 2.10(2) -2(1) 
                
4N/O 2.03(3) 8(3) 
-3(2) 0.2376 4828.91 273.75 5 
(2Im7)     
1Cl 2.31(6) 12(8) 
                
2N/O 1.96(2) 2(2) 
-3(1) 0.1338 2836.94 181.39 7 
1Cl 2.38(5) 13(8) 
2Im7 2.09(1) 0(1) 
                
3N/O 1.97(2) 4(2) 
-3(1) 0.1160 2452.51 156.81 7 
(1Im0)     
1Im7 2.10(1) -3(1) 
1Cl 2.36(4) 11(6) 
                
2N/O 1.97(3) 4(3) 
-3(1) 0.0962 2016.45 147.84 9 
1Cl 2.38(5) 12(6) 
1Im0 2.01(4) 2(5) 
1Im7 2.11(2) -3(1) 
                
2N/O 1.89(6) 6(6) 
10(4) 0.2276 4953.87 316.75 7 
(1Im0)     
1Cl 2.22(3) 4(3) 
1NOG-O1 1.96(7) 
4(6) 1NOG-O2 2.05(7) 
                
1N/O 1.91(2) -2(2) 
-3(2) 0.1123 2493.00 182.78 9 
1Cl 2.55(9) 19(16) 
1Im0 2.08(2) 0(2) 
1NOG-O1 1.98(2) 
0(2) 1NOG-O2 2.07(2) 
                
2N/O 1.89(5) 4(5) 
-9(3) 0.2268 4958.22 317.03 7 
(1Im7)     
1Cl 2.22(3) 4(3) 
1NOG-O1 1.97(5) 
4(7) 1NOG-O2 2.06(5) 
                
1N/O 1.91(3) -2(2) 
-2(2) 0.1186 2613.30 191.60 9 
1Cl 2.54(10) 21(20) 
1NOG-O1 1.98(3) 
1(3) 1NOG-O2 2.08(3) 
1Im7 2.08(3) -2(2) 
                
1Cl 2.23(3) 5(3) 
-9(4) 0.2246 4794.12 306.54 7 
2Im0 1.92(9) 12(9) 
1NOG-O1 1.94(7) 
6(7) 1NOG-O2 2.03(7) 
112 
 
                
1Cl 2.22(3) 5(3) 
-8(4) 0.2256 4819.36 308.15 7 
1NOG-O1 1.96(7) 
7(8) 1NOG-O2 2.06(7) 
2Im7 1.93(8) 9(8) 
                
1Cl 2.47(6) 11(8) 
-2(2) 0.1155 2553.12 187.18 9 
1Im0 2.02(5) 1(5) 
1NOG-O1 1.90(2) 
3(3) 1NOG-O2 2.00(2) 
1Im7 2.12(2) -3(2) 
                
3N/O 1.98(4) 8(4) 
-7(3) 0.2497 5115.51 290.00 5 
(1Im0)     
2Cl 2.28(4) 12(5) 
                
3N/O 2.00(4) 9(3) 
-6(2) 0.2353 4778.36 270.89 5 
(2Im0)     
2Cl 2.28(4) 13(5) 
                
2N/O 1.98(2) 392) 
-3(2) 0.1283 2669.92 170.71 7 
2Cl 2.38(5) 21(7) 
1Im0 2.10(1) -2(1) 
                
3N/O 1.98(4) 7(4) 
-7(3) 0.2559 5275.88 299.09 5 
(1Im7)     
2Cl 2.28(4) 12(5) 
                
1N/O 1.92(2) -1(2) 
-5(1) 0.1530 3241.27 207.25 7 
2Cl 2.32(4) 17(6) 
2Im0 2.06(2) 1(1) 
                
2N/O 1.95(2) 2(2) 
-5(2) 0.1234 2637.65 168.65 7 
(1Im0)     
1Im0 2.09(1) -2(1) 
2Cl 2.31(3) 16(5) 
                
1N/O 1.96(5) 3(6) 
-5(1) 0.1107 2351.07 172.37 9 
2Cl 2.32(4) 17(5) 
1Im0 1.95(4) 1(4) 
1Im0 2.09(2) -3(1) 
                
3N/O 2.00(4) 8(3) 
-6(4) 0.2376 4828.73 273.74 5 
(2Im7)     
2Cl 2.29(4) 14(5) 
                
1N/O 1.91(20 -2(1) 
-4(1) 0.1381 2954.40 188.90 7 2Cl 2.33(4) 17(5) 
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2Im7 2.06(2) 0(1) 
                
2N/O 1.95(2) 1(2) 
-5(2) 0.1261 2663.78 170.32 7 
(1Im0)     
1Im7 2.08(2) -3(1) 
2Cl 2.32(4) 16(5) 
                
1N/O 1.94(3) 0(2) 
-5(1) 0.1076 2268.29 166.30 9 
2Cl 2.34(4) 17(5) 
1Im0 1.99(3) 1(4) 
1Im7 2.09(2) -4(1) 
                
1Im0 1.87(4) 2(3) 
-10(3) 0.2404 5187.57 331.69 7 
2Cl 2.21(4) 12(5) 
1NOG-O1 1.96(5) 
4(6) 1NOG-O2 2.05(5) 
                
1Im7 1.87(4) 1(3) 
-10(3) 0.2393 5164.55 330.22 7 
2Cl 2.21(4) 12(5) 
1NOG-O1 1.96(5) 
4(6) 1NOG-O2 2.06(5) 
                
        Fe-Im(1Q5Y) - NOG(4V2W) - 6 
     
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
6N/O 2.08(2) 11(2) 
2(2) 0.2043 4119.31 209.74 3 (1Im0)     
                
5N/O 2.05(2) 15(3) 
-2(1) 0.1139 2377.51 134.78 5 1Im0 2.11(1) 0(1) 
                
6N/O 2.07(2) 10(2) 
0(2) 0.2087 4251.66 216.48 3 (2Im0)     
                
4N/O 2.02(2) 12(3) 
-2(1) 0.1290 2703.10 153.24 5 2Im0 2.11(2) 3(2) 
                
5N/O 2.01(2) 10(2) 
-1(1) 0.1126 2406.41 136.42 5 
(1Im0)     
1Im0 2.12(1) -1(1) 
                
4N/O 2.04(3) 15(4) 
-3(1) 0.1006 2145.54 137.19 7 
1Im0 1.98(4) 4(6) 
1Im0 2.11(4) -1(1) 
                
5N/O 2.01(2) 9(2) 
-1(1) 0.1209 2553.20 144.74 5 (1Im0)     
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1Im7 2.12(1) -1(1) 
                
4N/O 2.04(3) 10(3) 
-1(3) 0.1095 1708.36 109.23 7 
1Im0 2.11(2) -1(1) 
1Im7 2.19(42) 32(94) 
                
4N/O 2.10(2) 6(2) 
3(2) 0.1941 3893.28 220.71 5 
1NOG-O1 2.28(6) 
11(11) 1NOG-O2 2.38(6) 
                
4N/O 2.12(2) 4(2) 
1(2) 0.1737 3819.84 216.55 5 
(1Im0)     
1NOG-O1 1.90(3) 
3(3) 1NOG-O2 1.99(3) 
                
3N/O 2.01(3) 6(3) 
-1(2) 0.1051 2170.31 138.77 7 
1Im0 2.11(1) -1(1) 
1NOG-O1 2.10(7) 
17(14) 1NOG-O2 2.19(7) 
                
4N/O 2.10(2) 4(2) 
0(2) 0.1675 3717.23 210.73 5 
(2Im0)     
1NOG-O1 1.89(2) 
3(3) 1NOG-O2 1.99(2) 
                
2N/O 1.93(3) 3(2) 
-3(1) 0.1171 2510.72 160.54 7 
2Im0 2.09(2) 2(1) 
1NOG-O1 2.02(3) 
6(6) 1NOG-O2 2.12(3) 
                
3N/O 1.98(4) 7(3) 
-2(2) 0.1173 2560.80 163.74 7 
(1Im0)     
1Im0 2.11(2) -2(1) 
1NOG-O1 1.99(5) 
12(10) 1NOG-O2 2.09(5) 
                
2N/O 1.96(6) 7(7) 
-3(2) 0.1002 2148.20 157.50 9 
1Im0 2.11(2) -2(2) 
1Im0 1.99(6) 4(9) 
1NOG-O1 2.03(5) 
10(12) 1NOG-O2 2.12(5) 
                
3N/O 1.99(3) 6(3) 
-2(2) 0.1244 2681.42 171.45 7 
(1Im0)     
1Im7 2.11(2) -2(1) 
1NOG-O1 2.00(6) 
15(12) 1NOG-O2 2.10(6) 
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2N/O 1.95(3) 4(3) 
-3(1) 0.1001 2131.11 156.24 9 
1Im0 2.03(4) 1(5) 
1Im7 2.11(2) -3(2) 
1NOG-O1 2.05(5) 
12(11) 1NOG-O2 2.14(5) 
                
4N/O 2.11(2) 4(2) 
0(2) 0.1762 3854.24 218.50 5 
(2Im7)     
1NOG-O1 1.90(2) 
4(2) 1NOG-O2 1.99(2) 
                
2N/O 1.94(3) 2(2) 
-2(1) 0.1244 2656.91 169.88 7 
2Im7 2.09(2) 0(1) 
1NOG-O1 2.04(4) 
10(9) 1NOG-O2 2.14(4) 
                
5N/O 2.10(2) 8(2) 
4(2) 0.1903 3858.21 218.72 5 
(1Im0)     
1Cl 2.79(5) 10(8) 
                
4N/O 2.02(4) 9(3) 
-3(3) 0.2284 4603.20 260.96 5 
(1Im0)     
2Cl 2.33(7) 20(9) 
                
4N/O 2.33(2) 10(3) 
-2(2) 0.1020 2098.91 134.20 7 
1Im0 2.11(2) -1(1) 
1Cl 2.53(14) 28(22) 
                
3N/O 2.01(2) 7(2) 
-2(1) 0.1020 2081.35 133.08 7 
1Im0 2.11(1) -1(1) 
2Cl 2.46(8) 32(13) 
                
5N/O 2.10(2) 8(2) 
4(2) 0.1950 3949.91 223.92 5 
(1Im7)     
1Cl 2.78(5) 8(6) 
                
4N/O 2.02(3) 9(3) 
-4(2) 0.2174 4362.74 247.33 5 
(1Im7)     
2Cl 2.31(5) 19(8) 
                
4N/O 2.03(2) 10(3) 
-2(2) 0.1200 2468.65 157.85 7 
1Im7 2.11(2) -1(1) 
1Cl 2.54(17) 30(26) 
                
5N/O 2.04(3) 10(2) 
-3(2) 0.2118 4258.97 241.44 5 
(2Im0)     
1Cl 2.33(7) 15(12) 
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4N/O 2.02(3) 10(3) 
-5(2) 0.2125 4250.20 240.95 5 
(2Im0)     
2Cl 2.30(5) 17(7) 
                
3N/O 1.99(2) 7(3) 
-2(1) 0.1174 2468.46 157.83 7 
2Im0 2.11(2) 2(1) 
1Cl 2.44(9) 21(15) 
                
2N/O 1.96(2) 3(2) 
-3(1) 0.1225 2562.01 163.81 7 
2Im0 2.09(1) 1(1) 
2Cl 2.38(5) 24(9) 
                
4N/O 1.99(1) 7(2) 
-2(1) 0.1017 2150.53 137.50 7 
(1Im0)     
1Im0 2.11(1) -2(1) 
1Cl 2.37(6) 14(8) 
                
3N/O 1.97(2) 5(2) 
-4(1) 0.1040 2193.33 140.24 7 
(1Im0)     
1Im0 2.10(2) -2(1) 
2Cl 2.34(4) 21(6) 
                
3N/O 2.01(3) 11(5) 
-3(1) 0.0920 1948.92 142.89 9 
1Im0 1.98(5) 4(7) 
1Im0 2.11(2) -2(1) 
1Cl 2.39(9) 20(14) 
                
2N/O 1.99(4) 7(6) 
-4(1) 0.0909 1910.02 140.03 9 
1Im0 2.10(2) -2(1) 
1Im0 1.97(5) 3(6) 
2Cl 2.36(6) 24(9) 
                
5N/O 2.04(3) 10(2) 
-2(2) 0.2152 4327.40 245.32 5 
(2Im7)     
1Cl 2.33(8) 16(13) 
                
4N/O 2.02(30 9(3) 
-4(2) 0.2174 4363.74 247.33 5 
(2Im7)     
2Cl 2.31(5) 19(8) 
                
3N/O 1.99(2) 7(3) 
-2(1) 0.1328 2792.60 178.56 7 
2Im7 2.11(2) 1(1) 
1Cl 2.44(10) 21(16) 
                
2N/O 1.95(2) 2(2) 
-3(1) 0.1269 2681.15 171.43 7 
2Im7 2.09(2) 0(1) 
2Cl 2.39(5) 24(9) 
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4N/O 1.99(2) 7(2) 
-3(1) 0.1068 2252.03 144.00 7 
(1Im0)     
1Im7 2.11(1) -2(1) 
1Cl 2.38(6) 14(8) 
                
3N/O 1.97(2) 4(2) 
-4(1) 0.1084 2275.08 145.47 7 
(1Im0)     
1Im7 2.10(2) -3(1) 
2Cl 2.35(5) 21(7) 
                
3N/O 2.03(4) 10(6) 
-3(1) 0.0989 2104.56 154.30 9 
1Im0 2.11(2) -1(1) 
1Im7 1.96(5) 4(6) 
1Cl 2.40(14) 26(22) 
                
2N/O 2.01(4) 7(6) 
-4(1) 0.0989 2093.78 153.51 9 
1Im0 2.10(2) -2(1) 
1Im7 1.95(5) 3(4) 
2Cl 2.36(7) 27(11) 
                
3N/O 2.11(1) 1(1) 
0(1) 0.0900 1976.10 126.35 7 
(1Im0)     
1Cl 2.51(3) 7(3) 
1NOG-O1 1.89(1) 
0(1) 1NOG-O2 1.99(1) 
                
2N/O 1.90(6) 6(6) 
-9(3) 0.2359 4967.94 317.65 7 
(1Im0)     
2Cl 2.22(4) 11(5) 
1NOG-O1 2.00(7) 
7(12) 1NOG-O2 2.09(7) 
                
2N/O 2.00(14) 6(8) 
-1(2) 0.1042 2169.84 159.08 9 
1Cl 2.58(20) 19(22) 
1Im0 2.11(2) -1(1) 
1NOG-O1 1.99(13) 
9(26) 1NOG-O2 2.09(13) 
                
1N/O 1.91(2) -2(2) 
-2(1) 0.0945 2053.02 150.52 9 
2Cl 2.55(6) 25(11) 
1Im0 2.09(2) -1(1) 
1NOG-O1 1.98(2) 
0(2) 1NOG-O2 2.07(2) 
                
3N/O 1.93(5) 7(5) 
-8(4) 0.2249 4848.85 310.04 7 
(1Im7)     
1Cl 2.22(3) 3(3) 
1NOG-O1 2.02(8) 8(13) 
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1NOG-O2 2.12(8) 
                
2N/O 1.90(5) 5(5) 
-9(3) 0.2344 4981.55 218.52 7 
(1Im7)     
2Cl 2.21(3) 10(5) 
1NOG-O1 2.01(7) 
6(12) 1NOG-O2 2.10(7) 
                
2N/O 1.98(7) 4(5) 
-1(2) 0.1152 2400.39 175.99 9 
1NOG-O1 2.02(2) 
8(20) 1NOG-O2 2.11(2) 
1Im7 2.11(2) -2(1) 
1Cl 2.60(18) 21(26) 
                
1N/O 1.91(3) -1(2) 
-2(1) 0.1017 2193.70 160.83 9 
2Cl 2.55(7) 26(13) 
1Im7 2.09(2) -2(2) 
1NOG-O1 1.98(2) 
1(3) 1NOG-O2 2.07(2) 
                
3N/O 2.11(1) 2(1) 
-1(1) 0.1046 2329.11 148.92 7 
(2Im0)     
1Cl 2.50(3) 7(4) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
                
2Im0 2.10(2) 1(1) 
-1(1) 0.1288 2787.59 178.24 7 
2Cl 2.50(5) 19(7) 
1NOG-O1 1.90(2) 
2(2) 1NOG-O2 2.00(2) 
                
1N/O 1.89(1) -2(1) 
-2(1) 0.0868 1952.27 143.13 9 
1Cl 2.57(6) 15(11) 
2Im0 2.09(2) 3(2) 
1NOG-O1 1.97(2) 
0(2) 1NOG-O2 2.07(2) 
                
2Cl 2.50(5) 19(7) 
-1(1) 0.1288 2787.59 178.24 7 
2Im0 2.10(2) 1(1) 
1NOG-O1 1.90(2) 
2(2) 1NOG-O2 2.00(2) 
                
3N/O 1.95(6) 9(6) 
-7(3) 0.2157 4554.70 291.23 7 
(2Im7)     
1Cl 2.23(3) 4(3) 
1NOG-O1 2.02(8) 
11(13) 1NOG-O2 2.11(8) 
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2Cl 2.52(4) 17(6) 
0(1) 0.1071 2300.57 147.10 7 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
2Im7 2.11(1) 2(1) 
                
2N/O 2.07(3) -1(3) 
-1(1) 0.0925 2044.88 149.92 9 
(1Im0)     
1Im7 2.16(4) -3(3) 
1NOG-O1 1.88(2) 
1(2) 1NOG-O2 1.98(2) 
1Cl 2.49(4) 6(4) 
                
1N/O 2.12(3) -1(3) 
-1(3) 0.0898 1964.42 168.77 11 
1Cl 2.52(5) 9(6) 
1Im0 2.10(4) 1(4) 
1Im7 2.12(29) 17(32) 
1NOG-O1 1.90(2) 
1(2) 1NOG-O2 1.99(2) 
                
2Cl 2.48(5) 19(7) 
-2(1) 0.0965 2081.55 152.61 9 
1Im0 2.03(4) 1(5) 
1Im7 2.12(2) -3(2) 
1NOG-O1 1.90(2) 
2(2) 1NOG-O2 1.99(2) 
                
        
        Fe-Im(1Q5Y) - NOG(4V2W) - 
Best+Frac 
     
        
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
3N/O 2.11(1) 1(1) 
0(1) 0.0900 1976.10 126.35 7 
(1Im0)     
1Cl 2.51(3) 7(3) 
1NOG-O1 1.89(1) 
0(1) 1NOG-O2 1.99(1) 
                
3N/O 2.11(1) 1(1) 
0(1) 0.0849 1820.56 116.41 7 
(1Im0)     
1.5Cl 2.52(3) 11(4) 
1NOG-O1 1.89(1) 
0(1) 1NOG-O2 1.99(1) 
                
3N/O 2.11(1) 1(1) 
0(1) 0.0840 1786.23 114.21 7 
(1Im0)     
1.75Cl 2.53(3) 13(4) 
1NOG-O1 1.89(1) 
0(1) 1NOG-O2 1.99(1) 
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3N/O 1.95(6) 10(7) 
-8(4) 0.2332 4832.71 309.00 7 
(1Im0)     
2Cl 2.23(5) 11(6) 
1NOG-O1 2.05(12) 
14(26) 1NOG-O2 2.15(12) 
                
2.5N/O 1.92(6) 8(6) 
-9(4) 0.2332 4935.01 315.54 7 
(1Im0)     
1.5Cl 2.22(3) 7(4) 
1NOG-O1 2.00(9) 
8(13) 1NOG-O2 2.10(9) 
                
        
N r (Å) σ2 (x10-3 Å2) ΔEo (eV) R factor χ
2
 
Reduced 
χ2 #Var 
3N/O 2.11(1) 2(1) 
-1(1) 0.1046 2329.11 148.92 7 
(2Im0)     
1Cl 2.50(3) 7(4) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
                
3N/O 2.11(1) 2(1) 
-1(1) 0.1008 2205.54 141.02 7 
(2Im0)     
1.5Cl 2.51(4) 12(5) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.99(2) 
                
3N/O 2.11(1) 2(1) 
-1(1) 0.1000 2176.84 139.19 7 
(2Im0)     
1.75Cl 2.51(4) 14(5) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
                
3N/O 2.11(1) 2(1) 
-1(1) 0.0996 2160.29 138.13 7 
(2Im0)     
2Cl 2.51(4) 17(5) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
                
3N/O 2.11(1) 2(1) 
-1(1) 0.0996 2150.98 137.53 7 
(2Im0)     
2.5Cl 2.52(4) 22(6) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.98(2) 
                
2.5N/O 2.10(1) 2(1) 
-1(1) 0.1090 2362.14 151.04 7 (2Im0)     
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2Cl 2.51(4) 18(6) 
1NOG-O1 1.89(2) 
1(2) 1NOG-O2 1.99(2) 
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CHAPTER 4 
HYDROGEN SULFIDE INHIBITION AND RESCUE OF THE HUMAN 
HYPOXIA SENSING ENZYME FIH 
 
4.1 Introduction 
 Hydrogen  sulfide (H2S) is emerging as an effector of numerous physiological 
processes related to metabolism and the cardiovascular system.
1–5
 H2S has also displayed  
pro angiogenic/wound healing and anti-cancer effects, further adding to its potential as a 
therapeutic agent for a wide array of human diseases.
5–10
 Currently, H2S releasing agents 
are being developed as therapeutics for protection against myocardial reperfusion injury, 
lethal hypoxia, and inflammation.
4,5
 Many of the physiological responses to H2S 
treatment involve genes regulated by the transcription activator, Hypoxia Inducible 
Factor (HIF), suggesting that some of the physiological effects of H2S may arise from 
effects on the HIF pathway. Despite the recent surge in reports of the therapeutic 
potential, the molecular mechanisms governing cellular responses to H2S remain poorly 
understood.
6,7
  
 HIF is a heterodimeric protein consisting of a nuclear localized β-subunit and a 
cytosolic α-subunit, which is regulated by the non-heme Fe2+/αKG dependent oxygenase, 
Factor Inhibiting HIF (FIH).
11,12
 Under hypoxic conditions, HIF-1α translocates to the 
nucleus to dimerize with HIFβ, then recruits the transcriptional co-activator p300 to 
initiate gene expression.
13
 FIH hydroxylates HIF-1α-Asn803 in the c-terminal 
transactivation domain (CTAD), preventing HIF mediated gene expression.
13
 HIF 
regulated genes are associated with angiogenesis and vascularization, maintaining basal 
metabolism, erythropoiesis, and lung development.
14,15
 It’s been recently demonstrated 
that H2S treatment leads to an increase in HIF-1α mRNA and upregulation of HIF 
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dependent target genes.
16,17
 As the HIF hydroxylases Prolyl Hydroxylase Domain 2 
(PHD2) and FIH control HIF-1α abundance and transcriptional ability respectively, the 
activity of the HIF hydroxylases and physiological responses to H2S treatment may be 
mechanistically linked.  
 
 
Scheme 4.1: Proposed consensus mechanism of FIH and αKG-dependent 
oxygenases 
 
The active site of FIH contains a 2His 1Asp facial triad coordinated to the Fe
2+
 
center, a hallmark of the Fe
2+/αKG dependent enzyme superfamily.18–20 The chemistry of 
FIH proceeds through a sequential mechanism in which binding of HIF-CTAD stimulates 
aquo release from the diffusible ligand site, followed by O2 binding and the subsequent 
oxidative decarboxylation of αKG to form a reactivity ferryl intermediate (Scheme 4.1)21–
23
 which has been trapped and identified as the hydroxylating species in related enzymes 
taurine dioxygenase (TauD)
24,25
 and prolyl 4 hydroxlase (PH4)
26
. The ferryl hydroxylates 
the β carbon of CTAD-Asn803. CTAD binding appears to alter second coordination 
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sphere contacts that lead to aquo release. Asp
201
 H-bonds to the axial aquo ligand but 
rearranges upon CTAD binding to form new H-bond contacts with the backbone amide 
of CTAD and other second sphere residues.
21,23
 The subsequent rearrangement of the 
active site may serve to modulate the access of O2 and related molecules to this diffusible 
ligand site.  
 Given the correlation between H2S and HIF regulated pathways, a potential 
mechanism of action for H2S would be to directly bind to the open coordination site of 
FIH. Under conditions of low CTAD, FIH can also autohydroxylate to form an inactive 
Fe
3+
 complex. As H2S is a known reducing agent, another possible mode of action would 
be to quench the ferryl or reduce Fe
3+
 in autohydroxylated FIH to Fe
2+
. Interestingly, the 
active site appears to be well suited for polar species such as H2S/HS
−
 as there would be a 
stabilizing effect from hydrogen bonding to the Asp
201
 sidechain.   
 There have not been any in vivo demonstrations of H2S directly inhibiting the HIF 
hydroxylases that we are aware of, but studies have shown that exposure of C. elegans to 
H2S
17
 leads to HIF-1α nuclear translocation and expression of HIF-1α target genes, 
suggesting inhibition of the HIF hydroxylases. Here, we provide the first in vitro 
evidence that H2S directly interacts with one of the HIF hydroxylases, FIH. This provides 
a rationale for many of the physiological effects of H2S, and may provide intriguing 
directions for therapeutics related to anemia, cancer, and ischemic diseases. In the present 
work, we demonstrate through kinetics and spectroscopy that the anion, HS
−
 inhibits FIH 
activity by ligating to the metal cofactor. We also show that HS
−
 can reduce the ferric 
center of inactive FIH to the active ferrous state, restoring activity. This suggests a dual 
role for H2S in modulating FIH activity in cells.  
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4.2 Methods 
4.2.1 Protein Purification 
 All reagents were purchased and used as received from commercial vendors 
unless stated otherwise. Expression and purification of FIH was carried out as previously 
described in the literature.
27
 The N-terminal His6 tagged protein was purified using a Ni-
NTA column with subsequent removal of the tag via thrombin digestion. EDTA 
treatment was used to remove exogenous metals followed by further purified using size-
exclusion chromatography to afford the active dimer. Protein concentrations were 
determined by absorption spectroscopy measurements (ɛ280 = 48800 M
-1 
cm
-1
).
27
 
  4.2.2 CTAD Purification 
  A 39 amino acid peptide substrate corresponding to the c- terminal transactivation 
domain (CTAD) of HIF-1α788-826 containing a Cys800 → Ala substitution with sequence 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN was ordered from 
EZBiolabs (Asn
803 
bolded) as a desalted synthetic peptide with free N and C termini. The 
peptide was dissolved in 25% acetonitrile and purified by reverse-phase HPLC as 
previously reported.
27,28
 Two rounds of purification yielded CTAD >95% pure as 
determined using matrix assisted laser desorption ionization mass spectrometry (MALDI-
MS). The concentration was determined by measuring the UV-absorption at 293 nm in 
0.1 M NaOH (ε293 = 2400 M
-1 
cm
-1
).
28
 
 
4.2.3 Dose Response Assays 
Dose response assays were carried out according to previous reports from the 
literature.29 Reaction components, Asc (2 mM), FeSO4 (25 µM), αKG (25 µM), CTAD 
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(100 µM), and sulfide (0 – 0.52 mM) were incubated in 50 mM Hepes pH 6.00 – 8.00 at 
37°C for 1 minute and the reaction initiated by adding 5 μL of apo FIH to bring the final 
volume to 50 μL and a final concentration of FIH = 0.5 µM. Reactions were carried out 
under ambient O2 conditions (~ 217 µM]).
30 Aliquots of the reaction (5 μL) were 
quenched in 20μL of 75% acetonitrile with 0.2% trifluoroacetic acid saturated with 3,5 
Dimethoxy-4-hydroxycinnamic acid at designated time points. Initial rates were 
determined by calculating the mole fraction of peptide converted to product based on the 
relative intensities of the un-hydroxylated peptide (m/z = 4255) and hydroxylated peptide 
(m/z = 4271) using MALDI-MS.27,29  
4.2.4 EPR Spectroscopy  
 A 500 µL sample containing FIH (100 µM), Fe
2+
 (100 µM), and αKG (500 µM) 
in air saturated Hepes pH 7.40 was prepared and incubated at 23°C aerobically for 45 
minutes to allow auto-oxidation of FIH to occur, forming Fe
3+
 at the active site.
31
 
Aliquots of freshly prepared Na2S (50 mM) in 50 mM air saturated Hepes pH 7.40 were 
added to aliquots of the samples such that the final volumes were 100 µL and the final 
concentrations of sulfide were 0.5 mM and 1 mM. The samples were allowed to incubate 
for an additional 5 minutes at 23°C, at which point they were transferred to EPR tubes 
and flash frozen in liquid nitrogen. EPR samples were run using a finger dewar on a 
Bruker Elexsys E-500 EPR equipped with a DM4116 cavity at 9.609 GHz frequency, 6.0 
mW power, 10G modulation amplitude, 100 GHz modulation frequency, 327 ms time 
constant, 77K.  
4.2.5 Electronic Absorption Spectroscopy 
 An aerobic sample containing FIH (1 mM), FeSO4 (1 mM), αKG (2 mM), and 
sulfide (2 mM) was prepared and the spectrum collected from 300 – 1000 nm on an HP 
133 
 
845x UV-visible spectrophotometer. We noticed that the auto-hydroxylated ferric 
chromophore
28
 dominated the electronic transitions, so additional aerobic UV-Vis 
experiments were conducted in the presence of N-oxalylglycine (NOG), an αKG 
analogue that inhibits chemistry.
21
 A sample containing FIH (0.467 mM), FeSO4 (0.467 
mM), NOG (2 mM), and H2S (0.467 mM) in 50 mM Hepes pH 7.40 was prepared and 
purified by size exclusion chromatography using buffer containing 50 mM Tris 50 mM 
NaCl pH 8.00. The FIH containing fractions were concentrated and buffer exchanged into 
50mM Hepes pH 7.40. The protein concentration was verified (0.424 mM) and the 
electronic absorption spectrum was measured from 300 – 1000 nm. 
 Anaerobic UV-visible measurements were recorded using an Avantes AvaSpec-
128 Ultrafast Fiber Optic Spectrometer set up in a glovebox. All reagents were degassed 
using argon and brought into the glovebox with the exception of FeSO4 and Na2S, which 
were brought in as solids and prepared using degassed water and Hepes pH 7.40 
respectively. The sample contained FIH (1 mM), FeSO4 (1 mM), αKG (2 mM), and 
sulfide (2 mM) in a total volume of 100 µL.  
4.2.6 Rescue Assays 
 A 1 mL sample containing FIH (50 µM), FeSO4 (50 µM), and αKG (1 mM) in 
Hepes buffer pH 7.40 was prepared and incubated at 23°C overnight (~16 hours) to allow 
auto-hydroxylation and inactivation of FIH to occur. Auto-hydroxylated FIH was treated 
with a 10 mM stock of varied reducing agents, such that the working concentrations were 
49 µM FIH and 200 µM reductant, then incubated at 37°C for 15 minutes. Reactions 
were initiated by adding 5 µL of the treated samples to fresh tubes containing 45 µL of 
100 µM CTAD pre-incubated at 37°C in 50 mM Hepes pH 7.40 for 2 minutes, bringing 
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the total volume to 50 µL and the final concentration of FIH = 4.9 µM. Aliquots (5 µL) 
were quenched after 5 minutes as for the dose response assays, then analyzed using 
MALDI-MS.  
 For dose response measurements, aliquots of the auto-hydroxylated FIH samples 
were incubated with varying concentrations of sulfide at 37°C for 2 minutes and the 
reaction initiated by adding CTAD. Reactions were quenched as described above after 5 
minutes and the concentration of hydroxylated CTAD determined. The final 
concentrations were FIH (4.9 µM), FeSO4 (4.9 µM), αKG (185 µM), sulfide (0 – 1.5 
mM), and CTAD (100 µM). The data was fit to a simple dose response model (equation 
1) in which A1 is the top asymptote, A2 is the bottom asymptote, and p is the hill 
coefficient.   
𝑦 = 𝐴1 +
𝐴2−𝐴1
1+10(𝐿𝑂𝐺𝑥−𝑥)𝑝
  (1) 
 
4.2.7 Dynamic Light Scattering (DLS)  
 DLS samples were prepared by mixing FIH (50 µM), FeSO4  (49 µM), αKG (250 
µM), and H2S (49 µM) in 50 mM Hepes pH 7.40. Measurements were taken with a 
MALVERN Zetasizer Nano ZS instrument and analyzed as previously described.
32
 
Briefly, samples were incubated for 2 minutes at 25°C and 4 scans (12 measurements per 
scan) were collected using incident excitation laser of 633 nm. The data from the 4 scans 
were averaged and analyzed using the Stokes-Einstein equation as previously reported.
32
 
4.3 Results 
 As H2S is garnering increased attention as a potential therapeutic agent for various 
diseases, identifying molecular targets of H2S could aid in therapeutic development. 
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Recent studies have implicated the HIF hydroxylases as potential targets of H2S in 
cells.
16,17
 To test the hypothesis that FIH is a target of H2S, we performed inhibition 
assays under ambient [O2]. We measured a dose response curve at pH 7.00 and observed 
moderate inhibition of FIH (IC50 = 64 μM). As the pKa of H2S is 6.9,
3
 we measured the 
inhibition assays over the pH range 6.00 – 8.00 in order to test for the H2S/HS
−
 
speciation. We observed that the IC50 values were pH dependent and decreased as pH 
was increased from 6.00 to 8.00 (Figure 4.1), pointing to HS
− 
as the relevant inhibitor, 
since FIH activity is pH-independent in this range.
33
 As sulfide is ~ 80% HS
−
 and ~ 20% 
H2S at physiological pH (pH 7.40),
34
 our use of the term H2S or HS
−
 refers to total 
sulfide, which is distributed in a pH dependent equilibrium H2S + H2O ⇋  HS
−
 + H3O
+
.  
 
 
Figure 4.1:  pH dependent inhibition of FIH (0.5 µM) in 50 mM Hepes pH 6.00 – 
8.00 at 37°C; αKG (25 μM), FeSO4 (25 μM), CTAD (100 μM), sulfide (0 – 520 μM), 
ascorbate (2 mM). The inset is an example of a dose response curve at pH 7.40. 
 To determine a Ki(app) for sulfide inhibition, we performed steady state kinetic 
assays with varied concentrations of CTAD in the presence of constant sulfide 
concentrations (Figure 2). To obtain Ki(app), the data was fit to an uncompetitive inhibition 
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binding model (equation 2) in which Vmax (fixed at 31 min
-1
)
27
 and KM (fixed at 77 µM)
27
 
have their traditional meanings, [S] denotes the substrate concentration and [I] denotes 
the inhibitor ([sulfide]tot) concentration. A global fit performed in OriginPro version 9.1 
yielded Ki(app) = 60 ± 9 µM.  
v
E
=  
𝑘cat ×[CTAD]
𝐾
M(CTAD)
+[S](1+ 
[Sulfide]
Ki(𝑎𝑝𝑝)
)
          (2) 
 In enzymatic reactions, kcat/KM for a given substrate reports on all steps involving 
diffusional encounter with the substrate up through and including the first irreversible 
step, which is oxidative decarboxylation in the case of FIH (Scheme 4.2). According to 
the consensus mechanism, substrate binding precedes O2 binding, which leads to the first 
irreversible step. Under conditions of ambient [O2] = 217 µM
30
 (KM(O2) = 90 µM),
35
 both 
kcat and kcat/KM (CTAD) report on O2 reaction as this is the first irreversible step. A 
regression analysis plot (Figure 4.2) generated from the kinetic data revealed a decreasing 
slope, suggesting that sulfide was an uncompetitive inhibitor for CTAD, and a step after 
CTAD binding is perturbed, likely O2 binding or O2 reaction.  
 
Scheme 4.2: Kinetic mechanism of FIH 
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Figure 4.2: (Left) Steady state kinetics of FIH in the presence of sulfide (Right) 
Regression analysis of steady state kinetics data. Assays were performed at 37°C with 
FIH (0.5 µM), ascorbate (2 mM), αKG (500 µM), FeSO4 (25 µM), and CTAD (24 – 
288 µM) in 50 mM Hepes pH 7.40. 
 
 As HS
−
 inhibition could arise from many potential mechanisms, we measured the 
electronic environment of FIH in the presence of sulfide to test for binding. The use of 
electronic absorption spectroscopy for monitoring ligand access to non heme Fe centers 
has been demonstrated to be an effective method.
36,37
 Binding of αKG in Fe2+/αKG-
dependent enzymes leads to electronic transitions at ~ 500 nm attributed to metal to 
ligand charge transfer (MLCT) transitions from Fe
2+
 to the bidentate coordinated αKG.38–
40
 Anaerobic addition of αKG to (Fe)FIH resulted in a broad absorption centered at 500 
nm (Figure 4.3), indicating that αKG bound to Fe2+ in the FIH active site. Adding sulfide 
to the sample of (Fe+αKG)FIH caused the solution to turn a light yellow color with a new 
electronic transitions centered near 400 nm, and two weak transitions near 500 and 600 
nm (Figure 3),suggesting binding of sulfide to the Fe cofactor in FIH. Binding of HS
−
 to 
Fe
2+
 in the αKG-dependent oxygenase SyrB2 resulted in a change of the MLCT centered 
at 500 nm to two transitions centered at 540 nm and 600 nm.
36
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Figure 4.3: Electronic absorption spectra of aerobic and anaerobic (Fe+αKG)FIH 
treated with sulfide. (black) Anaerobic (red) Aerobic. FIH (1 mM), FeSO4 (1 mM), 
αKG (2 mM), and sulfide (2 mM).  
 
 To ensure that the electronic transitions observed were due to binding of sulfide at 
the active site, we decided to purify sulfide treated FIH by size exclusion chromatography 
(SEC). An aerobic sample was prepared and upon addition of αKG we noticed that the 
αKG dependent MLCT was shifted to ~583 nm, consistent with the formation of Fe3+ as a 
result of auto-hydroxylation of FIH (Figure 4).
28,31
 When sulfide was added, the transition 
at 583 nm disappeared and new transitions centered at 440 nm, 515 nm, and 605 nm 
(Figure 4.3) appeared. This suggested that sulfide reduced the ferric iron to the ferrous 
form. Studies have shown that H2S, mainly the anion (HS
−
), binds to Fe
2+
 or Fe
3+
 at heme 
or binuclear enzyme active sites.
 37,39–41
 Binding of HS
−
 to  Fe
3+
 in superoxide dismutase 
and cytochrome c oxidase (CcO) reduced Fe
3+
 → Fe2+, concomitant with a red shift in the 
soret band in CcO and a disappearance of the broad absorption near 350 nm in SOD,
37,41
 
suggesting reduction of Fe
3+FIH → Fe2+FIH 
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 To prevent auto-hydroxylation of FIH, we substituted αKG with N-oxalylglycine, 
an αKG mimic that binds in a similar manner but inhibits chemistry.21,28,42  Binding of 
sulfide to (Fe+NOG)FIH produced broad transitions at λmax ~ 440 nm, and 600 nm 
(Figure 4.4). The sample was purified by SEC and protein containing fractions were 
pooled and then concentrated with 50 mM Hepes pH 7.4 using a 30 kDa molecular 
weight cutoff filter.  The resultant electronic absorption spectra displayed transitions with 
λmax = 440 nm, 515 nm and 605 nm, similar to the transitions observed in the presence of 
αKG after sulfide treatment. This suggested that sulfide was bound relatively tightly to 
Fe
2+
 in FIH (Figure 4). Inductively coupled plasma atomic emission spectroscopy 
measurements post purification by SEC demonstrated that the FIH to Fe ratio was 1:0.6, 
consistent with an intact cofactor site in FIH. Our data suggests that sulfide binds to the 
active site metal in FIH as the electronic transitions and extinction coefficients observed 
are compatible with those observed for model complexes (ɛ ~ 700 – 6100 M-1 cm-1) of 
thiolate ligated non-heme Fe centers.
43
 Anaerobic and aerobic addition of HS- to Fe and 
αKG or NOG resulted in blackish solutions that failed to exhibit the well defined peaks 
observed in the presence of FIH (Figure 4.10). 
 
Figure 4.4: Electronic absorption spectra of (Fe+NOG+Sulfide)FIH
 
in 50 mM Hepes 
pH 7.40. (left) Spectra in the absence and presence of sulfide
 
before and after 
purification with SEC; FIH (467 µM), Fe
2+
 (467 µM), NOG (2 mM), sulfide (0, 467 
µM). After SEC, [FIH] = 424 µM. (Right) Difference spectra calculated by 
subtracting the spectrum of (Fe+NOG)FIH. 
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 Dynamic light scattering (DLS) experiments were conducted to test for metal 
sequestration by sulfide as this technique is a sensitive reporter of trace amounts of 
particulate formation in solutions. The hydrodynamic diameter (DH) of (Fe+αKG)FIH 
was 8.2 ± 2.3 nm (Figure 4.5), consistent with the reported crystallographic dimensions.
21
 
Adding sulfide to the preformed (Fe+αKG)FIH sample produced a DH of 7.8 ± 2.4 nm 
(Figure 5), within uncertainty to the hydrodynamic diameter in the absence of sulfide, 
indicating that Fe-S colloids were not formed. Formation of Fe-S colloids yields a 
hydrodynamic diameter of 168 ± 42 nm (Figure 4.5).  
 
Figure 4.5: DLS of (Fe+αKG)FIH and (Fe+αKG+Sulfide)FIH. FIH (50 μM), FeSO4 
(49 μM), αKG (250 μM), Sulfide (50 µM) in 50 mM Hepes pH 7.40. 
 
 FIH and other αKG dependent oxygenases catalyze auto-hydroxylation of nearby 
active site residues in the absence of prime substrate, rendering the enzymes inactive.
31,44
 
Auto-hydroxylated FIH (FIH-OH) was demonstrated to be inactive due to formation of 
an Fe
3+
-O-Trp
296 
adduct, resulting in an indigo colored protein solution with an electronic 
absorption transition centered at 583 nm.
28
 H2S is known to reduce metalloprotein active 
sites,
37,41,45
 raising the possibility that sulfide could potentially restore inactive FIH 
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activity by reducing Fe
3+
. H2S rapidly converts ferric (Fe
3+
) heme centers to the ferrous 
(Fe
2+
) states.
46–48
 
 A sample of FIH was incubated with FeSO4 and αKG at 23°C overnight for auto-
hydroxylation. Following incubation, the sample turned a light indigo color and displayed 
a transition centered at 583 nm. Aliquots of this sample were treated with 200 µM of a 
variety of reducing agents: ascorbate (Asc), dithiotrietol (DTT), glutathione (GSH), N-
acetylcysteine (NAC), and sulfide (HS
−
) for 15 minutes at 37°C to test for the reduction 
of auto-hydroxylated FIH. Post treatment, the samples were assessed for activity by 
mixing with fresh buffer containing CTAD, then analyzed for hydroxylated peptide using 
MALDI MS. Auto-hydroxylated FIH was inactive as previously reported,
28
  and rescue 
of activity was observed for the HS
−
 treated sample (Figure 6). The HS
−
 treated sample 
had significantly hydroxylated CTAD (~ 38 µM CTAD-OH) while other reductants 
yielded < 5 µM CTAD hydroxylated (Figure 4.6). This suggests that sulfide was able to 
access the active site of FIH and reduce the inactive Fe
3+
 cofactor to the active Fe
2+
 form.  
 
 
Figure 4.6: Rescue of auto-hydroxylated FIH activity by reductants. FIH (4.9 μM), 
Fe
2+
 (4.9 μM), αKG (185 μM), CTAD (100 µM), reductant (20 µM) in 50 mM Hepes 
pH 7.40.  
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 Fe
2+
 in non-heme enzymes are generally EPR silent due to the Fe having a low 
spin S = 2 spin configuration. Oxidation of Fe
2+
 yields a high spin S = 5/2 Fe
3+
 center that 
can be observed using X-band EPR spectroscopy. Samples of auto-hydroxylated FIH 
were treated with sulfide then monitored by EPR to test for reduction of Fe
3+
. The EPR 
spectrum of the auto-hydroxylated FIH exhibited geff = 4.30, 4.25 (Figure 7), 
corresponding to high spin Fe
3+
 (S = 5/2). This oxidation was FIH dependent as the 
sample of Fe and αKG in buffer failed to produce an EPR signal. Addition of sulfide 
resulted in loss of the high spin Fe
3+
 signal (Figure 7), indicating that Fe
3+
 was reduced to 
Fe
2+
 in the HS
−
 treated sample.  
 
Figure 4.7: X-Band EPR of auto hydroxylated FIH samples. FIH (100 μM), FeSO4 
(100 μM), αKG (500 μM), Sulfide (0 – 1 mM) in aerobic 50 mM Hepes pH 7.40. 
9.609 GHz, 6.0 mW power, 10 G modulation amplitude, 100 GHz, 77 K. 
 
 The concentration dependence of sulfide rescue of auto-hydroxylated FIH was 
tested by incubating auto-hydroxylated FIH with sulfide for 2 minutes and then initiating 
turnover by adding CTAD. Reactions were quenched after five minutes and assessed for 
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hydroxylation via MALDI-MS. We observed that sulfide
 
rescue of FIH activity was dose 
dependent, exhibiting an EC50 = 333 ± 32 µM (Figure 4.8). Interestingly, at doses > 600 
µM, there was inhibition that increased with increasing [sulfide] (Figure 4.10), consistent 
with higher concentrations of HS
−
 inhibiting activity. H2S is known to exhibit different 
effects based on its concentration. At high concentrations, H2S inhibits CcO activity but 
acts as a reductant at low concentrations.
41
 Thus, low concentrations of H2S can preserve 
mitochondrial function by decreasing the production of reactive oxygen species.
49
 As a 
nueroprotectant, low concentrations of H2S mediate oxidative stress whereas high 
concentrations have been shown to enhance cerebral damage.
49
 
 
Figure 4.8: Concentration dependence for sulfide rescue of auto-hydroxylated FIH 
activity. FIH (5 μM), FeSO4 (5 μM), αKG (185 μM), sulfide (0 - 600 µM) in 50 mM 
Hepes pH 7.40. EC50 = 333 ± 32 µM 
 
4.4 Discussion 
 There is an overwhelming amount of evidence that links the effects of H2S 
treatment to the HIF pathway,
16,17,50
 suggesting that sulfide may be a physiological 
regulator of HIF activity. Exposure of C. elegans to 50 ppm H2S ( ~ 2 µM at STP.) led to 
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HIF-1α nuclear localization and increased HIF target gene expression, which was 
positively correlated to survival in otherwise lethal concentrations of H2S.
17
 In fact, HIF-
1α was required for survival to lethal doses of H2S,
17
 suggesting that HIF may aid in 
relieving the stress caused by H2S inhibition of CcO. Treatment of vascular smooth 
muscle cells with 300 µM H2S resulted in stabilization of HIF-1α mRNA and HIF 
controlled gene mRNA such as VEGF, and stimulated binding to the HIF response 
element (HRE),
51
 an outcome that could be explained by the inhibition of the HIF 
hydroxylases in cells. Additionally, H2S has also exhibited pro-angiogenic activity in 
cultured endothelial cells, an effect that is enhanced under hypoxic conditions and 
thought to proceed through a pathway involving upregulation of HIF-1α.52,53 Na2S at a 
dose of 25.6 µmol/kg per day significantly augmented ischemic tissue VEGF levels and 
restored ischemic hind-limb blood flow in mice.
53
 If H2S bound to the iron in the HIF 
hydroxylases, the effects of sulfide treatment would be more potent under hypoxic 
conditions, suggesting a mechanistic linkage between H2S treatment and the HIF 
hydroxylases.  
 Our data demonstrated that FIH was inhibited in a dose and pH dependent manner 
by sulfide with maximum inhibition near physiological pH (IC50 ≈ 30 µM at pH 7.40), 
pinpointing the anion HS
−
 as the inhibiting species as ~ 80% of the total available sulfide 
exists as HS
−
 at pH 7.40.
34,54
 We also showed that sulfide rescued FIH activity in a dose 
dependent manner with EC50  = 333 µM. In studies where H2S was reported to be an 
inhibitor or reducing agent, it’s been suggested that the anionic form (HS−) was the 
relevant species causing the observed effects.
37,45,55
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 To date, there have been limited accounts of H2S directly inhibiting enzymes, 
including carbonic anyhdrase and its various isozymes (HS
−
, Ki = 0.0006 - 70 mM),
55
 and 
CcO, (H2S, Ki = 0.2 μM).
56
 Due to CcO inhibition, H2S is a toxic substance to aerobic 
organisms.  However, H2S treatment at a modest concentration (80 ppm or 3.4 µM in air 
at 15°C) induced a reversible suspended-animation state in mice, marked by low demand 
for O2 and reduced metabolic rate.
4
 This state resembled hibernation, suggesting a global 
metabolic response rather than simple CcO inhibition. The recent discovery that HIF 
plays a role in up-regulating the transcription of certain homeostasis networks and 
proteins in response to H2S treatment,
16
 coupled with our observation that HS
−
 inhibits 
FIH, implies that direct action on FIH and other hydroxylases that regulate HIF, such as 
the prolyl hydroxylase, may account for some of the broader metabolic effects of H2S.   
 In humans, the concentration of H2S that leads to acute poisoning is reported to be 
1000 – 2000 ppm (~ 41 – 82 µM at STP.)57,58 However, the toxicity of H2S is mitigated 
by its rapid oxidation in the mitochondria, and the presence of > 30 µM HS
−
 was shown 
to not disturb oxidative phosphorylation.
59
 Intoxicating mice with NaSH elevated 
endogenous H2S levels by 57%, 18% and 64% in brain, liver, and kidney respectively, 
suggesting that the concentration range must be steep for the switch over from beneficial 
to toxic effects.
59
 As such, no cytotoxic effects were observed in HCT116 human colon 
cancer cells upon treatment with 125 µM – 1 mM H2S
60
 or SH-SY5Y human 
neuroblastoma cells in the presence of 25 – 250 µM H2S.
61
 
 Current estimates of endogenous H2S levels in living tissue are still unclear as 
different observations have been reported based on the analytical method with estimates 
ranging from virtually undetectable to low micromolar.
62–65
 Recently, the use of H2S 
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specific electrodes have led to more reliable detection of sulfide levels. Reports of H2S 
levels in serum using H2S electrodes in healthy individuals and patients with chronic 
obstructive pulmonary disease are estimated to range from 30 – 100 µM.66,67 
Concentrations of H2S in mammalian brain tissue have been reported to be as high as 50 
– 160 µM,59 suggesting that the concentrations at which FIH is affected in our assays 
(IC50 = 34 µM, EC50 = 333 µM) are physiologically relevant in certain tissues, and are 
within range of the concentrations reported to elicit physiological changes. For example, 
H2S was reported to act as a vasorelaxant (IC50 = 125 µM) of rat aorta and portal veins
59
 
and demonstrated to inhibit NO synthase isoforms (IC50 = 130 – 210 µM).
68
 H2S levels in 
plasma have been demonstrated to rise to as high as 41 µM in various disease models 
such as pancreatitis, haemorrhagic, endotoxic, and septic shock, along with upregulation 
of the mRNA of CBS and CSE, the H2S generating enzymes.
6
  
 As the therapeutic potential for H2S in ischemic and hypoxia related disorders is 
now being realized, there is an urgent interest in elucidating molecular mechanisms of 
action for H2S. Our data implicates FIH as a potential target of H2S/HS
−
 in cells (HS
−
 
being more relevant). As HS
−
 is likely competing with O2 for binding, the concentration 
needed to attenuate FIH activity in vivo may be less due to the fact that [O2] in cells is 
typically about 5 % of ambient O2. 
14,69
  
 We established that HS
−
 accessed the (Fe+αKG)FIH cofactor to inhibit and rescue 
activity by three methods.  First, HS
−
 reacted with Fe resulting in electronic absorption 
bands with λmax = 440 nm, 515 nm and 605 nm.  These electronic transitions persisted 
following purification of HS
−
 treated FIH by SEC, suggesting that the active site was 
intact and contained HS
−
 bound to Fe. As the transitions arise from an EPR silent Fe 
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center and the DLS data suggested no Fe-S colloid formation, we interpret the transition 
to be S → Fe2+ ligand to metal charge transfers transition. The anaerobic (Fe+αKG)FIH 
sample exhibited the characteristic MLCT at 500 nm indicative of αKG binding to Fe2+ in 
FIH. Upon addition of H2S, the transition at 440 nm was prevalent but the peaks at 515 
nm and 605 nm were weak, likely due to slight protein precipitation. HS
−
 binding to Fe
2+
 
in related enzyme SyrB2 resulted in transitions centered at 540 nm and 600 nm.
36
 The 
lack of a carboxylate ligand in SyrB2 likely results in different orbital overlap with bound 
HS
−
, resulting in the observed difference in the transitions of SyrB2 compared to FIH.    
 A comparison of binding affinities shows that Fe
2+
 binds more tightly to the FIH 
active site than in solution with HS
−
.  HS
− 
binds Fe
2+
 with moderate affinity (log β for 
HS
−
/Fe
2+
 is 5.2).
70
 However, (Fe+αKG)FIH is estimated to bind Fe2+ with high affinity 
based on the binding of CO2
+
 (log β for (CO2
+
+αKG)FIH is 6.9);27 Fe2+ binding to the 
related enzyme taurine dioxygenase (apo-TauD) was similarly strong (log β = 7.0).71 
Based on thermodynamic considerations, Fe
2+
 is bound more tightly by FIH than by HS
−
. 
This is consistent with the electronic absorption spectra being unchanged after 
purification of (Fe+NOG+HS
−
)FIH by SEC and the hydrodynamic diameter being 
consistent with the presence of soluble Fe bound FIH following the addition of  HS
−
 to 
(Fe+αKG)FIH . 
 Second, HS
−
 reduced air-oxidized (Fe
3++αKG)FIH back to the Fe2+ state.  Air 
oxidized (Fe
3++αKG)FIH was light indigo, and displayed an EPR signal (geff = 4.30, 
4.25) indicative of Fe
3+
. As the g-values were not widely dispersed from g near 4.3, this 
suggested a nearly pure rhombic Fe
3+
 center that possessed close to ideal octahedral 
geometry.
37
 Upon HS
−
 addition, the light indigo color and EPR signal disappeared, 
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indicating reduction to (Fe
2++αKG)FIH. The rescue of FIH activity upon treatment with 
HS
−
 is consistent with reduction of Fe
3+
 back to Fe
2+
, which was also observed by the 
change in the characteristic (Fe
3++αKG)FIH UV-Vis transition centered at 583 nm. We 
interpret this to indicate that HS
−
 accessed the active site in order to reduce the Fe 
cofactor.  
 The antioxidant properties of H2S are well documented. Addition of HS
−
 to Fe
3+ 
superoxide dismutase (Fe
3+
SOD) led to a colorless sample coincident with the 
disappearance of the absorption transition at 350 nm, suggesting reduction of Fe
3+
 to 
Fe
2+
.
37
 EPR experiments demonstrated that low concentrations of H2S fully reduced the 
Fe
3+
 form of oxidized CcO in quantitative yield.
41
 H2S has also been demonstrated to act 
as an antioxidant that provides protection against oxidative stress in numerous cell 
lines.
72–74
 The conversion of HS
−
 → S0 + H+ + 2e- has a redox potential of +0.17 V, 
making it a weaker reductant than other well established reducing agents such as 
glutathione (-0.25 V), ascorbate (-0.066 V), and dithiotrietol (-0.33 V), which are much 
more abundant in cells.
34,75
 Despite being a weaker reductant, reduction of Fe
3+
 in FIH 
seemed to be HS
−
 specific under our conditions, perhaps speaking to the fact that FIH 
may be a physiological target for HS
−
. The smaller size of HS
−
 may afford it better access 
to metalloprotein active sites compared to the more abundant intracellular thiols such as 
GSH and cysteine.  
 Third, initial rates of turnover were unaffected by the order of reagent addition. 
When HS
−
 was added to pre-formed (Fe+αKG)FIH and the reaction initiated with CTAD, 
the rate was the same as when HS
−
 was pre-incubated with Fe
2+
 and αKG and turnover 
initiated with FIH. As rates are unchanged when Fe is pre-loaded in FIH or allowed to 
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react with HS
−
 in solution, this excludes kinetic formation of a solution-based HS
−
/Fe
2+
 
adduct as the mechanism of inhibition. Importantly, the addition of excess Fe (6 
equivalent with respect to HS
−
) failed to increase FIH activity, suggesting that inhibition 
is due to HS
−
 binding to  Fe
2+
 as opposed to Fe sequestration or ferryl quenching.  
 Our kinetic data suggests that HS
−
 likely competes with O2 for binding as it is an 
uncompetitive inhibitor of CTAD and the IC50 is unchanged in the presence of high 
[αKG] (Supplemental Figure 1). As the regression analysis for kcat/KM(CTAD), which 
reports on O2 binding, showed a decreasing slope, it suggested that diffusional encounter 
with O2 was perturbed. The relatively tight binding of sulfide to Fe
2+
 in FIH supports this 
model. UV-Vis and electrocatalytic data indicated that H2S bound to the reduced 5- 
coordinate Fe
2+
 site of CcO and served as a competitive inhibitor of O2.
41
  
 
Scheme 4.3: Proposed model for sulfide interaction with FIH. 
 
 In sum, our data indicates that HS
−
 directly interacts with the Fe
2+
 cofactor in 
(Fe+αKG)FIH. As FIH is part of the control mechanism to regulate HIF-controlled gene 
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expression in response to hypoxia, this suggests that FIH may serve as a pathway for 
regulating HIF activity in response to H2S in vivo. The IC50 (~30 µM) of inhibition and 
EC50 (~330 µM) of rescue are reasonable as these are within the range of some estimates 
of H2S levels in humans cells and serum.
58,66
 Based on the evidence presented here and in 
literature,
13-15
 we propose a model (Scheme 4.3) in which HS
−
 directly binds to the 
exposed coordination site of (Fe+αKG)FIH, inhibiting its activity and thereby promoting 
HIF transcriptional activity. However, in the absence of prime substrate, auto-
hydroxylated (inactive) FIH is rescued by HS
−
 binding to Fe
3+
 and reducing it to Fe
2+
. 
Coincidentally, maximum inhibition is observed at approximately physiological pH, 
lending credence to the hypothesis that the HIF hydroxylases are physiological targets of 
H2S. The data presented here offer insight into possible physiological targets as well as a 
mechanism of action for H2S function in cells, and suggests that other αKG dependent 
oxygenases may also be potential targets.  
4.5 Supplemental Figures 
 The IC50 is unchanged in the presence of high αKG, suggesting that sulfide is an 
uncompetitive inhibitor of αKG. 
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Figure 4.9: IC50 measurement at high αKG levels FIH (0.5 μM) in 50 mM Hepes pH 
7.00 at 37°C; αKG (500 μM), FeSO4 (25 μM), CTAD (100 μM), Sulfide (0 – 120 μM), 
ascorbate (2 mM). 
 
 
 
Figure 4.10: Concentration dependence for sulfide rescue of auto-hydroxylated FIH 
activity. Rescue is followed by inhibition. FIH (5 μM), FeSO4 (5 μM), αKG (185 μM), 
Sulfide (0 – 1.5 mM) in 50 mM Hepes pH 7.40. 
 
 
Table 4.1: Summary of IC50 values 
 
 
 
 
 
 
 
 
 
pH             IC50 (µM) 
6.00            307 ± 19 
6.25            244 ± 15 
6.50             152 ± 3 
6.75             137 ± 3 
7.00            64  ± 3 
7.50             34  ± 2 
8.00            45  ± 4 
152 
 
 
 
Figure 4.10: Anaerobic (black) and aerobic (red) UV-vis samples of Fe (400 µM), 
NOG/αKG (2 mM), and HS- (400 µM) in 50 mM Hepes pH 7.40. 
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